# **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: WO 00/06738 (11) International Publication Number: A2 C12N 15/31, C07K 14/315, 16/12, A61K 10 February 2000 (10.02.00) (43) International Publication Date: 31/70, 39/09, G01N 33/53, 33/68, C12Q 1/68 (74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strode, PCT/GB99/02452 (21) International Application Number: 20 Red Lion Street, London WC1R 4PJ (GB). (22) International Filing Date: 27 July 1999 (27.07.99) (81) Designated States: CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, (30) Priority Data: GB PT, SE). 27 July 1998 (27.07.98) 9816336.3 US 19 March 1999 (19.03.99) 60/125,329 Published (71) Applicant (for all designated States except US): MICROBIAL Without international search report and to be republished TECHNICS LIMITED [GB/GB]; 20 Trumpington Street, upon receipt of that report. Cambridge CB2 1QA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): LE PAGE, Richard, William, Falla [GB/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB). WELLS, Jeremy, Mark [GB/GB]; Actinova Ltd., 12 Pembroke Avenue, Denny End Industrial Centre, Waterbeech, Cambridge CB5 9PB (GB). HANNIFFY, Sean, Bosco [IE/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB). HANS-BRO, Philip, Michael [GB/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 IQP (GB).

#### (54) Title: NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS PNEUMONIAE

#### (57) Abstract

Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI .	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	· Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВЈ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil .	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada .	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	. NL	Netherlands	YU	Yugosłavia
CH	Switzerland	KG '	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM .	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal	al	
CU	Cuba	KZ .	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation	an Federation	
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

#### NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS PNEUMONIAE

The present invention relates to proteins derived from *Streptococcus pneumoniae*, nucleic acid molecules encoding such proteins, the use of the nucleic acid and/or proteins as antigens/immunogens and in detection/diagnosis, as well as methods for screening the proteins/nucleic acid sequences as potential anti-microbial targets.

Streptococcus pneumoniae, commonly referred to as the pneumococcus, is an important pathogenic organism. The continuing significance of Streptoccocus pneumoniae infections in relation to human disease in developing and developed countries has been authoritatively reviewed (Fiber, G.R., Science, 265: 1385-1387 (1994)). That indicates that on a global scale this organism is believed to be the most common bacterial cause of acute respiratory infections, and is estimated to result in 1 million childhood deaths each year, mostly in developing countries (Stansfield, S.K., Pediatr. Infect. Dis., 6: 622 (1987)). In the USA it has been suggested (Breiman et al, Arch. Intern. Med., 150: 1401 (1990)) that the pneumococcus is still the most common cause of bacterial pneumonia, and that disease rates are particularly high in young children, in the elderly, and in patients with predisposing conditions such as asplenia, heart, lung and kidney disease, diabetes, alcoholism, or with immunosupressive disorders, especially AIDS. These groups are at higher risk of pneumococcal septicaemia and hence meningitis and therefore have a greater risk of dying from pneumococcal infection. pneumococcus is also the leading cause of otitis media and sinusitis, which remain prevalent infections in children in developed countries, and which incur substantial costs.

25

5

10

15

20

The need for effective preventative strategies against pneumococcal infection is highlighted by the recent emergence of penicillin-resistant pneumococci. It has been reported that 6.6% of pneumoccal isolates in 13 US hospitals in 12 states were found

WO 00/06738 PCT/GB99/02452

to be resistant to penicillin and some isolates were also resistant to other antibiotics including third generation cyclosporins (Schappert, S.M., Vital and Health Statistics of the Centres for Disease Control/National Centre for Health Statistics, 214:1 (1992)). The rates of penicillin resistance can be higher (up to 20%) in some hospitals (Breiman et al, J. Am. Med. Assoc., 271: 1831 (1994)). Since the development of penicillin resistance among pneumococci is both recent and sudden, coming after decades during which penicillin remained an effective treatment, these findings are regarded as alarming.

For the reasons given above, there are therefore compelling grounds for considering improvements in the means of preventing, controlling, diagnosing or treating pneumococcal diseases.

Various approaches have been taken in order to provide vaccines for the prevention of pneumococcal infections. Difficulties arise for instance in view of the variety of serotypes (at least 90) based on the structure of the polysaccharide capsule surrounding the organism. Vaccines against individual serotypes are not effective against other serotypes and this means that vaccines must include polysaccharide antigens from a whole range of serotypes in order to be effective in a majority of cases. An additional problem arises because it has been found that the capsular polysaccharides (each of which determines the serotype and is the major protective antigen) when purified and used as a vaccine do not reliably induce protective antibody responses in children under two years of age, the age group which suffers the highest incidence of invasive pneumococcal infection and meningitis.

25

5

10

15

20

A modification of the approach using capsule antigens relies on conjugating the polysaccharide to a protein in order to derive an enhanced immune response, particularly by giving the response T-cell dependent character. This approach has

been used in the development of a vaccine against *Haemophilus influenzae*, for instance. There are, however, issues of cost concerning both the multipolysaccharide vaccines and those based on conjugates.

A third approach is to look for other antigenic components which offer the potential to be vaccine candidates. This is the basis of the present invention. Using a specially developed bacterial expression system, we have been able to identify a group of protein antigens from pneomococcus which are associated with the bacterial envelope or which are secreted.

10

15

Thus, in a first aspect the present invention provides a *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 1.

In a second aspect, the present invention provides a *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 2.

A protein or polypeptide of the present invention may be provided in substantially pure form. For example, it may be provided in a form which is substantially free of other proteins.

20

25

As discussed herein, the proteins and polypeptides of the invention are useful as antigenic material. Such material can be "antigenic" and/or "immunogenic". Generally, "antigenic" is taken to mean that the protein or polypeptide is capable of being used to raise antibodies or indeed is capable of inducing an antibody response in a subject. "Immunogenic" is taken to mean that the protein or polypeptide is capable of eliciting a protective immune response in a subject. Thus, in the latter case, the protein or polypeptide may be capable of not only generating an antibody response but, in addition, a non-antibody based immune response.

10

15

20

25

The skilled person will appreciate that homologues or derivatives of the proteins or polypeptides of the invention will also find use in the context of the present invention, ie as antigenic/immunogenic material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the present invention. In addition, it may be possible to replace one amino acid with another of similar "type". For instance replacing one hydrophobic amino acid with another.

One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either sequence as appropriate. It is possible to calculate amino acid identity or similarity (identity plus conservation of amino acid type) for an optimal alignment. A program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are found, each having a different score. Both types of identity analysis are contemplated in the present invention.

In the case of homologues and derivatives, the degree of identity with a protein or polypeptide as described herein is less important than that the homologue or derivative should retain the antigenicity or immunogenicity of the original protein or polypeptide. However, suitably, homologues or derivatives having at least 60% similarity (as discussed above) with the proteins or polypeptides described herein are provided. Preferably, homologues or derivatives having at least 70% similarity, more preferably at least 80% similarity are provided. Most preferably, homologues or derivatives having at least 90% or even 95% similarity are provided.

In an alternative approach, the homologues or derivatives could be fusion proteins, incorporating moieties which render purification easier, for example by effectively

tagging the desired protein or polypeptide. It may be necessary to remove the "tag" or it may be the case that the fusion protein itself retains sufficient antigenicity to be useful.

In an additional aspect of the invention there are provided antigenic/immunogenic fragments of the proteins or polypeptides of the invention, or of homologues or derivatives thereof.

For fragments of the proteins or polypeptides described herein, or of homologues or derivatives thereof, the situation is slightly different. It is well known that is possible to screen an antigenic protein or polypeptide to identify epitopic regions, ie those regions which are responsible for the protein or polypeptide's antigenicity or immunogenicity. Methods for carrying out such screening are well known in the art. Thus, the fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties. Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a protein or polypeptide, homologue or derivative as described herein. The key issue, once again, is that the fragment retains the antigenic/immunogenic properties.

20

10

15

Thus, what is important for homologues, derivatives and fragments is that they possess at least a degree of the antigenicity/immunogenicity of the protein or polypeptide from which they are derived.

Gene cloning techniques may be used to provide a protein of the invention in substantially pure form. These techniques are disclosed, for example, in J. Sambrook et al Molecular Cloning 2nd Edition, Cold Spring Harbor Laboratory Press (1989).

Thus, in a third aspect, the present invention provides a nucleic acid molecule

15

20

25

comprising or consisting of a sequence which is:

- (i) any of the DNA sequences set out in Table 1 or their RNA equivalents;(ii) a sequence which is complementary to any of the sequences of (i);
- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
- 10 (iv) a sequence which has substantial identity with any of those of (i), (ii) and (iii);
  - (v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 1.

In a fourth aspect the present invention provides a nucleic acid molecule comprising or consisting of a sequence which is:

- (i) any of the DNA sequences set out in Table 2 or their RNA equivalents;
- (ii) a sequence which is complementary to any of the sequences of (i);
- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
- (iv) a sequence which has substantial identity with any of those of (i), (ii) and (iii); or

WO 00/06738 PCT/GB99/02452

(v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 2.

The nucleic acid molecules of the invention may include a plurality of such sequences, and/or fragments. The skilled person will appreciate that the present invention can include novel variants of those particular novel nucleic acid molecules which are exemplified herein. Such variants are encompassed by the present invention. These may occur in nature, for example because of strain variation. For example, additions, substitutions and/or deletions are included. In addition, and particularly when utilising microbial expression systems, one may wish to engineer the nucleic acid sequence by making use of known preferred codon usage in the particular organism being used for expression. Thus, synthetic or non-naturally occurring variants are also included within the scope of the invention.

5

10

15

20

25

The term "RNA equivalent" when used above indicates that a given RNA molecule has a sequence which is complementary to that of a given DNA molecule (allowing for the fact that in RNA "U" replaces "T" in the genetic code).

When comparing nucleic acid sequences for the purposes of determining the degree of homology or identity one can use programs such as BESTFIT and GAP (both from the Wisconsin Genetics Computer Group (GCG) software package) BESTFIT, for example, compares two sequences and produces an optimal alignment of the most similar segments. GAP enables sequences to be aligned along their whole length and finds the optimal alignment by inserting spaces in either sequence as appropriate. Suitably, in the context of the present invention when discussing identity of nucleic acid sequences, the comparison is made by alignment of the sequences along their whole length.

Preferably, sequences which have substantial identity have at least 50% sequence identity, desirably at least 75% sequence identity and more desirably at least 90 or at least 95% sequence identity with said sequences. In some cases the sequence identity may be 99% or above.

5

Desirably, the term "substantial identity" indicates that said sequence has a greater degree of identity with any of the sequences described herein than with prior art nucleic acid sequences.

10

It should however be noted that where a nucleic acid sequence of the present invention codes for at least part of a novel gene product the present invention includes within its scope all possible sequence coding for the gene product or for a novel part thereof.

15

The nucleic acid molecule may be in isolated or recombinant form. It may be incorporated into a vector and the vector may be incorporated into a host. Such vectors and suitable hosts form yet further aspects of the present invention.

20

Therefore, for example, by using probes based upon the nucleic acid sequences provided herein, genes in *Streptococcus pneumoniae* can be identified. They can then be excised using restriction enzymes and cloned into a vector. The vector can be introduced into a suitable host for expression.

25

Nucleic acid molecules of the present invention may be obtained from *S.pneumoniae* by the use of appropriate probes complementary to part of the sequences of the nucleic acid molecules. Restriction enzymes or sonication techniques can be used to obtain appropriately sized fragments for probing.

Alternatively PCR techniques may be used to amplify a desired nucleic acid sequence. Thus the sequence data provided herein can be used to design two primers for use in PCR so that a desired sequence, including whole genes or fragments thereof, can be targeted and then amplified to a high degree.

5

10

15

20

25

Typically primers will be at least 15-25 nucleotides long.

As a further alternative chemical synthesis may be used. This may be automated. Relatively short sequences may be chemically synthesised and ligated together to provide a longer sequence.

There is another group of proteins from *S.pneumoniae* which have been identified using the bacterial expression system described herein. These are known proteins from *S.pneumoniae*, which have not previously been identified as antigenic proteins. The amino acid sequences of this group of proteins, together with DNA sequences coding for them are shown in Table 3. These proteins, or homologues, derivatives and/or fragments thereof also find use as antigens/immunogens. Thus, in another aspect the present invention provides the use of a protein or polypeptide having a sequence selected from those shown in Tables 1-3, or homologues, derivatives and/or fragments thereof, as an immunogen/antigen.

In yet a further aspect the present invention provides an immunogenic/antigenic composition comprising one or more proteins or polypeptides selected from those whose sequences are shown in Tables 1-3, or homologues or derivatives thereof, and/or fragments of any of these. In preferred embodiments, the immunogenic/antigenic composition is a vaccine or is for use in a diagnostic assay.

In the case of vaccines suitable additional excipients, diluents, adjuvants or the like

may be included. Numerous examples of these are well known in the art.

5

10

15

20

25

It is also possible to utilise the nucleic acid sequences shown in Tables 1-3 in the preparation of so-called DNA vaccines. Thus, the invention also provides a vaccine composition comprising one or more nucleic acid sequences as defined herein. DNA vaccines are described in the art (see for instance, Donnelly *et al.*, *Ann. Rev. Immunol.*, 15:617-648 (1997)) and the skilled person can use such art described techniques to produce and use DNA vaccines according to the present invention.

As already discussed herein the proteins or polypeptides described herein, their homologues or derivatives, and/or fragments of any of these, can be used in methods of detecting/diagnosing *S.pneumoniae*. Such methods can be based on the detection of antibodies against such proteins which may be present in a subject. Therefore the present invention provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one protein, or homologue, derivative or fragment thereof, as described herein. Suitably, the sample is a biological sample, such as a tissue sample or a sample of blood or saliva obtained from a subject to be tested.

In an alternative approach, the proteins described herein, or homologues, derivatives and/or fragments thereof, can be used to raise antibodies, which in turn can be used to detect the antigens, and hence *S.pneumoniae*. Such antibodies form another aspect of the invention. Antibodies within the scope of the present invention may be monoclonal or polyclonal.

Polyclonal antibodies can be raised by stimulating their production in a suitable animal host (e.g. a mouse, rat, guinea pig, rabbit, sheep, goat or monkey) when a protein as described herein, or a homologue, derivative or fragment thereof, is injected into the

WO 00/06738 PCT/GB99/02452

animal. If desired, an adjuvant may be administered together with the protein. Well-known adjuvants include Freund's adjuvant (complete and incomplete) and aluminium hydroxide. The antibodies can then be purified by virtue of their binding to a protein as described herein.

5

Monoclonal antibodies can be produced from hybridomas. These can be formed by fusing myeloma cells and spleen cells which produce the desired antibody in order to form an immortal cell line. Thus the well-known Kohler & Milstein technique (*Nature* **256** (1975)) or subsequent variations upon this technique can be used.

10

Techniques for producing monoclonal and polyclonal antibodies that bind to a particular polypeptide/protein are now well developed in the art. They are discussed in standard immunology textbooks, for example in Roitt *et al*, *Immunology* second edition (1989), Churchill Livingstone, London.

15

In addition to whole antibodies, the present invention includes derivatives thereof which are capable of binding to proteins etc as described herein. Thus the present invention includes antibody fragments and synthetic constructs. Examples of antibody fragments and synthetic constructs are given by Dougall et al in Tibtech 12 372-379 (September 1994).

20

25

Antibody fragments include, for example, Fab,  $F(ab')_2$  and Fv fragments. Fab fragments (These are discussed in Roitt *et al* [supra]). Fv fragments can be modified to produce a synthetic construct known as a single chain Fv (scFv) molecule. This includes a peptide linker covalently joining  $V_h$  and  $V_l$  regions, which contributes to the stability of the molecule. Other synthetic constructs that can be used include CDR peptides. These are synthetic peptides comprising antigen-binding determinants. Peptide mimetics may also be used. These molecules are usually conformationally

restricted organic rings that mimic the structure of a CDR loop and that include antigen-interactive side chains.

Synthetic constructs include chimaeric molecules. Thus, for example, humanised (or primatised) antibodies or derivatives thereof are within the scope of the present invention. An example of a humanised antibody is an antibody having human framework regions, but rodent hypervariable regions. Ways of producing chimaeric antibodies are discussed for example by Morrison *et al* in PNAS, **81**, 6851-6855 (1984) and by Takeda *et al* in Nature. **314**, 452-454 (1985).

10

5

Synthetic constructs also include molecules comprising an additional moiety that provides the molecule with some desirable property in addition to antigen binding. For example the moiety may be a label (e.g. a fluorescent or radioactive label). Alternatively, it may be a pharmaceutically active agent.

15

Antibodies, or derivatives thereof, find use in detection/diagnosis of *S.pneumoniae*. Thus, in another aspect the present invention provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested and antibodies capable of binding to one or more proteins described herein, or to homologues, derivatives and/or fragments thereof.

20

In addition, so-called "Affibodies" may be utilised. These are binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain (Nord et al,) Thus, Small protein domains, capable of specific binding to different target proteins can be selected using combinatorial approaches.

25

It will also be clear that the nucleic acid sequences described herein may be used to detect/diagnose S.pneumoniae. Thus, in yet a further aspect, the present invention

provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid sequence as described herein. Suitably, the sample is a biological sample, such as a tissue sample or a sample of blood or saliva obtained from a subject to be tested. Such samples may be pre-treated before being used in the methods of the invention. Thus, for example, a sample may be treated to extract DNA. Then, DNA probes based on the nucleic acid sequences described herein (ie usually fragments of such sequences) may be used to detect nucleic acid from *S.pneumoniae*.

In additional aspects, the present invention provides:

WO 00/06738

5

15

- (a) a method of vaccinating a subject against *S.pneumoniae* which comprises the step of administering to a subject a protein or polypeptide of the invention, or a derivative, homologue or fragment thereof, or an immunogenic composition of the invention;
- (b) a method of vaccinating a subject against *S.pneumoniae* which comprises the step of administering to a subject a nucleic acid molecule as defined herein;
- 20 (c) a method for the prophylaxis or treatment of *S.pneumoniae* infection which comprises the step of administering to a subject a protein or polypeptide of the invention, or a derivative, homologue or fragment thereof, or an immunogenic composition of the invention;
- 25 (d) a method for the prophylaxis or treatment of *S.pneumoniae* infection which comprises the step of administering to a subject a nucleic acid molecule as defined herein;

- (e) a kit for use in detecting/diagnosing *S.pneumoniae* infection comprising one or more proteins or polypeptides of the invention, or homologues, derivatives or fragments thereof, or an antigenic composition of the invention; and
- 5 (f) a kit for use in detecting/diagnosing S.pneumoniae infection comprising one or more nucleic acid molecules as defined herein.

Given that we have identified a group of important proteins, such proteins are potential targets for anti-microbial therapy. It is necessary, however, to determine whether each individual protein is essential for the organism's viability. Thus, the present invention also provides a method of determining whether a protein or polypeptide as described herein represents a potential anti-microbial target which comprises antagonising, inhibiting or otherwise interfering with the function or expression of said protein and determining whether *S. pneumoniae* is still viable.

15

10

A suitable method for inactivating the protein is to effect selected gene knockouts, ie prevent expression of the protein and determine whether this results in a lethal change. Suitable methods for carrying out such gene knockouts are described in Li et al, P.N.A.S., 94:13251-13256 (1997) and Kolkman et al, 178:3736-3741 (1996).

20 374

25

In a final aspect the present invention provides the use of an agent capable of antagonising, inhibiting or otherwise interfering with the function or expression of a protein or polypeptide of the invention in the manufacture of a medicament for use in the treatment or prophylaxis of *S.pneumoniae* infection.

As mentioned above, we have used a bacterial expression system as a means of identifying those proteins which are surface associated, secreted or exported and

10

15

20

25

thus, would find use as antigens.

The information necessary for the secretion/export of proteins has been extensively studied in bacteria. In the majority of cases, protein export requires a signal peptide to be present at the N-terminus of the precursor protein so that it becomes directed to the translocation machinery on the cytoplasmic membrane. During or after translocation, the signal peptide is removed by a membrane associated signal peptidase. Ultimately the localization of the protein (i.e. whether it be secreted, an integral membrane protein or attached to the cell wall) is determined by sequences other than the leader peptide itself.

likely to be antigens for use in vaccines, as diagnostic reagents or as targets for therapy with novel chemical entities. We have therefore developed a screening vector-system in *Lactococcus lactis* that permits genes encoding exported proteins to be identified and isolated. We provide below a representative example showing how given novel surface associated proteins from *Streptococcus pneumoniae* have been identified and characterized. The screening vector incorporates the staphylococcal nuclease gene *nuc* lacking its own export signal as a secretion reporter. Staphylococcal nuclease is a naturally secreted heat-stable, monomeric enzyme which has been efficiently expressed and secreted in a range of Gram positive bacteria (Shortle, *Gene*, 22:181-189 (1983); Kovacevic *et al.*, *J. Bacteriol.*,

162:521-528 (1985); Miller et al., J. Bacteriol., 169:3508-3514 (1987); Liebl et al.,

J. Bacteriol., 174:1854-1861 (1992); Le Loir et al., J. Bacteriol., 176:5135-5139

(1994); Poquet et al., J. Bacteriol., 180:1904-1912 (1998)).

We are specifically interested in surface located or exported proteins as these are

Recently, Poquet et al. ((1998), supra) have described a screening vector incorporating the nuc gene lacking its own signal leader as a reporter to identify exported proteins in Gram positive bacteria, and have applied it to L. lactis. This

vector (pFUN) contains the pAMβ1 replicon which functions in a broad host range of Gram-positive bacteria in addition to the ColE1 replicon that promotes replication in *Escherichia coli* and certain other Gram negative bacteria. Unique cloning sites present in the vector can be used to generate transcriptional and translational fusions between cloned genomic DNA fragments and the open reading frame of the truncated nuc gene devoid of its own signal secretion leader. The *nuc* gene makes an ideal reporter gene because the secretion of nuclease can readily be detected using a simple and sensitive plate test: Recombinant colonies secreting the nuclease develop a pink halo whereas control colonies remain white (Shortle, (1983), *supra*; Le Loir *et al.*, (1994), *supra*).

Thus, the invention will now be described with reference to the following representative example, which provides details of how the proteins, polypeptides and nucleic acid sequences described herein identified as antigenic targets.

15

10

5

We describe herein the construction of three reporter vectors and their use in *L.* lactis to identify and isolate genomic DNA fragments from *Streptococcus* pneumoniae encoding secreted or surface associated proteins.

20

The invention will now be described with reference to the examples, which should not be construed as in any way limiting the invention. The examples refer to the figures in which:

Figure 1: shows the results of a number of DNA vaccine trials; and

25

30

Figure 2: shows the results of further DNA vaccine trials.

## **EXAMPLE 1**

(i) Construction of the pTREP1-nuc series of reporter vectors

10

15

20

25

## (a) Construction of expression plasmid pTREP1

The pTREP1 plasmid is a high-copy number (40-80 per cell) theta-replicating gram positive plasmid, which is a derivative of the pTREX plasmid which is itself a derivative of the previously published pIL253 plasmid. pIL253 incorporates the broad Gram-positive host range replicon of pAMβ1 (Simon and Chopin, *Biochimie*, 70:559-567 (1988)) and is non-mobilisable by the *L lactis* sex-factor. pIL253 also lacks the *tra* function which is necessary for transfer or efficient mobilisation by conjugative parent plasmids exemplified by pIL501. The Enterococcal pAMβ1 replicon has previously been transferred to various species including *Streptococcus*, *Lactobacillus* and *Bacillus* species as well as *Clostridium acetobutylicum*, (Oultram and Klaenhammer, *FEMS Microbiological Letters*, 27:129-134 (1985); Gibson *et al.*, (1979); LeBlanc *et al.*, *Proceedings of the National Academy of Science USA*, 75:3484-3487 (1978)) indicating the potential broad host range utility. The pTREP1 plasmid represents a constitutive transcription vector.

The pTREX vector was constructed as follows. An artificial DNA fragment containing a putative RNA stabilising sequence, a translation initiation region (TIR), a multiple cloning site for insertion of the target genes and a transcription terminator was created by annealing 2 complementary oligonucleotides and extending with Tfl DNA polymerase. The sense and anti-sense oligonucleotides contained the recognition sites for Nhel and BamHI at their 5' ends respectively to facilitate cloning. This fragment was cloned between the XbaI and BamHI sites in pUC19NT7, a derivative of pUC19 which contains the T7 expression cassette from pLET1 (Wells et al., J. Appl. Bacteriol., 74:629-636 (1993)) cloned between the EcoRI and HindIII sites. The resulting construct was designated pUCLEX. The complete expression cassette of pUCLEX was then removed by cutting with HindIII and blunting followed by cutting with EcoRI before cloning into EcoRI and SacI (blunted) sites of pIL253 to generate the vector pTREX (Wells and Schofield, In

10

15

20

25

Current advances in metabolism, genetics and applications-NATO ASI Series, H 98:37-62 (1996)). The putative RNA stabilising sequence and TIR are derived from the Escherichia coli T7 bacteriophage sequence and modified at one nucleotide position to enhance the complementarity of the Shine Dalgarno (SD) motif to the ribosomal 16s RNA of Lactococcus lactis (Schofield et al. pers. coms. University of Cambridge Dept. Pathology.).

A Lactococcus lactis MG1363 chromosomal DNA fragment exhibiting promoter activity which was subsequently designated P7 was cloned between the EcoRI and BglII sites present in the expression cassette, creating pTREX7. This active promoter region had been previously isolated using the promoter probe vector pSB292 (Waterfield et al, Gene, 165:9-15 (1995)). The promoter fragment was amplified by PCR using the Vent DNA polymerase according to the manufacturer.

The pTREP1 vector was then constructed as follows. An artificial DNA fragment which included a transcription terminator, the forward pUC sequencing primer, a promoter multiple -cloning site region and a universal translation stop sequence was created by annealing two overlapping partially complementary synthetic oligonucleotides together and extending with sequenase according to manufacturers instructions. The sense and anti-sense (pTREPF and pTREPR) oligonucleotides contained the recognition sites for EcoRV and BamHI at their 5' ends respectively to facilitate cloning into pTREX7. The transcription terminator was that of the *Bacillus penicillinase* gene, which has been shown to be effective in Lactococcus (Jos *et al.*, *Applied and Environmental Microbiology*, 50:540-542 (1985)). This was considered necessary as expression of target genes in the pTREX vectors was observed to be leaky and is thought to be the result of cryptic promoter activity in the origin region (Schofield *et al.* pers. coms. University of Cambridge Dept. Pathology.). The forward pUC primer sequencing was included to enable direct sequencing of cloned DNA fragments. The translation stop sequence which encodes a stop codon in 3

different frames was included to prevent translational fusions between vector genes and cloned DNA fragments. The pTREX7 vector was first digested with EcoRI and blunted using the 5' - 3' polymerase activity of T4 DNA polymerase (NEB) according to manufacturer's instructions. The EcoRI digested and blunt ended pTREX7 vector was then digested with Bgl II thus removing the P7 promoter. The artificial DNA fragment derived from the annealed synthetic oligonucleotides was then digested with EcoRV and Bam HI and cloned into the EcoRI(blunted)-Bgl II digested pTREX7 vector to generate pTREP. A Lactococcus lactis MG1363 chromosomal promoter designated P1 was then cloned between the EcoRI and BgIII sites present in the pTREP expression cassette forming pTREP1. This promoter was also isolated using the promoter probe vector pSB292 and characterised by Waterfield et al., (1995), supra. The P1 promoter fragment was originally amplified by PCR using vent DNA polymerase according to manufacturers instructions and cloned into the pTREX as an EcoRI-BglII DNA fragment. The EcoRI-BglII P1 promoter containing fragment was removed from pTREX1 by restriction enzyme digestion and used for cloning into pTREP (Schofield et al. pers. coms. University of Cambridge, Dept. Pathology.).

PCT/GB99/02452

## (b) PCR amplification of the S. aureus nuc gene.

20

25

5

10

15

The nucleotide sequence of the *S. aureus nuc* gene (EMBL database accession number V01281) was used to design synthetic oligonucleotide primers for PCR amplification. The primers were designed to amplify the mature form of the nuc gene designated nucA which is generated by proteolytic cleavage of the N-terminal 19 to 21 amino acids of the secreted propeptide designated Snase B (Shortle, (1983), *supra*). Three sense primers (nucS1, nucS2 and nucS3, Appendix 1) were designed, each one having a blunt-ended restriction endonuclease cleavage site for EcoRV or Smal in a different reading frame with respect to the nuc gene. Additionally BgIII and BamHI were incorporated at the 5' ends of the sense and anti-sense primers

respectively to facilitate cloning into BamHI and BgIII cut pTREP1. The sequences of all the primers are given in Appendix 1. Three nuc gene DNA fragments encoding the mature form of the nuclease gene (NucA) were amplified by PCR using each of the sense primers combined with the anti-sense primer described above. The nuc gene fragments were amplified by PCR using *S. aureus* genomic DNA template, Vent DNA Polymerase (NEB) and the conditions recommended by the manufacturer. An initial denaturation step at 93 °C for 2 min was followed by 30 cycles of denaturation at 93 °C for 45 sec, annealing at 50 °C for 45 seconds, and extension at 73 °C for 1 minute and then a final 5 min extension step at 73 °C. The PCR amplified products were purified using a Wizard clean up column (Promega) to remove unincorporated nucleotides and primers.

## (c) Construction of the pTREP1-nuc vectors

5

10

15

20

25

The purified nuc gene fragments described in section b were digested with Bgl II and BamHI using standard conditions and ligated to BamHI and BglII cut and dephosphorylated pTREP1 to generate the pTREP1-nuc1, pTREP1-nuc2 and pTREP1-nuc3 series of reporter vectors. General molecular biology techniques were carried out using the reagents and buffer supplied by the manufacture or using standard conditions(Sambrook and Maniatis, (1989), *supra*). In each of the pTREP1-nuc vectors the expression cassette comprises a transcription terminator, lactococcal promoter P1, unique cloning sites (BglII, EcoRV or SmaI) followed by the mature form of the nuc gene and a second transcription terminator. Note that the sequences required for translation and secretion of the nuc gene were deliberately excluded in this construction. Such elements can only be provided by appropriately digested foreign DNA fragments (representing the target bacterium) which can be cloned into the unique restriction sites present immediately upstream of the *nuc* gene.

In possessing a promoter, the pTREP1-nuc vectors differ from the pFUN vector described by Poquet et al. (1998), supra, which was used to identify L. lactis exported proteins by screening directly for Nuc activity directly in L. lactis. As the pFUN vector does not contain a promoter upstream of the nuc open reading frame the cloned genomic DNA fragment must also provide the signals for transcription in addition to those elements required for translation initiation and secretion of Nuc. This limitation may prevent the isolation of genes that are distant from a promoter for example genes which are within polycistronic operons. Additionally there can be no guarantee that promoters derived from other species of bacteria will be recognised and functional in L. lactis. Certain promoters may be under stringent regulation in the natural host but not in L. lactis. In contrast, the presence of the P1 promoter in the pTREP1-nuc series of vectors ensures that promoterless DNA fragments (or DNA fragments containing promoter sequences not active in L. lactis) will still be transcribed.

15

20

25

10

5

# (d) Screening for secreted proteins in S. pneumoniae

Genomic DNA isolated from *S. pneumoniae* was digested with the restriction enzyme Tru9I. This enzyme which recognises the sequence 5'- TTAA -3' was used because it cuts A/T rich genomes efficiently and can generate random genomic DNA fragments within the preferred size range (usually averaging 0.5 - 1.0 kb). This size range was preferred because there is an increased probability that the P1 promoter can be utilised to transcribe a novel gene sequence. However, the P1 promoter may not be necessary in all cases as it is possible that many Streptococcal promoters are recognised in *L. lactis*. DNA fragments of different size ranges were purified from partial Tru9I digests of *S. pneumoniae* genomic DNA. As the Tru 9I restriction enzyme generates staggered ends the DNA fragments had to be made blunt ended before ligation to the EcoRV or SmaI cut pTREP1-nuc vectors. This was achieved by the partial fill-in enzyme reaction using the 5'-3' polymerase

10

15

20

activity of Klenow enzyme. Briefly Tru9I digested DNA was dissolved in a solution (usually between 10-20  $\mu$ l in total) supplemented with T4 DNA ligase buffer (New England Biolabs; NEB) (1X) and 33  $\mu$ M of each of the required dNTPs, in this case dATP and dTTP. Klenow enzyme was added (1 unit Klenow enzyme (NEB) per  $\mu g$ of DNA) and the reaction incubated at 25°C for 15 minutes. The reaction was stopped by incubating the mix at 75°C for 20 minutes. EcoRV or Smal digested pTREP-nuc plasmid DNA was then added (usually between 200-400 ng). The mix was then supplemented with 400 units of T4 DNA ligase (NEB) and T4 DNA ligase buffer (1X) and incubated overnight at 16°C. The ligation mix was precipitated directly in 100% Ethanol and 1/10 volume of 3M sodium acetate (pH 5.2) and used to transform L. lactis MG1363 (Gasson, 1983). Alternatively, the gene cloning site of the pTREP-nuc vectors also contains a BglII site which can be used to clone for example Sau3AI digested genomic DNA fragments. L. lactis transformant colonies were grown on brain heart infusion agar and nuclease secreting (Nuc<sup>+</sup>) clones were detected by a toluidine blue-DNA-agar overlay (0.05 M Tris pH 9.0, 10 g of agar per litre, 10 g of NaCl per liter, 0.1 mM CaCl2, 0.03% wt/vol. salmon sperm DNA and 90 mg of Toluidine blue O dye) essentially as described by Shortle, 1983, supra and Le Loir et al., 1994, supra). The plates were

then incubated at  $37^{\circ}$ C for up to 2 hours. Nuclease secreting clones develop an easily identifiable pink halo. Plasmid DNA was isolated from Nuc<sup>+</sup> recombinant *L. lactis* clones and DNA inserts were sequenced on one strand using the NucSeq sequencing primer described in Appendix 1, which sequences directly through the DNA insert.

# 25 Isolation of Genes Encoding Exported Proteins from S. pneumoniae

A large number of gene sequences putatively encoding exported proteins in S. pneumoniae have been identified using the nuclease screening system. These have

10

15

20

25

now been further analysed to remove artefacts. The sequences identified using the screening system have been analysed using a number of parameters.

- 1. All putative surface proteins were analysed for leader/signal peptide sequences using the software programs Sequencher (Gene Codes Corporation) and DNA Strider (Marck, *Nucleic Acids Res.*, 16:1829-1836 (1988)). Bacterial signal peptide sequences share a common design. They are characterised by a short positively charged N-terminus (N region) immediately preceding a stretch of hydrophobic residues (central portion-h region) followed by a more polar C-terminal portion which contains the cleavage site (c-region). Computer software is available which allows hydropathy profiling of putative proteins and which can readily identify the very distinctive hydrophobic portion (h-region) typical of leader peptide sequences. In addition, the sequences were checked for the presence of or absence of a potential ribosomal binding site (Shine-Dalgarno motif) required for translation initiation of the putative nuc reporter fusion protein.
- 2. All putative surface protein sequences were also matched with all of the protein/DNA sequences using the publicly databases [OWL-proteins inclusive of SwissProt and GenBank translations]. This allows us to identify sequences similar to known genes or homologues of genes for which some function has been ascribed. Hence it has been possible to predict a function for some of the genes identified using the LEEP system and to unequivocally establish that the system can be used to identify and isolate gene sequences of surface associated proteins. We should also be able to confirm that these proteins are indeed surface related and not artifacts. The LEEP system has been used to identify novel gene targets for vaccine and therapy.
- 3. Some of the genes identified proteins did not possess a typical leader peptide sequence and did not show homology with any DNA/protein sequences in the database. Indeed these proteins may indicate the primary advantage of our screening method, i.e. the isolation of atypical surface-related proteins, which may

10

have been missed in all previously described screening protocols or approaches based on sequence homology searches.

In all cases, only partial gene sequences were initially obtained. Full length genes were obtained in all cases by reference to the TIGR S.pneumoniae database (www@tigr.org). Thus, by matching the originally obtained partial sequences with the database, we were able to identify the full length gene sequences. In this way, as described herein, three groups of genes were clearly identified, ie a group of genes encoding previously unidentified S.pneumoniae proteins, a second group exhibiting some homology with known proteins from a variety of sources and a third group which encoded known S.pneumoniae proteins, which were, however, not known as antigens.

## **Example 2: Vaccine trials**

15

# pcDNA3.1+ as a DNA vaccine vector

## pcDNA3.1+

20 The vector chosen for use as a DNA vaccine vector was pcDNA3.1 (Invitrogen) (actually pcDNA3.1+, the forward orientation was used in all cases but may be referred to as pcDNA3.1 here on). This vector has been widely and successfully employed as a host vector to test vaccine candidate genes to give protection against pathogens in the literature (Zhang, et al., Kurar and Splitter, Anderson et al.). The 25 vector was designed for high-level stable and non-replicative transient expression in mammalian cells. pcDNA3.1 contains the ColE1 origin of replication which allows convenient high-copy number replication and growth in E. coli. This in turn allows rapid and efficient cloning and testing of many genes. The pcDNA3.1 vector has a large number of cloning sites and also contains the gene encoding ampicillin 30 resistance to aid in cloning selection and the human cytomegalovirus (CMV) immediate-early promoter/enhancer which permits efficient, high-level expression of the recombinant protein. The CMV promoter is a strong viral promoter in a wide range of cell types including both muscle and immune (antigen presenting) cells. This is important for optimal immune response as it remains unknown as to which 35 cells types are most important in generating a protective response in vivo. A T7 promoter upstream of the multiple cloning site affords efficient expression of the

15

20

25

30

modified insert of interest and which allows in vitro transcription of a cloned gene in the sense orientation.

Zhang, D., Yang, X., Berry, J. Shen, C., McClarty, G. and Brunham, R.C. (1997)

"DNA vaccination with the major outer-membrane protein genes induces acquired immunity to *Chlamydia trachomatis* (mouse pneumonitis) infection". *Infection and Immunity*, 176, 1035-40.

Kurar, E. and Splitter, G.A. (1997) "Nucleic acid vaccination of *Brucella abortus* ribosomal *L7/L12* gene elicits immune response". *Vaccine*, **15**, 1851-57.

Anderson, R., Gao, X.-M., Papakonstantinopoulou, A., Roberts, M. and Dougan, G. (1996) "Immune response in mice following immunisation with DNA encoding fragment C of tetanus toxin". *Infection and Immunity*, **64**, 3168-3173.

## Preparation of DNA vaccines

Oligonucleotide primers were designed for each individual gene of interest derived using the LEEP system. Each gene was examined thoroughly, and where possible, primers were designed such that they targeted that portion of the gene thought to encode only the mature portion of the gene protein. It was hoped that expressing those sequences that encode only the mature portion of a target gene protein, would facilitate its correct folding when expressed in mammalian cells. For example, in the majority of cases primers were designed such that putative N-terminal signal peptide sequences would not be included in the final amplification product to be cloned into the pcDNA3.1 expression vector. The signal peptide directs the polypeptide precursor to the cell membrane via the protein export pathway where it is normally cleaved off by signal peptidase I (or signal peptidase II if a lipoprotein). Hence the signal peptide does not make up any part of the mature protein whether it be displayed on the surface of the bacteria surface or secreted. Where an N-terminal leader peptide sequence was not immediately obvious, primers were designed to target the whole of the gene sequence for cloning and ultimately, expression in pcDNA3.1.

- Having said that, however, other additional features of proteins may also affect the expression and presentation of a soluble protein. DNA sequences encoding such features in the genes encoding the proteins of interest were excluded during the design of oligonucleotides. These features included:
- 40 1. LPXTG cell wall anchoring motifs.
  - 2. LXXC ipoprotein attachment sites.
  - 3. Hydrophobic C-terminal domain.

- 4. Where no N-terminal signal peptide or LXXC was present the start codon was excluded.
- 5. Where no hydrophobic C-terminal domain or LPXTG motif was present the stop codon was removed.

Appropriate PCR primers were designed for each gene of interest and any and all of the regions encoding the above features was removed from the gene when designing these primers. The primers were designed with the appropriate enzyme restriction site followed by a conserved Kozak nucleotide sequence (in most cases(NB except in occasional instances for example ID59) GCCACC was used. The Kozak sequence facilitates the recognition of initiator sequences by eukaryotic ribosomes) and an ATG start codon upstream of the insert of the gene of interest. For example the forward primer using a BamH1 site the primer would begin GCGGGATCCGCCACCATG followed by a small section of the 5' end of the gene of interest. The reverse primer was designed to be compatible with the forward primer and with a Not1 restriction site at the 5' end in most cases (this site is TTGCGGCCGC) (NB except in occasional instances for example ID59 where a Xho1 site was used instead of Not1).

## 20 PCR primers

The following PCR primers were designed and used to amplify the truncated genes of interest.

25 ID5

5

10

15

Forward Primer 5'
CGGATCCGCCACCATGGGTCTAATTGAAGACTTAAAAAATCAA 3'
Reverse Primer 5' TTGCGGCCGCCAATGCTAGACTAAACACAAGACTCA 3'

ID59

30

35

Forward Primer 5' CGCGGATCCATGAAAAAAATCTATTCATTTTAGCA 3' Reverse Primer 5' CCCTCGAGGGCTACTTCCGATACATTTTAAACTGTAGG 3'

ID51

Forward Primer 5' CGGATCCGCCACCATGAGTCATGTCGCTGCAAATG 3'
Reverse Primer 5' TTGCGGCCGCATACCAAACGCTGACATCTACG 3'

**ID29** 

Forward Primer 5' CGGATCCGCCACCATGCAAAAAGAGCGGTATGGTTATG 3'

5 Reverse Primer 5' TTGCGGCCGCACCCCCATTCTTAATCCCTT 3'

ID50

Forward Primer 5'

CGGATCCGCCACCATGGAGGTATGTGAAATGTCACGTAAA 3'

Reverse Primer 5' TTGCGGCCGCTTTTACAAAGTCAAGCAAGCC 3'

## Cloning

15 The insert along with the flanking features described above was amplified using-PCR against a template of genomic DNA isolated from type 4 S. pneumoniae strain 11886 obtained from the National Collection of Type Cultures. The PCR product was cut with the appropriate restriction enzymes and cloned in to the multiple cloning site of pcDNA3.1 using conventional molecular biological techniques. Suitably mapped clones of the genes of interested were cultured and the plasmids isolated on a large scale (>1.5 mg) using Plasmid Mega Kits (Qiagen). Successful cloning and maintenance of genes was confirmed by restriction mapping and sequencing ~700 base pairs through the 5' cloning junction of each large scale preparation of each construct.

## Strain validation

25

A strain of type 4 was used in cloning and challenge methods which is the strain from which the S. pneumoniae genome was sequenced. A freeze dried ampoule of a homogeneous laboratory strain of type 4 S. pneumoniae strain NCTC 11886 was obtained from the National Collection of Type Strains. The ampoule was opened and the cultured re suspended with 0.5 ml of tryptic soy broth (0.5% glucose, 5% blood). The suspension was subcultured into 10 ml tryptic soy broth (0.5% glucose, 5% blood) and incubated statically overnight at 37°C. This culture was streaked on to 5% blood agar plates to check for contaminants and confirm viability and on to blood agar slopes and the rest of the culture was used to make 20% glycerol stocks. The slopes were sent to the Public Health Laboratory Service where the type 4 serotype was confirmed.

A glycerol stock of NCTC 11886 was streaked on a 5% blood agar plate and incubated overnight in a CO2 gas jar at 37°C. Fresh streaks were made and optochin sensitivity was confirmed.

# Pneumococcal challenge

A standard inoculum of type 4 *S. pneumoniae* was prepared and frozen down by passaging a culture of pneumococcus 1x through mice, harvesting from the blood of infected animals, and grown up to a predetermined viable count of around 10<sup>9</sup> cfu/ml in broth before freezing down. The preparation is set out below as per the flow chart.

10	Streak pneumococcal culture and confirm identity
	V V
15 .	Grow over-night culture from 4-5 colonies on plate above
20	Animal passage pneumococcal culture (i.p. injection of cardiac bleed to harvest)
25	Grow over-night culture from animal passaged pneumococcus
	V
30	Grow day culture (to pre-determined optical density) from over-night of anima passage and freeze down at -70°C - This is standard minimum
35	V
	Thaw one aliquot of standard inoculum to viable count
40	V V

Use standard inoculum to determine effective dose (called Virulence Testing)



All subsequent challenges - use standard inoculum to effective dose

An aliquot of standard inoculum was diluted 500x in PBS and used to inoculate the mice.

Mice were lightly anaesthetised using halothane and then a dose of  $1.4 \times 10^5$  cfu of pneumococcus was applied to the nose of each mouse. The uptake was facilitated by the normal breathing of the mouse, which was left to recover on its back.

## S. pneumoniae Vaccine trials

15

5

10

20

25

30

35

40

Vaccine trials in mice were carried out by the administration of DNA to 6 week old CBA/ca mice (Harlan, UK). Mice to be vaccinated were divided into groups of six and each group was immunised with recombinant pcDNA3.1+ plasmid DNA containing a specific target-gene sequence of interest. A total of 100  $\mu$ g of DNA in Dulbecco's PBS (Sigma) was injected intramuscularly into the tibialis anterior muscle of both legs (50  $\mu$ l in each leg). A boost was carried using the same procedure 4 weeks later. For comparison, control groups were included in all vaccine trials. These control groups were either unvaccinated animals or those administered with non-recombinant pcDNA3.1+ DNA (sham vaccinated) only, using the same time course described above. 3 weeks after the second immunisation, all mice groups were challenged intra-nasally with a lethal dose of S. pneumoniae serotype 4 (strain NCTC 11886). The number of bacteria administered was monitored by plating serial dilutions of the inoculum on 5% blood agar plates. A problem with intranasal immunisations is that in some mice the inoculum bubbles out of the nostrils, this has been noted in results table and taken account of in calculations. A less obvious problem is that a certain amount of the inoculum for each mouse may be swallowed. It is assumed that this amount will be the same for each mouse and will average out over the course of inoculations. However, the sample sizes that have been used are small and this problem may have significant effects in some experiments. All mice remaining after the challenge were killed 3 or 4 days after infection. During the infection process, challenged mice were monitored for the development of symptoms associated with the onset of S. pneumoniae induced-disease. Typical symptoms in an appropriate order included piloerection, an increasingly hunched posture, discharge from eyes, increased lethargy and reluctance to move. The latter symptoms usually coincided with the development of a moribund state at which stage the mice were culled to prevent further suffering. These mice were deemed to be very close to death, and the time of culling was used

to determine a survival time for statistical analysis. Where mice were found dead, the survival time was taken as the last time point when the mouse was monitored alive.

## 5 <u>Interpretation of Results</u>

10

15

A positive result was taken as any DNA sequence that was cloned and used in challenge experiments as described above which gave protection against that challenge. Protection was taken as those DNA sequences that gave statistically significant protection (to a 95% confidence level (p < 0.05)) and also those which were marginal or close to significant using Mann-Whitney or which show some protective features for example there were one or more outlying mice or because the time to the first death was prolonged. It is acceptable to allow marginal or non-significant results to be considered as potential positives when it is considered that the clarity of some of the results may be clouded by the problems associated with the administration of intranasal infections.

Trials 1-6 (see figure 1)

Results

31

ID51 (6) < 36.0 50.0 99.9T 50.0\* 53.6 8.89 99.9 24.4 59.4 control (6) Unvacc (101.2)\*T71.6\* 98.5 50.8 68.4 60.7 60.7 18.3 ID59 (5) 0.2862 55.3 8.69 98.0 58.5 55.3 53.5 98.0 control (5) Unvacc Mean survival times (hours) 58.0 48.0 12.5 75.0 46.7 58.0 75.0 60.1 ID59 (2) mouse died 0.006455.0 55.0 55.0 69.5 74.0 61.7 9.3 control (2) Unvace 49.0 51.0 49.0 55.0 49.0 49.0 50.3 2.4 mouse died ID5 (I) 0.25650.1722 61.0 59.7 61.0 57.0 72.0 47.5 8.8 3.1+(1)pcDNA 61.0 47.5 50.5 50.5 72.0 55.3 50.5 control (1) Unvace 47.5 57.0 55.6 47.5 47.5 77.0 57.0 p value 2 p value 1 number Mouse Mean ps

\* - bubbled when dosed so may not have received full inoculum.

T - terminated at end of experiment having no symptoms of infection.

Numbers in brackets - survival times disregarded assuming incomplete dosing

p value 1 refers to significance tests compared to unvaccinated controls

p value 2 refers to significance tests compared to pcDNA3.1+ vaccinated controls

## Statistical Analyses.

Trial 1 - None of the other groups had significantly longer survival times than the controls. The survival times of the unvaccinated and pcDNA3.1 control groups were not significantly different. One of the mice from ID5 was an outlying result and the mean survival times for ID5 were extended but not significantly so.

Trial 2 - The group vaccinated with ID59 had significantly longer survival times than the unvaccinated control group.

10 Trial 5 - The group vaccinated with ID59 again survived for an average of almost 10 hours longer than the controls but the results were not quite statistically significant.

Trial 6 - The group vaccinated with ID51 did not have survival times significantly higher than unvaccinated controls (p = < 36.0), however, there were 2 outlying mice in the vaccinated group.

15

5

# Vaccine trials 7 and 8 (See figure 2)

	Mean survival times (hours)						
Mouse number	Unvacc control (7)	ID29 (7)	Unvacc control (8)	ID50 (8)			
1	59.6	73.1	45.1	60.6			
2	47.2	54.8	50.8	60.6			
3	59.6	59.3	60.4	51.1			
4	70.9	54.8*	55.2	60.6			
5	68.6*	59.3	45.1	60.6			
6	76.0	54.8	45.1	60.6			
Mean	63.6	59.35	50.2	59.1			
sd	10.3	7.1	6.4	3.9			
p value 1	. •	< 39.0	-	0.0048			

<sup>\* -</sup> bubbled when dosed so may not have received full inoculum.

T - terminated at end of experiment having no symptoms of infection.

Numbers in brackets - survival times disregarded assuming incomplete dosing p value 1 refers to significance tests compared to unvaccinated controls

# Statistical Analyses.

Trial 7 - The ID29 vaccinated group showed prolonged times to the first death. T Trial 8 - The group vaccinated with ID50 survived significantly longer than unvaccinated controls.

# Appendix I - Oligonucleotide primers

nucS1

Bgl II Eco RV

5 5'- cgagatetgatatetcacaaacagataacggcgtaaatag -3'

nucS2

Bgl II Sma I

5'- gaagatetteeeegggateaeaaacagataacggegtaaatag -3'

10

nucS3

Bgl II Eco RV

5'- cgagatctgatatccatcacaaacagataacggcgtaaatag -3'

15 nucR

Bam HI

5'- cgggatccttatggacctgaatcagcgttgtc -3'

NucSeq

5'- ggatgctttgtttcaggtgtatc -3'

pTREPF

5'- catgatatcggtacctcaagctcatatcattgtccggcaatggtgtgggctttttttgttttagcggataa caatttcacac -3'

25

 $pTREP_R$ 

5'- geggateeeegggettaattaatgtttaaacaetagtegaagatetegegaatteteetgtgtgaaatt gttateegeta -3'

30 pUCF

5'- cgccagggttttcccagtcacgac -3'

 $V_{\mathbf{R}}$ 

5'- tcagggggggggggcctatg -3'

 $v_1$ 

35

5'- tcgtatgttgtgtggaattgtg -3'

 $V_2$ 

5'- tccggctcgtatgttgtgtggaattg -3'

#### TABLE 1

#### ID4 1200 bp

- 5 ATGAGAAATATGTGGGTTGTAATCAAGGAAACCTATCTTCGACATGTCGAGTCATGGAGTTTCTTCTTTATGGTGA TTTCGCCGTTCCTCTTTTAGGAATCTCTGTAGGAATTGGGCATCTCCAAGGTTCTTCTATGGCTAAAAATAATAA AGTGGCAGTAGTGACAACAGTGCCATCTGTAGCAGAAGGACTGAAGAATGTAAATGGTGTTAACTTCGACTATAA AGACGAAGCAAGTGCCAAAGAAGCAATTAAAGAAGAAAATTAAAAGGTTATTTGACCATTGATCAAGAAGATA 10 GTGTTCTAAAGGCAGTTTATCATGGCGAAACATCGCTTGAAAATGGAATTAAATTTGAGGTTACAGGTACACTCA ATGAACTGCAAAATCAGCTTAATCGTTCAACTGCTTCCTTGTCTCAAGAGCAGGAAAAACGCTTAGCGCAGACAA TTCAATTCACAGAAAAGATTGATGAAGCCAAGGAAAATAAAAAGTTTATTCAAACAATTGCAGCAGGTGCCTTAG GATTCTTTCTTTATATGATTCTGATTACCTATGCGGGTGTAACAGCTCAGGAAGTTGCCAGTGAAAAAGGCACCAA AATTATGGAAGTCGTTTTTCTAGCATAAGGGCAAGTCACTATTTCTATGCGCGGATGATGGCTCTGTTTCTAGTG 15. ATTTTAACGCATATTGGGATCTATGTTGTAGGTGGTCTGGCTGCCGTTTTGCTCTTTAAAGATTTGCCATTCTTGGC TCAGTCTGGTATTTTGGATCACTTGGGAGATGCTATCTCACTGAATACCTTGCTCTTTATTTTGATCAGTCTTTTCA TGTACGTAGTCTTGGCAGCCTTCCTAGGATCTATGGTTTCTCGTCCTGAGGACTCAGGGAAAGCCTTGTCGCCTTT GATGATTTTGATTATGGGTGGTTTTTTTGGAGTGACAGCTCTAGGTGCAGCTGGTGACAATCTCCTCTTGAAGATT GGTTCTTATATTCCCTTTATTTCGACCTTCTTTATGCCGTTTCGAACGATTAATGACTATGCGGGGGGGAGCAGAAG 20 CATGGATTTCACTTGCTATTACAGTGATTTTTGCGGTGGTAGCAACAGGATTTATCGGACGCATGTATGCTAGTCT
- MRNMWVVIKETYLRHVESWSFFFMVISPFLFLGISVGIGHLQGSSMAKNNKVAVVTTVPSVAEGLKNVNGVNFDYKD EASAKEAIKEEKLKGYLTIDQEDSVLKAVYHGETSLENGIKFEVTGTLNELQNQLNRSTASLSQEQEKRLAQTIQFTEKI DEAKENKKFIQTIAAGALGFFLYMILITYAGVTAQEVASEKGTKIMEVVFSSIRASHYFYARMMALFLVILTHIGIYVVG GLAAVLLFKDLPFLAQSGILDHLGDAISLNTLLFILISLFMYVVLAAFLGSMVSRPEDSGKALSPLMILIMGGFFGVTALG AAGDNLLLKIGSYIPFISTFFMPFRTINDYAGGAEAWISLAITVIFAVVATGFIGRMYASLVLQTDDLGIWKTFKRALSYK Z

CGTTCTTCAAACGGATGATTTAGGGATTTGGAAAACCTTTAAACGTGCCTTATCTTATAAATAG

## 30 <u>ID5 1125 bp</u>

- GAAAGTCTTCTCGTATCCATTGTAATCAGTGCATACAATGAAGAAAAATATCTGCCTGGTCTAATTGAAGACTTAA AAAATCAAACCTATCCTAAAGAGGATATTGAAATTCTATTTATAAATGCTATGTCCACAGATGGGACCACAGCTA 35 TCATTCAGCAATTTATAAAGGAAGATACAGAGTTTAACTCAATTAGATTGTATAACAATCCTAAGAAAAATCAAG TGAGACTTTTGTAATGAACAATGTGGCTATTATTCAACAAGGTGAATTTGTCTGTGGGGGGGCCTAGACCGACGATT GTCGAAGGAAAAGGAAAATGGGCAGAGACCTTGCATCTTGTTGAGGAAAATATGTTTGGCAGTAGCATTGCCAAT TATCGAAATAGTTCTGAGGATAGATATGTTTCTTCTATTTTTCATGGAATGTATAAACGAGAGGTTTTCCAGAAGG 40 TTGGTTTAGTAAATGAGCAACTTGGCCGAACTGAAGATAATGATATTCATTATAGAATTCGAGAATATGGTTATAA AATCCGCTATAGCCCAAGTATTCTATCTTATCAGTATATTCGACCAACATTCAAGAAAATGCTGCATCAAAAGTAT TCAAATGGTTTGTGGATTGGCTTGACAAGTCATGTTCAGTTTAAGTGTTTATCATTATTTCACTATGTTCCTTGTTT ATTTGTTTTGAGTCTTGTGTTTAGTCTAGCATTGTTACCGATCACATTCGTATTCATAACTTTACTATTAGGTGCCT ATTTTCTACTTTGTCATTACTCACTTTGCTGACTTTATTAAAACATAAAAATGGATTTCTAATTGTGATGCCCTTT 45 ATTTTATTTTCCATTCACTTTGCTTATGGCCTTGGGACGATTGTAGGTTTAATTAGAGGATTTAAATGGAAGAAGG
- PGKVLKIMIEWWKEKFRRVVVTQNVESLLVSIVISAYNEEKYLPGLIEDLKNQTYPKEDIEILFINAMSTDGTTAIIQQFIK
  EDTEFNSIRLYNNPKKNQASGFNLGVKHSVGDLILKIDAHSKVTETFVMNNVAIIQQGEFVCGGPRPTIVEGKGKWAET
  LHLVEENMFGSSIANYRNSSEDRYVSSIFHGMYKREVFQKVGLVNEQLGRTEDNDIHYRIREYGYKIRYSPSILSYQYIRP
  TFKKMLHQKYSNGLWIGLTSHVQFKCLSLFHYVPCLFVLSLVFSLALLPITFVFITLLLGAYFLLLSLLTLLTLLKHKNGF
  LIVMPFILFSIHFAYGLGTIVGLIRGFKWKKEYKRTIIYLDKISQINQNMLZ

#### ID11 696 bp

55

60

GGATACTCGTGTGAAACGTCCGGAAGATATCGAAAATACATTGCAGATGACACTTTTGGGAGTTGTGCCAAACTTGGGTAAGTTGAAATAG

MMKEQNTIEIDVFQLVKSLWKRKLMILIVALVTGAGAFAYSTFIVKPEYTSTTRIYVVNRNQGDKPGLTNQDLQAGTYL VKDYREIILSQDVLEEVVSDLKLDLTPKGLANKIKVTVPVDTRIVSISVNDRVPEEASRIANSLREVAAQKIISITRVSDVT TLEEARPAISPSSPNIKRNTLIGFLAGVIGTSVIVLHLELLDTRVKRPEDIENTLQMTLLGVVPNLGKLKZ

### ID19 555 bp

- ATCCTTGATGGTCACGTCAAGGAAACAGTAGTGGTAGATGGTCAGTTGACAACCAGTCGGGGTCCTTCAACA GCCCTTGCCTTTGCCTACGAGTTGGTGGAGCAACTAGGAGGGGACGCAGAGAGTTTACGAACAGGAATGCTCTAT CGAGATGTCTTTGGTAAAAATCAGTAA
- MVKVAVILAQGFEEIEALTVVDVLRRANITCDMVGFEEQVTGSHAIQVRADHVFDGDLSDYDMIVLPGGMPGSAHLR DNQTLIQELQSFEQEGKKLAAICAAPIALNQAEILKNKRYTCYDGVQEQILDGHYVKETVVVDGQLTTSRGPSTALAFA YELVEQLGGDAESLRTGMLYRDVFGKNQZ

#### ID27 306 bp

- - MVGMVEPNLESLIKDLYNHARHDLSEDLVAALLETTKKLPTTNEQLQAVRLSGLVNRELLLNPKHPAPELLNLARFVK REEAKYRGTATSALMYEELFKMLZ

# 35 <u>ID29 945 bp</u>

- MFLKKEREVISMRKWTKGFLIFGVVTTVIGFILLFVGIQSDGIKSLLSMSKEPVYDSRTEKLTFGKEVENLEITLHQHTLTI TDSFDDQIHISYHPSLSAHHDLITNQNDRTLSLTDKKLSETPFLSSGIGGILHIASSYSSRFEEVILRLPKGRTLKGINISANR GQTTIINASLENATLNTNSYILRIEGSRIKNSKLTTPNIVNIFDTVLTDSQLESTENHFHAENIQVHGKVELTAKDYLRIILD QKESQRINWDISSNYGSIFQFTREKPESRGTELSNPYKTEKTDVKDQLIARSDDNIDLISTPSRRZ

GATAATATTGATCTAATATCCACACCAAGCAGACGTTGA

## 55 <u>ID30 879 bp</u>

- 5 MKQEWFESNDFVKTTSKNKPEEQAQEVADKAEETIADLDTPIEKNTQLEEEVPQAEVELESQQEEKIEAPEDSEARTEIE EKKASNSTEEEPDLSKETEKVTIAEESQEALPQQKATTKEPLLISKSLESPYIPDQAPKSRDKWKEQVLDFWSWLVEAIKS PTSKLETSITHSYTAFLLLILFSASSFFFSIYHIKHAYYGHIASINSRFPEQLAPLTLFSIISILVATTLFFFSFLLGSFVVRRFIH QEKDWTLDKVLQQYSQLLAIPISSLLLLVSLLSLIAYDLQPSCVZ
- 10 ід 10105 990 ыр
- ACTGAAAAAACCGATGTCAAGGATCAACTCATTGCGAGATCTGATGATAATATTGATCTAATATCCACACCAAGC
  AGACGTTGA

  MQLASSVYSLFVWYNLFLKKEREVISMRKWTKGFLIFGVVTTVIGFILLFVGIQSDGIKSLLSMSKEPVYDSRTEKLTFG
  KEVENLEITLHQHTLTITIOSFDDQIHISYHPSLSAHHDLITNQNDRTLSLTDKKLSETPFLSSGIGGILHIASSYSSRFEEVIL
- RLPKGRTLKGINISANRGQTTIINASLENATLNTNSYILRIEGSRIKNSKLTTPNIVNIFDTVLTDSQLESTENHFHAENIQV HGKVELTAKDYLRIILDQKESQRINWDISSNYGSIFQFTREKPESRGTELSNPYKTEKTDVKDQLIARSDDNIDLISTPSRR Z

#### ID107 - 78bp

35 -

- MICKMKQGGSRACWGWRVGEGRCYFN

## ID109 714 bp

- DKEALSNLNLQIENGEIMGLIGHNGAGKSTTIKSLVSIISPSSGRILVDGQELSENRLAIKRKIGYVADSPDLFLRLTANEF WELIASSYDLSRSDLEASLARLLNVFDFAENRYQVIETLSHGMRQKVFVIGALLSDPDIWVLDEPLTGLDPQAAFDLKQ MMKEHAQKGKTVLFSTHVLEVAEQVCDRIAILKKGHLIYCGKVEDLRKDHPDQSLESIYLSLAGRKEEVADASQGHZ
- 60 <u>ID112 360 bp</u>

MALFSERGAVRKTPMASPIMRPMMVPTIEIKRVIPAPRKSCCQFSERILATWLKKLLLVSSVVVASAGCSLIIRSIKATWSS FEMVSMLALIWLIRLSFLRSPIAIAVSSSPVLKPGSTZ

5 ID 128 - 3.43

35

ATGAAATTTAGTAAAAAATATATAGCAGCTGGATCAGCTGTTATCGTATC CTTGAGTCTATGTGCCTATGCACTAAACCAGCATCGTTCGCAGGAAAATA AGGACAATAATCGTGTCTCTTATGTGGATGGCAGCCAGTCAAGTCAGAAA 10 AGTGAAAACTTGACACCAGACCAGGTTAGCCAGAAAGAAGGAATTCAGGC TGAGCAAATTGTAATCAAAATTACAGATCAGGGCTATGTAACGTCACACG GTGACCACTATCATTACTATAATGGGAAAGTTCCTTATGATGCCCTCTTT AGTGAAGAACTCTTGATGAAGGATCCAAACTATCAACTTAAAGACGCTGA TATTGTCAATGAAGTCAAGGGTGGTTATATCATCAAGGTCGATGGAAAAT 15 ATTATGTCTACCTGAAAGATGCAGCTCATGCTGATAATGTTCGAACTAAA GATGAAATCAATCGTCAAAAACAAGAACATGTCAAAGATAATGAGAAGGT TAACTCTAATGTTGCTGTAGCAAGGTCTCAGGGACGATATACGACAAATG ATGGTTATGTCTTTAATCCAGCTGATATTATCGAAGATACGGGTAATGCT TATATCGTTCCTCATGGAGGTCACTATCACTACATTCCCAAAAGCGATTT 20 TGCAACCGAGTCAGTTAAGCTATTCTTCAACAGCTAGTGACAATAACACG TCTCCAGAGTCTTTTGAAGGAACTCTATGATTCACCTAGCGCCCAACGTT ACAGTGAATCAGATGGCCTGGTCTTTGACCCTGCTAAGATTATCAGTCGT 25 ACACCAAATGGAGTTGCGATTCCGCATGGCGACCATTACCACTTTATTCC TTACAGCAAGCTTTCTGCCTTAGAAGAAAAGATTGCCAGAATGGTGCCTA TCAGTGGAACTGGTTCTACAGTTTCTACAAATGCAAAACCTAATGAAGTA GTGTCTAGTCTAGGCAGTCTTTCAAGCAATCCTTCTTTAACGACAAG TAAGGAGCTCTCTTCAGCATCTGATGGTTATATTTTTAATCCAAAAGATA 30 TCGTTGAAGAAACGCTACAGCTTATATTGTAAGACATGGTGATCATTTC CATTACATTCCAAAATCAAATTGGGCAACCGACTCTTCCAAACAA TAGTCTAGCAACACCTTCTCCATCTCTTCCAATCAATCCAGGAACTTCAC ATGAGAAACATGAAGAAGATGGATACGGATTTGATGCTAATCGTATTATC

MKFSKKYIAAGSAVIVSLSLCAYALNQHRSQENKDNNRVSYVDGSQSSQK
SENLTPDQVSQKEGIQAEQIVIKITDQGYVTSHGDHYHYYNGKVPYDALF
SEELLMKDPNYQLKDADIVNEVKGGYIIKVDGKYYVYLKDAAHADNVRTK
DEINRQKQEHVKDNEKVNSNVAVARSQGRYTTNDGYVFNPADIIEDTGNA
YIVPHGGHYHYIPKSDLSASELAAAKAHLAGKNMQPSQLSYSSTASDNNT
QSVAKGSTSKPANKSENLQSLLKELYDSPSAQRYSESDGLVFDPAKIISR
TPNGVAIPHGDHYHFIPYSKLSALEEKIARMVPISGTGSTVSTNAKPNEV
VSSLGSLSSNPSSLTTSKELSSASDGYIFNPKDIVEETATAYIVRHGDHF
HYIPKSNQIGQPTLPNNSLATPSPSLPINPGTSHEKHEEDGYGFDANRII
AEDESGFVMSHGDHNHYFFKKDLTEEQIKVRKNI\*

GCTGAAGATGAATCAGGTTTTGTCATGAGTCACGGAGACCACAATCATTA

TTTCTTCAAGAAGGACTTGACAGAAGAGCAAATTAAGGTGCGCAAAAACA

#### TABLE 2

#### ID2 840 bp

- ATTTGATGGATGATGTTGCTGAATATGCGAATCAAGTCTATGTAATGGAAAAGGGACGTTTAGTAAAGGGGGGCA AACCAAGTGATGTCTTTCAAGACGTTGTTTTTTATGGAAGAAGTTCAGTTGGGAGTACCTAAAATTACGGCCTTTTG TAAACGATTGGCTGATAGAGGCGTGTCATTTAAACGATTACCGATTAAGATAGAGGAGGTCCAAAA TGGATAG
- MGIALENVNFTYQEGTPLASAALSDVSLTIEDGSYTALIGHTGSGKSTILQLLNGLLVPSQGSVRVFDTLITSTSKNKDIR QIRKQVGLVFQFAENQIFEETVLKDVAFGPQNFGVSEEDAVKTAREKLALVGIDESLFDRSPFELSGGQMRRVAIAGILA MEPAILVLDEPTAGLDPLGRKELMTLFKKLHQSGMTIVLVTHLMDDVAEYANQVYVMEKGRLVKGGKPSDVFQDVV FMEEVQLGVPKITAFCKRLADRGVSFKRLPIKIEEFKESLNGZ

#### ID 3 6360 bp

- AGAAGATAAAGTTGTCTATATTGCTGAATTTAAAGATAAAGAATCTGGAGAAAAAGCAATCAAGGAACTATCCAG
  TCTTAAGAATACAAAAGTTTTATATACTTATGATAGAATTTTTAACGGTAGTGCCATAGAAACAACTCCAGATAAC
  TTGGACAAAATTAAACAAATAGAAGGTATTTCATCGGTTGAAAGGGCACAAAAAGTCCAACCCATGATGAATCAT
  GCCAGAAAGGAAATTGGAGTTGAGGAAGCTATTGATTACCTAAAGTCTATCAATGCTCCGTTTGGGAAAAATTTT
  GATGGTAGAGGTATGGTCATTTCAAATATCGATACTGGAACAGATTATAGACATAAGGCTATGAGAATCGATGAT
- GATGCCAAAGCCTCAATGAGATTTAAAAAAGAAGACTTAAAAAGCACTGATAAAAAATTATTGGTTGAGTGATAAA
  ATCCCTCATGCGTTCAATTATATATGGTGGCAAAATCACTGTAGAAAAATATGATGATGGAAGGGATTATTTTG
  ACCCACATGGGATGCATATTGCAGGGATTCTTGCTGGAAATGATACTGAACAAGACATCAAAAACTTTAACGGCA
  TAGATGGAATTGCACCTAATGCACAAATTTTCTCTTACAAAATGTATTCTGACGCAGGATCTGGGTTTGCGGGTGA
  TGAACAATGTTTCATGCTATTGAAGATTCTATCAAACACAACGTTGATGTTTTTCGGTATCATCTGTTTTACA

- TTCACTATAGGCGCAAATTCTAGCTTTGATTTGAATGCGGTTATAAATGTTGGAGAGGCCAAAAACAAAAATAAA
  TTTGTAGAATCATTTATTCATTTTGAGTCAGTGGAAGCGATGGAAGCTCTAAACTCCAGCGGGAAGAAAATAAAC
  TTCCAACCTTCTTTGTCGATGCCTCTAATGGGATTTGCTGGGAATTGGAACCACGAACCAATCCTTGATAAATGGG
  CTTGGGAAGAAGGGTCAAGATCAAAAACACTGGGAGGTTATGATGATGATGGTAAACCGAAAATTCCAGGAACCT
  TAAATAAGGGAATTGGTGGAGAACATGGTATAGATAAATTTAATCCAGCAGGAGTTATACAAAATAGAAAAGATA
  AAAATACAACATCCCTGGATCAAAATCCAGAATTATTTGCTTTCAATAACGAAGGGATCAACGCTCCATCATCAA
  GTGGTTCTAAGATTGCTAACATTTATCCTTTAGATTCAAATGGAAATCCTCAAGATGCTCAACTTGAAAGAGGATT

AAATCAAAGAGACTTAAAAGTCATTTCGAGAGAACACTTTATTAGAGGAATTTTAAATTCTAAAAGCAATGATGC AAAGGGAATCAAATCATCTAAAACTAAAAGTTTGGGGTGACTTGAAGTGGGATGGACTCATCTATAATCCTAGAGG TAGAGAAGAAATGCACCAGAAAGTAAGGATAATCAAGATCCTGCTACTAAGATAAGAGGTCAATTTGAACCGAT 5 TGCGGAAGGTCAATATTTCTATAAATTTAAATATAGATTAACTAAAGATTACCCATGGCAGGTTTCCTATATTCCT GTAAAAATTGATAACACCGCCCCTAAGATTGTTTCGGTTGATTTTTCAAATCCTGAAAAAATTAAGTTGATTACAA AGGATACTTATCATAAGGTAAAAGATCAGTATAAGAATGAAACGCTATTTGCGAGAGATCAAAAAGAACATCCTG AAAAATTTGACGAGATTGCGAACGAAGTTTGGTATGCTGGCGCCCCTCTTGTTAATGAAGATGGAGAGGTTGAAA AAAATCTTGAAGTAACTTACGCAGGTGAGGGTCAAGGAAGAAATAGAAAACTTGATAAAGACGGAAATACCATTT 10 ATGAAATTAAAGGTGCGGGAGATTTAAGGGGAAAAATCATTGAAGTCATTGCATTAGATGGTTCTAGCAATTTCA CAAAGATTCATAGAATTAAATTTGCTAATCAGGCTGATGAAAAGGGGGATGATTTCCTATTATCTAGTAGATCCTGA TCAAGATTCATCTAAATATCAAAAGCTTGGCGAGATTGCAGAATCTAAATTTAAAAATTTAGGAAATGGAAAAGA GGGTAGTCTAAAAAAAGATACAACTGGGGTAGAACATCATCATCAAGAAAATGAAGAGTCTATTAAAGAAAAAT CTAGTTTTACTATTGATAGAAATATTTCAACAATTAGAGACTTTGAAAAATAAAGACTTAAAGAAACTCATTAAAAA 15 GAAATTTAGAGAAGTTGATTTTACAAGTGAAACTGGTAAGAGAATGGAGGAATACGATTATAAATACGATGA TAAAGGAAATATAATAGCCTACGATGATGGGACTGATCTAGAATATGAAACTGAGAAACTTGACGAAATCAAATC AAAAATTTATGGTGTTCTAAGTCCGTCTAAAGATGGACACTTTGAAATTCTTGGAAAGATAAGTAATGTTTCTAAA AATGCCAAGGTATATTATGGGAATAACTATAAATCTATAGAAATCAAAGCGACCAAGTATGATTTCCACTCAAAA 20 TTGTTAAAGATAATGATCAGAAAAAGCTGAAATTAAAATTAGAATGCCTGAAAAAATTAAGGAAACTAAATCAG ÄTTTÄÄCTÄÄÄÄTTGGÄÄTCTGGTÄÄÄÄÄTCTATTCTGATTCAGAAAACAACAATATCTGTTAAAGGATAATATCAT TCTAAGAAAAGGCTATGCACTAAAAGTGACTACCTATAATCCTGGAAAAACGGATATGTTAGAAGGAAATGGAGT CTATAGCAAGGAAGATATAGCAAAAATACAAAAGGCCAATCCTAATCTAAGAGCCCTTTCAGAAACAACAATTTA 25 TGCTGATAGTAGAAATGTTGAAGATGGAAGAAGTACCCAATCTGTATTAATGTCGGCTTTGGACGGCTTTAACATT ATAAGGTATCAAGTGTTTACATTTAAAATGAACGATAAAGGGGAAGCTATCGATAAAGACGGAAATCTTGTGACA GATTCTTCTAAACTTGTATTATTTGGTAAGGATGATAAAGAATACACTGGAGAGGATAAGTTCAATGTAGAAGCTA TAAAAGAAGATGGCTCCATGTTATTTATTGATACCAAACCAGTAAACCTTTCAATGGATAAGAACTACTTTAATCC 30 AACTGGGAATTGAGAGTTAATGAATCGGTTGTAGATAATTATTTAATCTACGGAGATTTACACATTGATAACACTA GAGATTTTAATATTAAGCTGAATGTTAAAGACGGTGACATCATGGACTGGGGAATGAAAGACTATAAAGCAAACG GATTTCCAGATAAGGTAACAGATATGGATGGAAATGTTTATCTTCAAACTGGCTATAGCGATTTGAATGCTAAAGC AGTTGGAGTCCACTATCAGTTTTTATATGATAATGTTAAACCCGAAGTAAACATTGATCCTAAGGGAAATACTAGT ATCGAATATGCTGATGGAAAATCTGTAGTCTTTAACATCAATGATAAAAGAAATAATGGATTCGATGGTGAGATT. 35 CAAGAACAACATATTTATATAAATGGAAAAGAATATACATCATTTAATGATATTAAACAAATAATAGACAAGACA GGAGAGGTAAGTGAATTAAAACCTCATAGGGTAACTGTGACCATTCAAAATGGAAAAGAAATGAGTTCAACGATA GTGTCGGAAGAAGATTTTATTTTACCTGTTTATAAGGGTGAATTAGAAAAAGGATACCAATTTGATGGTTGGGAAA TTTCTGGTTTCGAAGGTAAAAAAGACGCTGGCTATGTTATTAATCTATCAAAAGATACCTTTATAAAACCTGTATT 40 GATTCAACTAAGGATGTTACAGCTACAGTTCTTGATAAAAACAATATCAGTAGTAAATCAACTACTAACAATCCT AATAAGTTGCCAAAAACTGGAACAGCAAGCGGAGCCCAGACACTATTAGCTGCCGGAATAATGTTTATAGTAGGA ATTTTTCTTGGATTGAAGAAAAAAAAAATCAAGATTAA 45 YPVVLADTSSSEDALNISDKEKVAENKEKHENIHSAMETSQDFKEKKTAVIKEKEVVSKNPVIDNNTSNEEAKIKEENSN KSQGDYTDSFVNKNTENPKKEDKVVYIAEFKDKESGEKAIKELSSLKNTKVLYTYDRIFNGSAIETTPDNLDKIKQIEGIS SVERAQKVQPMMNHARKEIGVEEAIDYLKSINAPFGKNFDGRGMVISNIDTGTDYRHKAMRIDDDAKASMRFKKEDL KGTDKNYWLSDKIPHAFNYYNGGKITVEKYDDGRDYFDPHGMHIAGILAGNDTEQDIKNFNGIDGIAPNAQIFSYKMY 50 SDAGSGFAGDETMFHAIEDSIKHNVDVVSVSSGFTGTGLVGEKYWQAIRALRKAGIPMVVATGNYATSASSSSWDLVA NNHLKMTDTGNVTRTAAHEDAIAVASAKNQTVEFDKVNIGGESFKYRNIGAFFDKSKITTNEDGTKAPSKLKFVYIGK GQDQDLIGLDLRGKIAVMDRIYTKDLKNAFKKAMDKGARAIMVVNTVNYYNRDNWTELPAMGYEADEGTKSQVFSI SGDDGVKLWNMINPDKKTEVKRNNKEDFKDKLEQYYPIDMESFNSNKPNVGDEKEIDFKFAPDTDKELYKEDIIVPAG STSWGPRIDLLLKPDVSAPGKNIKSTLNVINGKSTYGYMSGTSMATPIVAASTVLIRPKLKEMLERPVLKNLKGDDKIDL 55 TSLTKIALQNTARPMMDATSWKEKSQYFASPRQQGAGLINVANALRNEVVATFKNTDSKGLVNSYGSISLKEIKGDKK YFTIKLHNTSNRPLTFKVSASAITTDSLTDRLKLDETYKDEKSPDGKQIVPEIHPEKVKGANITFEHDTFTIGANSSFDLN AVINVGEAKNKNKFVESFIHFESVEAMEALNSSGKKINFQPSLSMPLMGFAGNWNHEPILDKWAWEEGSRSKTLGGYD DDGKPKIPGTLNKGIGGEHGIDKFNPAGVIQNRKDKNTTSLDQNPELFAFNNEGINAPSSSGSKIANIYPLDSNGNPQDA QLERGLTPSPLVLRSAEEGLISIVNTNKEGENQRDLKVISREHFIRGILNSKSNDAKGIKSSKLKVWGDLKWDGLIYNPRG 60 REENAPESKONQOPATKIRGQFEPIAEGQYFYKFKYRLTKOYPWQVSYIPVKIDNTAPKIVSVOFSNPEKIKLITKOTYHK VKDQYKNETLFARDQKEHPEKFDEIANEVWYAGAALVNEDGEVEKNLEVTYAGEGQGRNRKLDKDGNTIYEIKGAG DLRGKIIEVIALDGSSNFTKIHRIKFANQADEKGMISYYLVDPDQDSSKYQKLGEIAESKFKNLGNGKEGSLKKDTTGVE HHHQENEESIKEKSSFTIDRNISTIRDFENKDLKKLIKKKFREVDDFTSETGKRMEEYDYKYDDKGNIIAYDDGTDLEYE TEKLDEIKSKIYGVLSPSKDGHFEILGKISNVSKNAKVYYGNNYKSIEIKATKYDFHSKTMTFDLYANINDIVDGLAFAG 65 DMRLFVKDNDQKKAEIKIRMPEKIKETKSEYPYVSSYGNVIELGEGDLSKNKPDNLTKMESGKIYSDSEKQQYLLKDNII

LRKGYALKVTTYNPGKTDMLEGNGVYSKEDIAKIQKANPNLRALSETTIYADSRNVEDGRSTQSVLMSALDGFNIIRYQ VFTFKMNDKGEAIDKDGNLVTDSSKLVLFGKDDKEYTGEDKFNVEAIKEDGSMLFIDTKPVNLSMDKNYFNPSKSNKI YVRNPEFYLRGKISDKGGFNWELRVNESVVDNYLIYGDLHIDNTRDFNIKLNVKDGDIMDWGMKDYKANGFPDKVTD MDGNVYLQTGYSDLNAKAVGVHYQFLYDNVKPEVNIDPKGNTSIEYADGKSVVFNINDKRNNGFDGEIQEQHIYINGK EYTSFNDIKQIIDKTLNIKIVVKDFARNTTVKEFILNKDTGEVSELKPHRVTVTIQNGKEMSSTIVSEEDFILPVYKGELEK GYQFDGWEISGFEGKKDAGYVINLSKDTFIKPVFKKIEEKKEEENKPTFDVSKKKDNPQVNHSQLNESHRKEDLQREEH SQKSDSTKDVTATVLDKNNISSKSTTNNPNKLPKTGTASGAQTLLAAGIMFIVGIFLGLKKKNQDZ

#### ID6 597 bp

5

10

15

25

- 20 LELNKKRHATKHFTDKLVDPKDVRTAIEIATLAPSAHNSQPWKFVVVREKNAELAKLAYGSNFEQVSSAPVTIALFTDT DLAKRARKIARVGGANNFSEEQLQYFMKNLPAEFARYSEQQVSDYLALNAGLVAMNLVLALTDQGIGSNIILGFDKSK VNEVLEIEDRFRPELLITVGYTDEKLEPSYRLPVDEIIEKRZ

#### ID7 1401 bp

- ATGACAGCAATTGATTTTACAGCAGAAGTAGAAAAACGCAAAGAAGACCTCTTGGCTGACTTGTTTAGCCTTTTG
  GAAATCAATTCAGAACGTGATGACAGCAAGGCTGATGCCCAGCATCCATTTGGGCCTGGTCCAGTAAAAGCCTTG
  GAGAAATTCCTTGAAATCGCAGACCGCGATGGCTACCCAACTAAGAATGTTGATAACTATGCAGGACATTTTGAG
  TTTGGTGATGGAGAAAGATCTCGGAATCTTTGCCCATATGGATGTGGTGCCTGCTGGTAGCGGTTGGGACACAG
  ACCCTTACACACCAACTATCAAAGAATGTCGCCTTTATGCGCGGGGGCTTCGGACGATAAGGGTCCTACAACAG
  CTTGTTACTATGGTTTGAAAATCATCAAAGAAATTGGGTCTTCCAACTTCTAAGAAAGTTCGCTTCATCGTTTGAAC
  AGACGAAGAATCAGGCTGGGCAGACATGGACTACTACTTTTGAGCACGTAGGACTTGCCAAACCAGATTTCGGTTT
  CTCACCAGATGCTGAATTTCCAATCATCAATGGTGAAAAAAGGAAATATCACGGAATACCTCCACTTTTGCAGGAGA
  AAATACAGGTGTTGCCCGTCTTCACAGCTTTACAGGTGGTTTACGTGAAAATATGGTACCAGAATCAGCAACAGC
  AGTCGTTTCAGGTGACTTGGCAAGCTAAACTAGATGCCTTTTGTTGCAGAACACACAAACTTAGAGGAGA
  ACTCCAAGAAGAAGCTGGCAAAATACAAGGTGACCATTTGGTAAAATCAGCCCACGGTGCTATGCCTGCTTCAGG
- TGTCAATGGCGCAACTTACCTTGCCCTCTTCCTCAGCCAGTTTGGCTTTGCTGGTCCAGCCAAAGACTACCTTGAC
  ATCGCAGGTAAAATTCTCTTGAACGATCATGAGGGTGAAAATCTTAAGATTGCTCATGTGGATGAAAAGATGGGT
  GCTCTTTCTATGAATGCCGGCGTCTTCCACTTCGATGAAAACAAGTGCTGATAATACCATTGCCCTCAACATCCGCT
  ATCCAAAAGGAACAAGTCCAGAACAAATCAAGTCAATCCTTGAAAACTTGCCAGTTGTTTCTGTTTAGCCTGTCTGA
  ACACGGTCACACGCCTCACTATGTGCCAATGGAAGATCCACTTGTGCAAACCTTGTTGAAAATCTATGAAAAACA
  AACTGGCTTTAAAGGTCATGAACAAGTCATCGGTGGTGGAACCTTTGGTCGCTTGCTAGAACCGCGGAGTTGCCTA
  CGGTGCTATGTTCCCAGACTCGATTGATACCATGCACCAAGCCAATGAATTTATCGCCTTGGATGATCTTTTCCGA
- 45
  GCAGCAGCAATTTATGCCGAAGCTATTTACGAATTGATCAAATAA

  MTAIDFTAEVEKRKEDLLADLFSLLEINSERDDSKADAQHPFGPGPVKALEKFLEIADRDGYPTKNVDNYAGHFEFGD
  GEEVLGIFAHMDVVPAGSGWDTDPYTPTIKDGRLYARGASDDKGPTTACYYGLKIIKELGLPTSKKVRFIVGTDEESGW
  ADMDYYFEHVGLAKPDFGFSPDAEFPIINGEKGNITEYLHFAGENTGVARLHSFTGGLRENMVPESATAVVSGDLADL
  QAKLDAFVAEHKLRGELQEEAGKYKVTIIGKSAHGAMPASGVNGATYLALFLSQFGFAGPAKDYLDIAGKILLNDHEG
  ENLKIAHVDEKMGALSMNAGVFHFDETSADNTIALNIRYPKGTSPEQIKSILENLPVVSVSLSEHGHTPHYVPMEDPLVQ
  TLLNIYEKQTGFKGHEQVIGGGTFGRLLERGVAYGAMFPDSIDTMHQANEFIALDDLFRAAAIYAEAIYELIKZ

#### ID8 1617 bp

- MYTIIKSNIKKFSLLTIFIVAGQLLLIYAATINALVLNELIAMNLERFLKLSIYQMIVWCGIIFLDWVVKNYQVEVIQEFNL EIRNRVATDISNSTYQEFHSKSSGTYLSWLNNDVQTLNDQAFKQLFLVIKGISGTIFAVVTLNHYHWSLTVATLFSLMIM LLVPKIFASKMREVSLNLTNQNEAFLKSSETILNGFDVLASLNLLYVLPKKIKEAGILLKMVIQRKTTVETLAGAISFFLNI FFQISLVFLTGYLAIKGIVKIGTIEAIGALTGVIFTALGELGGQLSSIIGTKPIFLKLYSINPIESNKMNDIEPNEVNRDFPLYE AKNICYKYGDKEILKNLNFCFQRNEKYLILGESGSGKSTLLKLLNGFLRDYSGELRFCGDDIKKTSYLNMVSNVLYVDQ KAYLFEGTIRDNILLEENYTDEEILQSLEQVGLSVKDFPNNILDYYVGDDGRLLSGGQKQKITLARGLIRNKKIVLIDEGT SAIDRRTSLAIERKILDREDLTVIIVTHAPHPELKQYFTKIYQFPKDFIZ

#### ID9 705 bp

- 35 ITVKQIMDEIAVSDMTARRYLQELADKDLLIRVHGGAEKLRTNSLLTNERSNIEKQALQTAEKQEIAHFAGSLVEERETI FIGPGTTLEFFARELPIDNIRVVTNSLPVFLILSERKLTDLILIGGNYRDITGAFVGTLTLQNLSNLQFSKAFVSCNGIQNGA LATFSEEEGEAQRIALNNSNKKYLLADHSKFNKFDFYTFYNVSNLDTIVSDSKLSDSILFKLSKHIKVIKPZ

#### ID10 483 bp

**ACATTAAAGTCATCAAGCCTTAA** 

- 40 ATGACTGAGTTTTCGTTAGATCTTCTTCTAGAAGCCATTAAACTAGCTCGTTGGACCTACTACTATCACTTGAAAC
  AGCTAGACAAAACAGATAAAGACCAAGAGCTTAAAACTGAAATTCAATCCATCTTTATCGAACACAAGGGAAATT
  ATGCTTATCGCCGGGTTCATTTAGAACTAAGAAATCGTGGTTATCTGGTAAATCATAAAAGAGTTCAAGGCTTG2T
  GAAAGTACTCAATTTACAAGCCAAATTGGAAGACGAAAATATTCTTCTCATAAAGGAGACGTTGGTAAGAA
  GGCAGAGAATCTCATTCAAGCCCAATTTGAAGGCTCTAAAACAATGGAAAAGTGCTACACAGATGTGACTGAATT
  TGCCATTCCAGCAAGTACTCAAAAGCTTTACTTATCACCAGTTTTAGATGGCTTTAACAGCGAAATTATTGCTTTT
  AATCTTTCTTGTTCGCCTAATTTAGAATAA
- MTEFSLDLLLEAIKLARWTYYYHLKQLDKTDKDQELKTEIQSIFIEHKGNYAYRRVHLELRNRGYLVNHKRVQGLMK VLNLQAKMRKKRKYSSHKGDVGKKAENLIQAQFEGSKTMEKCYTDVTEFAIPASTQKLYLSPVLDGFNSEIIAFNLSCS PNLEZ

## ID14 1266 bp

. 65

GTCTTTGTAGAATCTATCGGTATTGGTGAGTCTATGTACTACGGACCAGGTGCGGGTCAAAAACCAACTGCAACA

10

PGFGTVASGVPFLLKENGGKINQSAHSDIKVAKVLVKDEDEKNRLLAAGNDFNFVTNVDDILSDQDITIVVELMGRIEP AKTFITRALEAGKHVVTANKDLLAVHGAELLEIAQANKVALYYEAAVAGGIPILRTLANSLASDKITRVLGVVNGTSNF MVTKMVEEGWSYDDALAEAQRLGFAESDPTNDVDGIDAAYKMVILSQFAFGMKIAFDDVAHKGIRNITPEDVAVAQE LGYVVKLVGSIEETSSGIAAEVTPTFLPKAHPLASVNGVMNAVFVESIGIGESMYYGPGAGQKPTATSVVADIVRIVRRL NDGTIGKDFNEYSRDLVLANPEDVKANYYFSILALDSKGQVLKLAEIFNAQDISFKQILQDGKEGDKARVVIITHKINKA QLENVSAELKKVSEFDLLNTFKVLGEZ

#### ID16 1725 bp

15 ATGAAACACCTATTATCTTACTTCAAACCCTACATCAAGGAATCAATTTTAGCCCCCTTGTTCAAGCTGTTAGAAG CTGTTTTTGAGCTCTTGGTTCCCATGGTGATTGCTGGGATTGTTGACCAATCTTTACCTCAGGGAGATCAAGGTCA TCTCTGGATGCAGATTGGCCTGCTCCTTATCTTTGCAGTAATTGGCGTTTTAGTGGCCTTGATAGCTCAATTTTACT CAGCAAAGGCAGCAGTAGGTTCTGCTAAGGAATTGACAAACGATCTTTATCGTCATATTCTTTCCTTGCCCAAGGA 20 AATCAATTCCTGCGTCTCTTTTTACGAGCGCCCATTATCGTTTTTTGGTGCCATTTTTATGGCTTATCGAATCTCAGC TGAGTTGACTTTCTGGTTCTTAGTCTTGGTTGCCATTTTGACCATTGTCATTGTAGGGTTATCTCGATTGGTCAATC CTTTCTACAGTAGTCTCAGAAAGAAAACGGACCAACTGGTTCAGGAAACGCGCCAGCAATTGCAAGGGATGCGG TTATTCGTGCTTTTGGTCAAGAAAAACGAGAGTTACAGATTTTTCAAACCCTTAACCAAGTTTATGCTAGATTACA 25 AGAAAAGACAGGTTTCTGGTCTAGTTTATTAACACCTCTGACCTATCTGATTGTCAATGGAACTCTTCTCGTTATT ATCTGGCAAGGCTATATTTCAATTCAAGGAGGAGTGCTCAGTCAAGGTGCTCTCATTGCTCTTATCAATTACCTCT TACAGATTTTGGTGGAATTGGTCAAGCTAGCCATGTTGATCAATTCCCTCAACCAGTCCTATATCTCAGTCAAGCG GGTTTTACAAGTCCAAGAATTGACCTTTACCTATCCTGATGCGGCCCAGCCTTCTCTGAGATACATTTCCTTTGAT 30 ATGACTCAAGGACAAATTCTAGGTATCATCGGGGGAACTGGTTCTGGTAAATCAAGCTTTGGTGCAACTCTTACTTG GACTTTATCCAGTAGACAAGGGGAACATTGACCTTTATCAAAATGGACGTAGTCCTCTTAATTTGGAGCAGTGGC GGTCTTGGATTGCCTATGTACCTCAAAAGGTCGAACTCTTTAAAGGAACCATTCGTTCCAACTTGACTCTAGGTTT CAATCAAGAAGTATCTGACCAGGAACTCTGGCAGGCCTTGGAGATTTGCGCAAGCTAAGGATTTTGTCAGTGAAAA 35 CGCCCGAGCAGTCTTGCGCCAGGCTCCGTTTCTCATCCTAGATGATGCAACCTCGGCACTGGATACCATTACAGAG TCCAAGCTCTTGAAAGCTATTAGAGAAAATTTTCCAAACACGAGCTTAATTTTGATCTCTCAACGAACCTCAACTT TACAGATGGCGGACCAGATTCTCCTCTTGGAAAAAGGTGAGTTGCTAGCTGTTGGCAAGCACGATGACTTGATGA AATCCAGCCAAGTCTATTGTGAAATCAATGCATCCCAACATGGAAAGGAGGACTAG

40 mkhllsyfkpyikesilaplfklleavfellvpmviagivdqslpqgdqghlwmqiglllifavigvlvaliaqfysaka avgsakeltndlyrhilslpkdsrdrlttsslvtrltsdtyqiqtginqflrlflrapiivfgaifmayrisaeltfwflvl vailtivivglsrlvnpfysslrkktdqlvqetrqqlqgmrvirafgqekrelqifqtlnqvyarlqektgfwsslltpl tylivngtllviiwqgyisiqggvlsqgalialinyllqilvelvklamlinslnqsyisvkrieevfveapedihseleqkq atrdkvlqvqeltftypdaaqpslryisfdmtqgqilgiiggtgsgksslvqllglypvdkgnidlyqngrsplnleq wrswiayvpqkvelfkgtirsnltlgfnqevsdqelwqaleiaqakdfvsekeglldalveaggrnfsggqkqrlsia ravlrqapflilddatsaldtiteskllkairenfpntslilisqrtstlqmadqilllekgellavgkhddlmkssqvyc einasqhgkedz

#### ID18 1224 bp

50

ATGAAACGTTCTCTCGACTCAAGAGTCGATTACAGTTTGCTCTTGCCAGTATTTTTTCTACTGGTCATCGGTGTGGT GGCTATCTATATAGCCGTTAGTCATGATTATCCCAATAATATTCTGCCCATTTTAGGGCAGCAGGTCGCCTGGATT GCCTTGGGGCTTGTGATTGGTTTTGTGGTCATGCTCTTTAATACAGAATTTCTTTTGGAAGGTGACCCCCTTTCTATA TATTTTAGGCTTGGGACTTATGATCTTGCCGATTGTATTTTATAATCCAAGCTTAGTTGCATCAACGGGTGCCAAA 55 AACTGGGTATCAATAAATGGAATTACCCTATTCCAACCGTCAGAATTTATGAAGATATCCTATATCCTCATGTTGG CTCGTGTCATTGTCCAATTTACAAAGAAACATAAGGAATGGAGACGCACGGTTCCGCTGGACTTTTTGTTAATTTT CTGGATGATTCTCTTTACCATTCCAGTCCTAGTTCTTTTAGCACTTCAAAGTGACTTGGGGACGGCTTTGGTTTTTG TAGCCATTTTCTCAGGAATCGTTTTATTATCAGGGGTTTCTTGGAAAATTATTATCCCAGTATTTGTGACTGCTGTA 60 CCTACCAAATTAATCGGATTTTGGCTTGGCTCAATCCCTTTGAGTTTGCCCAAACAACGACTTACCAGCAGGCTCA AGGGCAGATTGCCATTGGGAGTGGTTGTTTTGGTCAGGGATTTAATGCTTCGAATCTGCTTATCCCAGTTCGA GAGTCAGATATGATTTTTACGGTTATTGCAGAAGATTTTGGCTTTATTGGCTCTGTCCTGGTTATTGCCCTCTATCT CATGTTGATTTACCGTATGTTGAAGATTACTCTTAAATCAAATAACCAGTTCTACACTTATATTTCCACAGGTTTGA TTATGATGTTGCTCTTCCACATCTTTGAGAATATCGGTGCTGTGACTGGACTACTTTCCTTTGACGGGGATTCCCTTG 65 CCTTTCATTTCGCAAGGGGGATCAGCTATTATCAGTAATCTGATTGGTTTGGTTTTGCTTTTATCGATGAGTTACCA GACTAATCTAGCTGAAGAAAAGAGCGGAAAAGTCCCATTCAAACGGAAAAAGGTTGTATTAAAACAAATTAAATAA

- MKRSLDSRVDYSLLLPVFFLLVIGVVAIYIAVSHDYPNNILPILGQQVAWIALGLVIGFVVMLFNTEFLWKVTPFLYILGL GLMILPIVFYNPSLVASTGAKNWVSINGITLFQPSEFMKISYILMLARVIVQFTKKHKEWRRTVPLDFLLIFWMILFTIPVL VLLALQSDLGTALVFVAIFSGIVLLSGVSWKIIIPVFVTAVTGVAGFLAIFISKDGRAFLHQIGMPTYQINRILAWLNPFEF AQTTTYQQAQGQIAIGSGGLFGQGFNASNLLIPVRESDMIFTVIAEDFGFIGSVLVIALYLMLIYRMLKITLKSNNQFYTY ISTGLIMMLLFHIFENIGAVTGLLPLTGIPLPFISQGGSAIISNLIGVGLLLSMSYQTNLAEEKSGKVPFKRKKVVLKQIKZ
- 10 <u>ID22 987 bp</u>
- ATGGTGGCTAAGAAAAAAATCTTATTTTTATGTGGTCTTTTTCTCTTGGAGGTGGTGCAGAGAAGATTCTATCAA CCATTGTTTCAAATCTGGATCCAGAAAAGTATGATATTGATATTCTTGAAATGGAGCACTTTGACAAGGGATATGA ATCTGTTCCAAAGCATGTACGCATTTTAAAATCCCTTCAAGATTATCGCCAAACCAGATGGTTACGAGCTTTTTTG 15 TGGAGAATGAGAATTTATTTTCCAAGACTGACTCGTCGTTTGCTTGTAAAAGATGATTATGATGTTGAAGTTTCTT TTACCATTATGAATCCACCACTGTTGTTCTCTAAAAGAAGAGAAGTCAAGAAGATATCTTGGATTCATGGAAGTAT TGAAGAACTTCTTAAGGATAGCTCTAAAAGAGAATCACATAGAAGCCAGTTGGATGCTGCGAATACAATTGTAGG GATTTCAAAAAAGACCAGCAATTCTATCAAGGAAGTTTATCCAGATTATACTTCTAAATTACAGACAATCTACAAT GGATATGATTTTCAGACTATTCTAGAAAAATCTCAAGAGAAGATCGATATCGAGATTGCTCCTCAAAGTATCTGTA 20 CTATCGGACGGATTGAGGAAAATAAGGGTTCTGACCGTGTAGTGGAAGTGATACGATTATTACACCAAGAGGGAA AAAACTATCATCTCTATTTTATCGGGGCTGGTGATATGGAAGAGGAACTGAAAAAACGAGTCAAAGAGTATGGGA ATGTCTAAACAAGAAGGTTTTCCTGGAGTGTATGTGGAGGCCTTGAGTCTGGGACTCCCTTTTATCTCTACGGACG TTGGAGGGGCTGAGGAATTATCCCAAGAAGGACGATTTGGACAAATCATTGAGAGCAATCAAGAGGCAGCTCAG 25 TTACAAAACAAATCGAACAAGTAGAAAAAACTATTAGAGGAGTAG
- MVAKKKILFFMWSFSLGGGAEKILSTIVSNLDPEKYDIDILEMEHFDKGYESVPKHVRILKSLQDYRQTRWLRAFLWRM RIYFPRLTRRLLVKDDYDVEVSFTIMNPPLLFSKRREVKKISWIHGSIEELLKDSSKRESHRSQLDAANTIVGISKKTSNSIK EVYPDYTSKLQTIYNGYDFQTILEKSQEKIDIEIAPQSICTIGRIEENKGSDRVVEVIRLLHQEGKNYHLYFIGAGDMEEEL KKRVKEYGIEDYVHFLGYQKNPYQYLSQTKVLLSMSKQEGFPGVYVEALSLGLPFISTDVGGAEELSQEGRFGQIIESNQ EAAQAITNYMTSASNFDVDEASQFIQQFTITKQIEQVEKLLEEZ
- 35 ID23 1434 bp
- ATGGAAACTGCATTAATTAGTGTGATTGTGCCAGTCTATAATGTGGCGCAGTACCTAGAAAAATCGATAGCTTCCA TTCAGAAGCAGACCTATCAAAATCTGGAAATTATTCTTGTTGATGATGGTGCAACAGATGAAAGTGGTCGCTTGTG TGATTCAATCGCTGAACAAGATGACAGGGTGTCAGTGCTTCATAAAAAGAACGAAGGATTGTCGCAAGCACGAAA 40 CAGAGCTTATATGAGCAATTAGTTCAAGAAGATGCGGATGTTTCGAGCTGTGGTGTCATGAATGTCTAATG ATGAAAGCCCACAGTCAGCCAATCAGGATGACTATTTTGTCTGATTCTCAAACATTTCTAAAGGAATACCTCAT AGGTGAAAAAATACCTGGGACGATTTGCAATAAGCTAATCAAGAGACAGATTGCAACTGCCCTATCCTTTCCTAA GGGGTTGATTTACGAAGATGCCTATTACCATTTTGATTTAATCAAGTTGGCCAAGAAGTATGTGGTTAATACTAAA CCCTATTATTACTATTTCCATAGAGGGGATAGTATTACGACCAAACCCTATGCAGAGAAGGATTTAGCCTATATTG 45 ATATCTACCAAAAGTTTTATAATGAAGTTGTGAAAAACTATCCTGACTTGAAAGAGGTCGCTTTTTTTCAGATTGGC CTATGCCCACTTCTTTATTCTGGATAAGATGTTGCTAGATGATCAGTATAAACAGTTTGAAGCCTATTCTCAGATT CATCGTTTTTTAAAAGGCCATGCCTTTGCTATTTCTAGGAATCCAATTTTCCGTAAGGGGAGAAGAATTAGTGCTT TGGCCCTATTCATAAATATTTCCTTATATCGATTCTTATTACTGAAAAATATTGAAAAAATCTAAAAAATTACATTA 50
- METALISVIVPYNVAQYLEKSIASIQKQTYQNLEIILVDDGATDESGRLCDSIAEQDDRVSVLHKKNEGLSQARNDGM KQAHGDYLIFIDSDDYIHPEMIQSLYEQLVQEDADVSSCGVMNVYANDESPQSANQDDYFVCDSQTFLKEYLIGEKIPG TICNKLIKRQIATALSFPKGLIYEDAYYHFDLIKLAKKYVVNTKPYYYYFHRGDSITTKPYAEKDLAYIDIYQKFYNEVV KNYPDLKEVAFFRLAYAHFFILDKMLLDDQYKQFEAYSQIHRFLKGHAFAISRNPIFRKGRRISALALFINISLYRFLLLK NIEKSKKLHZ

## ID24 735bp

MRIKEKTNNINGGIKNVSKHYGHSIILKDINFALNKGEIVGLAGRNGVGKSTLMKILVQNNQPTSGNIISSDNVGYLIEEP KLFLSKTGLENLKYLSNLYGVDYNQERFRCLIQELDLTQSINKKVKTYSLGTKQKLALLLTLVTEPDILILDEPTNGLDIE SSQIVLAVLKKLALHENVGILISSHKLEDIEEICERVLFLENGLLTFQKVGKDSHNFLFEIAFSSATDRDIFITKQEFWDIVZ

## 10 <u>ID25 1704bp</u>

5

ATGACTGAATTAGATAAACGTCACCGCAGTAGCATTTATGACAGCATGGTTAAATCACCTAACCGTGCTATGCTTC GTGCGACTGGTATGACAGATAAGGACTTTGAAACATCGATTGTGGGAGTGATTTCGACTTGGGCGGAAAATACAC CATGTAACATTCACTTGCATGATTTCGGGAAACTGGCTAAAGAAGGTGTCAAATCTGCAGGCGCTTGGCCTGTAC 15 AGTTTGGAACCATTACCGTAGCGGACGGGATCGCTATGGGAACGCCTGGTATGCGTTTCTCTCTAACATCTCGTGA CATCATCGCGGACTCCATCGAGGCGGCTATGAGTGGTCACAACGTGGATGCCTTCGTCGCTATCGGTGGCTGTGA CAAGAACATGCCTGGATCTATGGTTGCTATTGCTAATATGGATATCCCAGCTATTTTCGCCTATGGTGGAACTATT GCACCGGGAAATCTTGATGGTAAAGATATCGACTTGGTTTTCTGTCTTTTGAAGGTATCGGAAAATGGAACCACGGT 20 ACTGCTAATACCATGGCAACTGCTATCGAAGTTCTAGGGATGAGTTTTGCCAGGGTCATCCTCTCACCCAGCTGAAT CAGCTGATAAGAAAGAAGATATCGAAGCAGCAGGACGTGCTGTTGTTAAGATGTTGGAACTTGGTCTCAAACCAT CAGATATCTTGACTCGTGAAGCCTTTGAAGATGCTATCACTGTAACGATGGCTCTCGGTGGTTCTACAAACGCCAC TCTTCACTTGCTCGCCATTGCCCATGCCGCAAATGTTGACTTGTCACTTGAGGACTTCAATACGATTCAAGAACGT GTGCCTCACTTGGCCGACTTGAAACCATCTGGTCAGTATGTCTTCCAAGACCTCTACGAAGTCGGTGGTGTCCCTG 25 CGGTTATGAAGTATTTGTTGGCAAATGGTTTCCTTCACGGAGATCGCATCACATGTACTGGTAAGACTGTAGCTGA AAACTTGGCTGACTTTGCAGACTTGACTCCAGGCCAAAAAGTTATCATGCCACTTGAAAATCCAAAACGTGCGGA TGGTCCGCTTATCATCTTGAACGGGAACCTTGCTCCTGACGGTGCAGTTGCCAAGGTATCAGGTGTTAAAGTGCGT CGTCACGTTGGGCCAGCTAAGGTCTTTGACTCAGAAGAAGATGCGATTCAGGCCGTTCTGACAGATGAAATCGTT

MTELDKRHRSSIYDSMVKSPNRAMLRATGMTDKDFETSIVGVISTWAENTPCNIHLHDFGKLAKEGVKSAGAWPVQFG
TITVADGIAMGTPGMRFSLTSRDIIADSIEAAMSGHNVDAFVAIGGCDKNMPGSMIAIANMDIPAIFAYGGTIAPGNLDG
KDIDLVSVFEGIGKWNHGDMTAEDVKRLECNACPGPGGCGGMYTANTMATAIEVLGMSLPGSSSHPAESADKKEDIE
AAGRAVVKMLELGLKPSDILTREAFEDAITVTMALGGSTNATLHLLAIAHAANVDLSLEDFNTIQERVPHLADLKPSGQ
YVFQDLYEVGGVPAVMKYLLANGFLHGDRITCTGKTVAENLADFADLTPGQKVIMPLENPKRADGPLIILNGNLAPDG
AVAKVSGVKVRRHVGPAKVFDSEEDAIQAVLTDEIVDGDVVVVRFVGPKGGPGMPEMLSLSSMIVGKGQGDKVALLT
DGRFSGGTYGLVVGHIAPEAQDGGPIAYLRTGDIVTVDQDTKEISMAVSEEELEKRKAETTLPPLYSRGVLGKYAHIVSS

## 45 <u>ID26 274bp</u>

50

ASRGAVTDFWNMDKSGKKZ-

ATGTTATAATAAAAATAAAGAATTTAAGGAGAAATACAATATGTCAATTTTTATTGGAGGAGCATGGCCATATGC AAACGGTTCGTTACATATTGGTCACGCGCGCAGCGCTTTTACCGGGGGGATATTCTTGCAAGATACTATCGTCAGAA GGGAGAGGAAGTTTTATATGTTTCTGGAAGTGATTGTAATGGAACCCCTATTTCTATCAGAGCTAAAAAAGAAAA TAAGTCTGTGAAAGAAATTGCTGATTTTTATCATAAGGAATTTAATCCA

CYNKNKEFKEKYNMSIFIGGAWPYANGSLHIGHAAALLPGDILARYYRQKGEEVLYVSGSDCNGTPISIRAKKENKSVK EIADFYHKEFNP

## 55 <u>ID28 1065bp</u>

TGACCCAGAAGTCTTCCTCGCAGTTGATTGCTCACCAGCAGGTGATGTCTACGGTGGTCAAGGCAAGATTGGAGA
TGGAACCTTGATTCGTTTCTATGATCCAGGTCACTTGCTTCTCCCAGGGATGAAGGATTTCCTTTTGACAACGGCT
GAAGAAGCTGGTATCAAGTACCAATACTACTGTGGTAAAGGCGGAACAGATGCAGGTGCAGCTCATCTGAAAAAT
GGTGGTGTCCCATCAACAACTATCGGTGTCTGCGCTCGTTATATCCATTCTCACCAAACCCTCTATGCAATGGATG
ACTTCCTAGAAAGCGCAAGCTTTCTTACAAGCCTTGGTGAAGAAATTGGATCGTTCAACGGTTGATTTGATTAAACA
TTATTAA

MTTLFSKIKEVTELAAVSGHEAPVRAYLREKLTPHVDEVVTDGLGGIFGIKHSEAVDAPRVLVASHMDEVGFMVSEIKP DGTFRVVEIGGWNPMVVSSQRFKLLTRDGHEIPVISGSVPPHLTRGKGGPTMPAIADIVFDGGFADKAEAESFGIRPGDT IVPDSSAILTANEKNIISKAWDNRYGVLMVSELAEALSGQKLGNELYLGSNVQEEVGLRGAHTSTTKFDPEVFLAVDCS PAGDVYGGQGKIGDGTLIRFYDPGHLLLPGMKDFLLTTAEEAGIKYQYYCGKGGTDAGAAHLKNGGVPSTTIGVCARY IHSHQTLYAMDDFLEAQAFLQALVKKLDRSTVDLIKHYZ

## ID31 1182bp

- 15 ATGGAATTITCTATGAAATCAGTCAAAGGACTACTCTTTATCATAGCTAGTTTTATCTTGACTCTTTTTGACTTGGAT GAACACTTCTCCCCAATTCATGATTCCAGGACTAGCTTTAACAAGCCTATCTCTGACTTTTATCCTAGCCACTCGT CTCCCACTACTAGAAAGCTGGTTTCACAGTTTTGGAGAAGGTCTACACCGTCCACAAATTCACAGCCTTTCTCAA TCATCCTACTAATCTTTCATAACTTTAGTATGGGCGGTTTGTGGGGGCTCTCGCTTAGCTGCTCAGTTTGGCAATCTT 20 GCCATCTATATCTTTGCCAGCATCATCCTTGTCGCCTATTTAGGCAAATACATCCAATACGAAGCTTGGCGATGGA T<u>TCACCGCCTGGTTTACCTAGCCT</u>ATATTTTAGGACTCTTTCACATCTACATGATAATGGGCAATCGTCTCACA TTTAATCTTCTAAGTTTTCTTGGTAGCTATGCCCTTTTAGGCTTACTAGCTGGTTTTTATATCATTTTTCTATAT CAAAAGATTTCCTTCCCCTATCTAGGGAAAATTACCCATCTCAAACGCTTAAATCACGATACTAGAGAAATTCAA ATCCATCTTAGCAGACCTTTCAACTATCAATCAGGACAATTTGCCTTTCTAAAGATTTTCCAAGAAGGCTTTGAAA 25 GTGCTCCGCATCCCTTTTCTATCTCAGGAGGTCATGGTCAAACTCTTTACTTTACTGTTAAAACTTCAGGCGACCA TACCAAGAATATCTATGATAATCTTCAAGCCGGCAGCAAAGTAACCCTAGACAGAGCTTACGGACACATGATCAT AGAAGAAGGACGAGAAAATCAGGTTTGGATTGCTGGAGGTATTGGGATCACCCCCTTCATCTCTTACATCCGTGA ACATCCTATTTTAGATAAACAGGTTCACTTCTACTATAGCTTCCGTGGAGATGAAAATGCAGTCTACCTAGATTTA CTCCGTAACTATGCTCAGAAAAATCCTAATTTTGAACTCCATCTAATCGACAGTACGAAAGACGGCTATCTTAATT 30 TTGAACAAAAAGAAGTGCCCGAACATGCAACCGTCTATATGTGTGGTCCTATTTCTATGATGAAGGCACTTGCCA AACAGATTAAGAAACAAAATCCAAAAACAGAGCATATTTAC
- MEFSMKSVKGLLFIIASFILTLLTWMNTSPQFMIPGLALTSLSLTFILATRLPLLESWFHSLEKVYTVHKFTAFLSIILLIFH NFSMGGLWGSRLAAQFGNLAIYIFASIILVAYLGKYIQYEAWRWIHRLVYLAYILGLFHIYMIMGNRLLTFNLLSFLVGS YALLGLLAGFYIIFLYQKISFPYLGKITHLKRLNHDTREIQIHLSRPFNYQSGQFAFLKIFQEGFESAPHPFSISGGHGQTLY FTVKTSGDHTKNIYDNLQAGSKVTLDRAYGHMIIEEGRENQVWIAGGIGITPFISYIREHPILDKQVHFYYSFRGDENAV YLDLLRNYAQKNPNFELHLIDSTKDGYLNFEQKEVPEHATVYMCGPISMMKALAKOIKKONPKTEHIY

## 40

MTFKSGFVAILGRPNVGKSTFLNHVMGQKIAIMSDKAQTTRNKIMGIYTTDKEQIVFIDTPGIHKPKTALGDFMVESAYS
TLREVDTVLFMVPADEARGKGDDMIIERLKAAKVPVILVVNKIDKVHPDQLLSQIDDFRNQMDFKEIVPISALQGNNVS
RLVDILSENLDEGFQYFPSDQITDHPERFLVSEMVREKVLHLTREEIPHSVAVVVDSMKRDEETDKVHIRATIMVERDSQ
KGIIIGKGGAMLKKIGSMARRDIELMLGDKVFLETWVKVKKNWRDKKLDLADFGYNEREYZ

#### ID33 855bp

60

CTGCTTCTTGTTTTTACAGAAGGAGGACTTATGCCTGAATTACCTGAGGTTGAAACCGTTTGTCGTGGCTTAGAAA
AATTGATTATAGGAAAGAATTTCGAGTATAGAAATTCGCTACCCCAAGATGATTAAGACGGATTTTGGAAGAGT
TTCAAAGGGAATTGCCTAGTCAGATTATCGAGTCAATGGGACGTCGTGGAAAATATTTGCTTTTTTTATCTGACAGA
CAAGGTCTTGATTTCCCATTTGCGGATGGAGGGCAAGTATTTTTACTATCCAGACCAAGGACCTGAACGCAAGCAT
GCCCATGTTTTCTTTCATTTTGAAGATGGTGGCACGCTTGTTTATGAGGATGTTCGCAAGTTTTGGAACCATGGAAC

MLLVFTEGGLMPELPEVETVCRGLEKLIIGKKISSIEIRYPKMIKTDLEEFQRELPSQIIESMGRRGKYLLFYLTDKVLISHL
RMEGKYFYYPDQGPERKHAHVFFHFEDGGTLVYEDVRKFGTMELLVPDLLDVYFISKKLGPEPSEQDFDLQVFQSALA
KSKKPIKSHLLDQTLVAGLGNIYVDEVLWRAQVHPARPSQTLTAEEATAIHDQTIAVLGQAVEKGGSTIRTYTNAFGED
GSMQDFHQVYDKTGQECVRCGTIIEKIQLGGRGTHFCPNCQRRDZ

#### ID34 633bp

MSKLSKEGLMGKIIGITGGIASGKSTVTNFLRQQGFQVVDADAVVHQLQKPGGRLFEALVQHFGQEIILENGELNRPLL ASLIFSNPDEREWSKQIQGEIIREELATLREQLAQTEEIFFMDIPLLFEQDYSDWFAETWLVYVDRDAQVERLMKRDQLS KDEAESRLAAQWPLEKKKDLASQVLDNNGNQNQLLNQVHILLEGGRQDDRDZ

## 30 прз 1269ьр

GAGATTAACTGGAAGGATAATCTGCGCATTGCCTGGTTTGGTAATTTTCTGACAGGAGCCAGTATTTCTTTGGTTG TACCTTTTATGCCCATCTTCGTGGAAAATCTAGGTGTAGGGAGTCAGCAAGTCGCTTTTTATGCAGGCTTAGCAAT 35 TTCTGTCTCTGCTATTTCCGCGGCGCTCTTTTCTCCTATTTGGGGTATTCTTGCTGACAAATACGGCCGAAAACCCA TGATGATTCGGGCAGGTCTTGCTATGACTATCACTATGGGAGGCTTGGCCTTTGTCCCAAATATCTATTGGTTAAT CTTTCTTCGTTTACTAAACGGTGTATTTGCAGGTTTTGTTCCTAATGCAACGGCACTGATAGCCAGTCAGGTTCCA AAGGAGAAATCAGGCTCTGCCTTAGGTACTTTGTCTACAGGCGTAGTTGCAGGTACTCTAACTGGTCCCTTTATTG 40 TGACTATTTGCTTTATCAAGGAAGATTTTCAACCAGTAGCCAAGGAAAAGGCTATTCCAACAAAAGGAATTATTTAC CTCGGTTAAATATCCCTATCTTTTGCTCAATCTCTTTTTAACCAGTTTTGTCATCCAATTTTCAGCTCAATCGATTG AGTATGGGCTTTTCCAGCATGATGAGTGCAGGAGTCATGGGCAAGCTAGGTGACAAGGTGGGCAATCATCGTCTC TTGGTTGTCGCCCAGTTTTATTCAGTCATCATCTATCTCCTCTGTGCCAATGCCTCTAGCCCCCTTCAACTAGGACT 45 CTATCGTTTCCTCTTTGGATTGGGAACCGGTGCCTTGATTCCCGGGGTTAATGCCCTACTCAGCAAAATGACTCCC AAAGCCGGCATTTCGAGGGTCTTTGCCTTCAATCAGGTATTCTTTTATCTGGGAGGTGTTGTTGGTCCCATGGCAG GTTCTGCAGTAGCAGGTCAATTTGGCTACCATGCTGTCTTTTATGCGACAAGCCTTTGTGTTGCCTTTAGTTGTCTC TTTAACCTGATTCAATTTCGAACATTATTAAAAGTAAAGGAAATCTAG

MIIMAIRTSFLIKCISFLREVGKMTEINWKDNLRIAWFGNFLTGASISLVVPFMPIFVENLGVGSQQVAFYAGLAISVSAIS
AALFSPIWGILADKYGRKPMMIRAGLAMTITMGGLAFVPNIYWLIFLRLLNGVFAGFVPNATALIASQVPKEKSGSALG
TLSTGVVAGTLTGPFIGGFIAELFGIRTVFLLVGSFLFLAAILTICFIKEDFQPVAKEKAIPTKELFTSVKYPYLLLNLFLTS
FVIQFSAQSIGPILALYVRDLGQTENLLFVSGLIVSSMGFSSMMSAGVMGKLGDKVGNHRLLVVAQFYSVIIYLLCANAS
SPLQLGLYRFLFGLGTGALIPGVNALLSKMTPKAGISRVFAFNQVFFYLGGVVGPMAGSAVAGQFGYHAVFYATSLCV
AFSCLFNLIQFRTLLKVKEIZ

#### ID36 1311bp

- MALPTIAIVGRPNVGKSTLFNRIAGERISIVEDVEGVTRDRIYATGEWLNRSFSMIDTGGIDDVDAPFMEQIKHQAEIAM EEADVIVFVVSGKEGITDADEYVARKLYKTHKPVILAVNKVDNPEMRNDIYDFYALGLGEPLPISSVHGIGTGDVLDAI VENLPNEYEEENPDVIKFSLIGRPNVGKSSLINAILGEDRVIASPVAGTTRDAIDTHFTDTDGQEFTMIDTAGMRKSGKV YENTEKYSVMRAMRAIDRSDVVLMVINAEEGIREYDKRIAGFAHEAGKGMIIVVNKWDTLEKDNHTMKNWEEDIREQ FQYLPYAPIIFVSALTKQRLHKLPEMIKQISESQNTRIPSAVLNDVIMDAIAINPTPTDKGKRLKIFYATQVATKPPTFVIFV NEEELMHFSYLRFLENQIRKAFVFEGTPIHLIARKRKZ

## 20 <u>ID37 714bp</u>

- MTETIKLMKAHTSVRRFKEQEIPQVDLNEILTAAQMASSWKNFQSYSVIVVRSQEKKDALYELVPQEAIRQSAVFLLFV GDLNRAEKGARLHTDTFQPQGVEGLLISSVDAALAGQNALLAAESLGYGGVIIGLVRYKSEEVAELFNLPDYTYSVFG MALGVPNQHHDMKPRLPLENVVFEEEYQEQSTEAIQAYDRVQADYAGARATTSWSQRLAEQFGQAEPSSTRKNLEQK KLLZ

## ID38 729bp

- MTEIRLEHVSYAYGQERILEDINLQVTSGEVVSILGPSGVGKTTLFNLIAGILEVQSGRIVLDGEENPKGRVSYMLQKDLL LEHKTVLGNIILPLLIQKVDKAEAISRADKILATFQLTAVRDKYPHELSGGMRQRVALLRTYLFGHKLFLLDEAFSALDE MTKMELHAWYLEIHKQLQLTTLIITHSIEEALNLSDRIYILKNRPGQIVSEIKLDWSEDEDKEVQKIAYKRQILAELGLDK Z

## 55 <u>ID39 2433bp</u>

AAGAACAACCCTGTCTTGGTTGGGGATGCTGGTGTCGGGAAAACAGCTCTGGCGCTTGGTCTTGCCCAGCGTATTG CTAGTGGTGACGTGCCTGCGGAAATGGCTAAGATGCGCGTGTTAGAACTTGATTTGATGAATGTCGTTGCAGGGA CACGCTTCCGTGGTGACTTTGAAGAACGCATGAATAATATCATCAAGGATATTGAAGAAGATGGCCAAGTCATCC 5 GAAACCAGCCTTGGCGCGTGGAACTTTGAGAACGGTTGGTGCCACTACTCAGGAAGAATATCAAAAACATATCGA AAAAGATGCGGCACTTTCTCGTCGTTTCGCTAAAGTGACGATTGAAGAACCAAGTGTGGCAGATAGTATGACTAT TTTACAAGGTTTGAAGGCGACTTATGAGAAACATCACCGTGTACAAATCACAGATGAAGCGGTTGAAACAGCGGT TAAGATGGCTCATCGTTATTTAACCAGTCGTCACTTGCCAGACTCTGCTATCGATCTCTTGGATGAGGCGGCAGCA ACAGTGCAAAATAAGGCAAAGCATGTAAAAGCAGACGATTCAGATTTGAGTCCAGCTGACAAGGCCCTGATGGAT 10 GGCAAGTGGAAACAGGCAGCCCAGCTAATCGCAAAAGAAGAGGGAAGTACCTGTCTACAAAGACTTGGTGACAGA GTCTGATATTTTGACCACCTTGAGTCGCTTGTCAGGAATCCCAGTTCAAAAACTGACTCAAACGGATGCTAAGAAG TATTTAAATCTTGAAGCAGAACTCCATAAACGGGTTATCGGTCAAGATCAAGCTGTTTCAAGCATTAGCCGTGCCA TTCGCCGCAACCAGTCAGGGATTCGCAGTCATAAGCGTCCGATTGGTTCCTTTATGTTCCTAGGGCCTACAGGTGT CGGGAAAACTGAATTAGCCAAGGCTCTGGCAGAAGTTCTTTTTGACGACGAATCAGCCCTTATCCGCTTTGATATG 15 AGTGAGTATATGGAGAAATTTGCAGCTAGTCGTCTCAACGGAGCTCCTCCAGGCTATGTAGGATATGAAGAAGGT GATATCTTTAATGTTCTCTTGCAGGTTCTGGATGACGGTGTCTTGACAGATAGCAAGGGACGCAAGGTCGATTTTT  ${\tt CAAATACCATTATGACATCGAATCTAGGTGCGACTGCCCTTCGTGATGATAAGACTGTTGGTTTTGGGGC}$ TAAGGATATTCGTTTTGACCAGGAAAATATGGAAAAACGCATGTTTGAAGAACTGAAAAAAGCTTATAGACCGGA 20 ATTCATCAACCGTATTGATGAGAAGGTGGTCTTCCATAGCCTATCTAGTGATCATATGCAGGAAGTGGTGAAGATT ATGGTCAAGCCTTTAGTGGCAAGTTTGACTGAAAAAGGCATTGACTTGAAATTACAAGCTTCAGCTCTGAAATTGT TAGCAAATCAAGGATATGACCCAGAGATGGGAGCTCGCCCACTTCGCAGAACCCTGCAAACAGAAGTGGAGGAC TTAAAATTTGATATTGCATAA 25  ${\tt MNYSKALNECIESAYMVAGHFGARYLESWHLLIAMSNHSYSVAGATLNDYPYEMDRLEEVALELTETDYSQDETFTE}$ LPFSRRLQVLFDEAEYVASVVHAKVLGTEHVLYAILHDSNALATRILERAGFSYEDKKDQVKIAALRRNLEERAGWTR EDLKALRQRHRTVADKQNSMANMMGMPQTPSGGLEDYTHDLTEQARSGKLEPVIGRDKEISRMIQILSRKTKNNPVLV GDAGVGKTALALGLAQRIASGDVPAEMAKMRVLELDLMNVVAGTRFRGDFEERMNNIIKDIEEDGQVILFIDELHTIM 30 GSGSGIDSTLDAANILKPALARGTLRTVGATTQEEYQKHIEKDAALSRRFAKVTIEEPSVADSMTILQGLKATYEKHHRV QITDEAVETAVKMAHRYLTSRHLPDSAIDLLDEAAATVQNKAKHVKADDSDLSPADKALMDGKWKQAAQLIAKEEEV PVYKDLVTESDILTTLSRLSGIPVQKLTQTDAKKYLNLEAELHKRVIGQDQAVSSISRAIRRNQSGIRSHKRPIGSFMFLGP TGVGKTELAKALAEVLFDDESALIRFDMSEYMEKFAASRLNGAPPGYVGYEEGGELTEKVRNKPYSVLLFDEVEKAHP DIFNVLLQVLDDGVLTDSKGRKVDFSNTIIIMTSNLGATALRDDKTVGFGAKDIRFDQENMEKRMFEELKKAYRPEFIN 35 RIDEKVVFHSLSSDHMQEVVKIMVKPLVASLTEKGIDLKLQASALKLLANQGYDPEMGARPLRRTLOTEVEDKLAELL LKGDLVAGSTLKIGVKAGQLKFDIAZ

#### ID40 1008bp

- 40 ATGAAGAAAACATGGAAAGTGTTTTTAACGCTTGTAACAGCTCTTGTAGCTGTTGTGCTTGTGGCCTGTGGTCAAG GAACTGCTTCTAAAGACAACAAAGAGGCAGAACTTAAGAAGGTTGACTTTATCCTAGACTGGACACCAAATACCA ACCACACAGGGCTTTATGTTGCCAAGGAAAAAGGTTATTTCAAAGAAGCTGGAGTGGATGTTGATTTGAAATTGC CACCAGAAGAAAGTTCTTCTGACTTGGTTATCAACGGAAAGGCACCATTTGCAGTGTATTTCCAAGACTACATGGC TAAGAAATTGGAAAAAGGAGCAGGAATCACTGCCGTTGCAGCTATTGTTGAACACAATACATCAGGAATCATCTC 45 ACTTGCTATGTTGAAAACCTTGGTAGAATCTCAAGGTGGAGACTTTGAGAAGGTTGAAAAAGTACCAAATAACGA CTCAAACTCAATCACCGATTGCCAATGGCGTCTTTGATACTGCTTGGATTTACTACGGTTGGGATGGTATCCTT GCTAAATCTCAAGGTGTAGATGCTAACTTCATGTACTTGAAAGACTATGTCAAGGAGTTTGACTACTATTCACCAG TTATCATCGCAAACAACGACTATCTGAAAGATAACAAAGAAGAAGCTCGCAAAGTCATCCAAGCCATCAAAAAA 50 GGCTACCAATATGCCATGGAACATCCAGAAGAAGCTGCAGATATTCTCATCAAGAATGCACCTGAACTCAAGGAA AAACGTGACTTTGTCATCGAATCTCAAAAATACTTGTCAAAAGAATACGCAAGCGACAAGGAAAAATGGGGTCAA TTTGACGCAGCTCGCTGGAATGCTTTCTACAAATGGGATAAAGAAAATGGTATCCTTAAAGAAGACTTGACAGAC AAAGGCTTCACCAACGAATTTGTGAAATAA
- MKKTWKVFLTLVTALVAVVLVACGQGTASKDNKEAELKKVDFILDWTPNTNHTGLYVAKEKGYFKEAGVDVDLKLP PEESSSDLVINGKAPFAVYFQDYMAKKLEKGAGITAVAAIVEHNTSGIISRKSDNVSSPKDLVGKKYGTWNDPTELAML KTLVESQGGDFEKVEKVPNNDSNSITPIANGVFDTAWIYYGWDGILAKSQGVDANFMYLKDYVKEFDYYSPVIIANND YLKDNKEEARKVIQAIKKGYQYAMEHPEEAADILIKNAPELKEKRDFVIESQKYLSKEYASDKEKWGQFDAARWNAFY KWDKENGILKEDLTDKGFTNEFVKZ

#### ID41 762bp

TTGATGAGAAACTTGAGAAGTATACTGAGACGACACATTAGTCTATTGGGCTTTTCTCGGAGTATTGTCAATCTGGC
AGTTAGCAGGTTTTCTTAAACTTCTCCCCAAGTTTATCCTGCCGACACCTCTTGAAATTCTCCAGCCCTTTGTTCGT
GACAGAGAATTTCTCTGGCACCATAGCTGGGCGACCTTGAGAGTGGCTTTACTGGGGCTGATTTTGGAGTTTTTGA

- MMRNLRSILRRHISLLGFLGVLSIWQLAGFLKLLPKFILPTPLEILQPFVRDREFLWHHSWATLRVALLGLILGVLIACLM AVLMDSLTWLNDLIYPMMVVIQTIPTIAIAPILVLWLGYGILPKIVLIILTTTFPIIVSILDGFRHCDKDMLTLFSLMRAKP WQILWHFKIPVSLPYFYAGLRVSVSYAFITTVVSEWLGGFEGLGVYMIQSKKLFQYDTMFAIIILVSIISLLGMKLVDISE KYVIKWKRSZ

#### ID42 372bp

 ${\tt MIFNPICCMIREKKGDRDMAFTNTHMRSASFGIVTSLPDDIIDSFWYIIDHFLKNVFELEEELEFQLLNNQGKITFHFSSQHLPTAIDFDFNHPFDPRYPPRVLVLDMDGRETILLPEENDLFZ}$ 

## 25 <u>ID43 1569bp</u>

- ACAGCGGTGTCATTCTATCTTATAGAAAAGTAATAATCAATTGTTAAAAATAGTAAAAAATTGGAGGTTCTG ATGAAATATTTTGTTCCTAATGAGGTATTCAGTATTCGTAAATTAAAGGTGGGGACTTGCTCGGTACTATTGGCAA TTTCAATTTTGGGAAGCCAAGGTATTTTATCGGATGAAGTTGTTACTAGTTCTTCACCGATGGCTACAAAAGAGTC 30 TTCTAATGCAATTACTAATGATTTAGATAATTCACCAACTGTTAATCAGAATCGTTCTGCTGAAATGATTGCCTCT AATTCAACCACTAATGGTTTAGATAATTCGTTAAGTGTTAATAGCATCAGCTCTAATGGTACTATTCGTTCCAATT CACAATTAGACAACAGAACAGTTGAATCTACAGTAACATCTACTAATGAAAATAAGAGTTATAAGGAAGATGTTA TAAGTGACAGAATTATCAAAAAAGAATTTGAAGATACTGCTTTAAGTGTAAAAGATTATGGTGCAGTAGGTGATG GGATTCATGATGACGACAAGCAATTCAAGATGCAATAGATGCTGCAGCTCAAGGGCTAGGTGGAGGAAATGTAT 35 ATTTTCCTGAAGGAACTTATTTAGTAAAAGAAATTGTTTTTTTAAAAAGTCATACACACTTAGAATTGAATGAGAA GGTGCGCAAGTAGAATGGGGCCCAACAGAAGATATTAGTTATTCTGGTGGTACGATTGATATGAACGGTGCTTTG AATGAAGAAGGAACTAAAGCAAAAAATCTACCACTTATAAATTCTTCAGGTGCATTTGCTATTGGGAATTCAAAT AACGTAACTATAAAAAATGTAACATTCAAGGATAGTTATCAAGGGCATGCTATTCAAATTGCAGGTTCGAAAAAT 40 AGAGCATTCAGATTGAACCATTAACTAGAAAAGGTTTTCCTTATGCCTTGAATGATGATGGGAAAAAATCTGAAA ATGTGACTATTCAAAATTCCTATTTTGGCAAAAGTGATAAATCTGGGGAATTAGTAACAGCAATTGGCACACTA TCAAACATTGTCGACACAGAACCCCTCTAATATTAAAATTCAAAATAATCATTTTGATAACATGATGTATGCAGGT GTACGTTTTACAGGATTCACTGATGTATTAATCAAAGGAAATCGCTTTGATAAGAAAGTTAAAGGAGAGAGTGTA 45 CATTATCGAGAAAGCGGAGCAGCTTTAGTAAAATGCTTATAGCTATAAAAAACACTAAAGACCTATTAGATTTAAAT AAACAGGTGGTTATCGCCGAAAATATATTTAATATTGCCGATCCTAAAACAAAAGCGATACGAGTTGCAAAAGAT GAACAACCAAATATTGAATTATTACGAGTTAGTGATAATTTAGTAGTCTCAGAGAATAGT
- QRCHSIYFKKSNNQLLKIVKKLEVLMKYFVPNEVFSIRKLKVGTCSVLLAISILGSQGILSDEVVTSSSPMATKESSNAITN DLDNSPTVNQNRSAEMIASNSTTNGLDNSLSVNSISSNGTIRSNSQLDNRTVESTVTSTNENKSYKEDVISDRIIKKEFEDT ALSVKDYGAVGDGIHDDRQAIQDAIDAAAQGLGGGNVYFPEGTYLVKEIVFLKSHTHLELNEKATILNGINIKNHPSIVF MTGLFTDDGAQVEWGPTEDISYSGGTIDMNGALNEEGTKAKNLPLINSSGAFAIGNSNNVTIKNVTFKDSYQGHAIQIA GSKNVLVDNSRFLGQALPKTMKDGQIISKESIQIEPLTRKGFPYALNDDGKKSENVTIQNSYFGKSDKSGELVTAIGTHY QTLSTQNPSNIKIQNNHFDNMMYAGVRFTGFTDVLIKGNRFDKKVKGESVHYRESGAALVNAYSYKNTKDLLDLNKQ VVIAENIFNIADPKTKAIRVAKDSAECLGKVSDITVTKNVINNNSKETEQPNIELLRVSDNLVVSENS

#### ID44\_324bp

GTGATGAAAGAACTCAGCTATTAAAAGGTGTTCTTGAAGGTTGTCTTTGGATATGATTGGTCAAAAAGAGCGG
TATGGTTATGAGTTCAGACTTTGCGAGAGGCTGGATTTGATACTATCGTTCAGGAACTATTTATCCTTTGTT
GCAAAAGTTAGAAAAAAATCAATGGATAAGAGGCGACATGCGCCCGTCGCCAGATGGTCCAGATCGGAAGTATTT
TTCATTAATGAAAGAAGAGAGAGAGCGTGTCTCAGTCTTTTGGCAACAATGGGACGATTTGAGTCAAAAAGTAGA
AGGGATTAAGAATGGGGGTTAA

 $\label{lem:maketqllkgvlegcvldmig} MMKETQLLKGVLEGCVLDMIGQKERYGYELVQTLREAGFDTIVPGTIYPLLQKLEKNQWIRGDMRPSPDGPDRKYFSLMKEGEERVSVFWQQWDDLSQKVEGIKNGGZ$ 

ID45 816bp

- MKKMKYYEETSALLHEFSEENQKYFEELWESFNLAGFLYDEDYLREQIYLMMLDFSEAERDGMSAEDYLGKNPKKIM KEILKGAPRSSIKESLLTPILVLAVLRYYQLLSDFSKGPLLTVNLLTFLGQLLIFLIGFGLVATILRRSLVQDSPKMKIGTYI VVGTIVLLVVLGYVGMASFIQEGAFYIPAPWDSLSVFTISLVIGIWNWKEAVFRPFVSMIIAHLVVGSLLRYYEWMGISN VFLTKVIPLAVLFIGIFVLFRGFKKIKWSEVZ

GAATCTTTGTCTTGTTCCGTGGGTTTAAGAAGATAAAATGGAGTGAAGTATAG

#### ID46 348bp

- - MFFYLYSMKIKEQTRKLAAGCSKHCFEVVDETDEVSSKHVFEVVDETDEVSSKHCFEVVDTDEVSSKHCFEVVDETDEVSSKHCFEVVDTDEVSSKHCFEVVDTDEVSSKHCFEVVDTDEVSSKHCFEVVDTDEVSSKHCFEVVDTDEVSSKHC

# 35

- ATGCAGAATCTGAAATTTGCCTTTTCATCTATCATGGCTCACAAGATGCGTTCTTTGCTTACTATGATTGGGATTAT TATCGGTGTTTCATCAGTTGTTGTGATTATGGCTTTGGGTGATTCCCTATCTCGTCAAGTCAATAAAGATATGACTA AATCTCAGAAAAATATTAGCGTCTTTTTCTCTCCTAAAAAAAGTAAAGACGGGTCTTTTACTCAGAAACAATCAGC TTTTACGGTTTCTGGAAAGGAAGAGGAAGTTCCTGTTGAACCGCCAAAACCGCAAGAATCCTGGGTCCAAGAGGC 40 AGCTAAACTGAAGGGAGTGGATAGTTACTATGTAACCAATTCAACGAATGCCATCTTGACCTATCAAGATAAAAA GGTTGAGAATGCTAATTTGACAGGTGGAAACAGAACTTACATGGACGCTGTTAAGAATGAAATTATTGCAGGTCG TAGTCTGAGAGAGCAAGATTTCAAAGAGTTTGCAAGTGTCATTTTGCTAGATGAGGAATTGTCCATTAGTTTATTT GAATCTCCTCAAGAGGCTATTAACAAGGTTGTAGAAGTCAATGGATTTAGTTACCGGGTCATTGGGGTTTATACTA GTCCGGAGGCTAAAAGATCAAAAATATATGGGTTTGGTGGCTTGCCTATTACTACCAATATCTCCCTTGCTGCGAA 45 TTTTAATGTAGATGAAATAGCTAATATTGTCTTTCGAGTGAATGATACCAGTTTAACCCCAACTCTGGGTCCAGAA CTGGCACGAAAAATGACAGAGCTTGCAGGCTTACAACAGGGAGAATACCAGGTGGCAGATGAGTCCGTTGTATTT GCAGAAATTCAACAATCGTTTAGTTTTATGACGACGATTATTAGTTCCATCGCAGGGATTTCTCTCTTTTGTTGGAG GAACTGGTGTCATGAACATCATGCTGGTTTCGGTGACAGAGCGCACTCGTGAGATTGGTCTTCGTAAGGCTTTGGG TGCAACACGTGCCAATATTTTAATTCAGTTTTTGATTGAATCCATGATTTTGACCTTGTTAGGTGGCTTAATTGGCT 50 TGACAATTGCAAGTGGTTTAACTGCCTTAGCAGGTTTGTTACTGCAAGGTTTAATAGAAGGTATAGAAGTTGGAGT
- MQNLKFAFSSIMAHKMRSLLTMIGIIIGVSSVVVIMALGDSLSRQVNKDMTKSQKNISVFFSPKKSKDGSFTQKQSAFTVS
  GKEEEVPVEPPKPQESWVQEAAKLKGVDSYYVTNSTNAILTYQDKKVENANLTGGNRTYMDAVKNEIIAGRSLREQDF
  KEFASVILLDEELSISLFESPQEAINKVVEVNGFSYRVIGVYTSPEAKRSKIYGFGGLPITTNISLAANFNVDEIANIVFRVN
  DTSLTPTLGPELARKMTELAGLQQGEYQVADESVVFAEIQQSFSFMTTIISSIAGISLFVGGTGVMNIMLVSVTERTREIG
  LRKALGATRANILIQFLIESMILTLLGGLIGLTIASGLTALAGLLLQGLIEGIEVGVSIPVALFSLAVSASVGMIFGVLPANK
  ASKLDPIEALRYEZ

#### ID48 705bp

CTGATGAAGCAACTAATTAGTCTAAAAAATATCTTCAGAAGTTACCGTAATGGTGACCAAGAACTGCAGGTTCTC
AAAAATATCAATCTAGAAGTGAATGAGGGTGAATTTGTAGCCATCATGGGACCATCTGGGTCTGGTAAGTCCACT
CTGATGAATACGATTGGCATGTTGGATACACCAACCAGTGGAGAATATTATCTTGAAGGTCAAGAAGTGGCTGGG

MMKQLISLKNIFRSYRNGDQELQVLKNINLEVNEGEFVAIMGPSGSGKSTLMNTIGMLDTPTSGEYYLEGQEVAGLGEK
QLAKVRNQQIGFVFQQFFLLSKLNALQNVELPLIYAGVSSSKRRKLAEEYLDKVELTERSHHLPSELSGGQKQRVAIARA
LVNNPSIILADEPTGALDTKTGNQIMQLLVDLNKEGKTIIMVTHEPEIAAYAKRQIVIRDGVISSDSAQLGKEENZ

#### ID49 1200bp

- MKKKNGKAKKWQLYAAIGAASVVVLGAGGILLFRQPSQTALKDEPTHLVVAKEGSVASSVLLSGTVTAKNEQYVYFD
  ASKGDLDEILVSVGDKVSEGQALVKYSSSEAQAAYDSASRAVARADRHINELNQARNEAASAPAPQLPAPVGGEDATV
  QSPTPVAGNSVASIDAQLGDARDARADAAAQLSKAQSQLDATTVLSTLEGTVVEVNSNVSKSPTGASQVMVHIVSNEN
  LQVKGELSEYNLANLSVGQEVSFTSKVYPDKKWTGKLSYISDYPKNNGEAASPAAGNNTGSKYPYTIDVTGEVGDLKQ
  GFSVNIEVKSKTKAILVPVSSLVMDDSKNYVWIVDEQQKAKKVEVSLGNADAENQEITSGLTNGAKVISNPTSSLEEGKE
  VKADEATNZ

## 40 ID50 759bp

- ATGTCACGTAAACCATTTATCGCTGGTAACTGGAAAATGAACAAAAATCCAGAAGAAGCATAAGCATTCGTTGAA
  GCAGTTGCATCAAAACTTCCTTCATCAGATCTTGTTGAAGCAGGTATCGCTGCTCCAGCTCTTGATTTGACAACTG
  TTCTTGCTGTTGCAAAAGGCTCAAACCTTAAAGTTGCTGCTCAAAACTGCTACTTTGAAAATGCAGGTGCTTTCAC
  TGGTGAAACTAGCCCACAAGTTTTGAAAGAAATCGGTACTACGTTGTTATCGGTCACTCAGAACGCGTGA

  45
  CTACTTCCATGAAACTGATGAAACTAACAAAAAAAGCAAATCTTTGCGAACGGTATCGTTCCAATCAT
  CTGTTGTGGTGAATCACTTGAAACTTACGAAGCTGGTAAAGCTGAATTCGTAAGTTGCTAAGTATCTGCTA
  TTGGCTGGATTGACTGCTGAACAAGTTGCTGCTCAGTTATCAGCCAATCTTGGGCTAATCGGTACTGGTA
- AATCAGCTTCACAAGACGATGCACAAAAAATGTGTAAAGTTGTTCGTGACGTTGTAGCTGCTGACTTTTGGTCAAG
  AAGTCGCAGACAAAGTTCGTGTTCAATACGGTGGTTCTGTTAAACCTGAAAATGTTGCTTCATACATGGCTTGCCC
  AGACGTTGACGGTGCCCTTGTAGGTGGTGCGTCACTTGAAGCTGAAAGCTTCTTGGCTTTGCTTGACTTTGTAAAA
  TAA
- MSRKPFIAGNWKMNKNPEEAKAFVEAVASKLPSSDLVEAGIAAPALDLTTVLAVAKGSNLKVAAQNCYFENAGAFTG ETSPQVLKEIGTDYVVIGHSERRDYFHETDEDINKKAKAIFANGMLPIICCGESLETYEAGKAAEFVGAQVSAALAGLTA EQVAASVIAYEPIWAIGTGKSASQDDAQKMCKVVRDVVAADFGQEVADKVRVQYGGSVKPENVASYMACPDVDGAL VGGASLEAESFLALLDFVKZ

## ID51 1473bp

- TACTACTTCAAGAAGTGGGGTTACATGGCTAAAAGCCAATGGCAAGGAAGTTATTTCTTGAATGGTCAAGGAGCT ATGATGCAAAATGAATGGCTCTATGATCCAGCCTATTCTGCTTATTTTTATCTAAAATCCGATGGAACTTATGCTA ACCAAGAGTGGCAAAAAGTGGGCGGCAAATGGTACTATTTCAAGAAGTGGGGCTATATGGCTCGGAATGAGTGGC 5 TGCGGCCTCTGGTGAGCTCAAAGAAAAAAAGATTTGAATGTCGGCTGGGTTCACAGAGATGGTAAGCGCTATTT CTTTAATAATAGAGAAGAACAAGTGGGAACCGAACATGCTAAGAAAGTCATTGATATTAGTGAGCACAATGGTCG TATCAATGATTGGAAAAAGGTTATTGATGAGAACGAAGTGGATGGTGTCATTGTTCGTCTAGGTTATAGCGGTAA AGAAGACAAGGAATTGGCGCATAACATTAAGGAGTTAAACCGTCTGGGAATTCCTTATGGTGTCTATCTCTATAC CTATGCTGAAAATGAGACCGTGCTGAGAGTGACGCTAAACAGACCATTGAACTTATAAAGAAATACAATATGAAC 10 CTGTCTTACCCTATCTATTATGATGTTGAGAATTGGGAATATGTAAATAAGAGCAAGAGAGCTCCAAGTGATACA GGCACTTGGGTTAAAATCATCAACAAGTACATGGACACGATGAAGCAGGCGGGTTATCAAAATGTGTATGTCTAT AGCTATCGTAGTTTATTACAGACGCGTTTAAAACACCCAGATATTTTAAAACATGTAAACTGGGTAGCGGCCTATA CGAATGCTTTAGAATGGGAAAACCCTCATTATTCAGGAAAAAAAGGTTGGCAATATACCTCTTCTGAATACATGA AAGGAATCCAAGGGCGCGTAGATGTCAGCGTTTGGTATTAA
- MKTKIGLASICLLGLATSHVAANETEVAKTSQDTTTASSSSEQNQSSNKTQTSAEVQTNAAAHWDGDYYVKDDGSKAQ SEWIFDNYYKAWFYINSDGRYSQNEWHGNYYLKSGGYMAQNEWIYDSNYKSWFYLKSDGAYAHQEWQLIGNKWYY FKKWGYMAKSQWQGSYFLNGQGAMMQNEWLYDPAYSAYFYLKSDGTYANQEWQKVGGKWYYFKKWGYMARNE WQGNYYLTGSGAMATDEVIMDGTRYIFAASGELKEKKDLNVGWVHRDGKRYFFNNREEQVGTEHAKKVIDISEHNG RINDWKKVIDENEVDGVIVRLGYSGKEDKELAHNIKELNRLGIPYGVYLYTYAENETDAESDAKQTIELIKKYNMNLSY PIYYDVENWEYVNKSKRAPSDTGTWVKIINKYMDTMKQAGYQNVYVYSYRSLLQTRLKHPDILKHVNWVAAYTNAL EWENPHYSGKKGWQYTSSEYMKGIQGRVDVSVWYZ

# 25 ID52 774bp

- ATGAAAAAATTTGCCAACCTTTATCTGGGACTGGTCTTCTGGTCCTCTACCTGCCTATCTTTTACTTGATTGGCTA
  TGCCTTTAATGCTGGTGATGATAGATAGCTTTACAGGTTTTAGCTGGACTCACTTTGAAACCATGTTTGGAGAT
  GGGAGACTCATGCTGATTTTGGCTCAGACATTTTTCTTGGCTTCCTATCAGCCTTGATAGCGACCATTATCGGGA
  CTTTTGGTGCCATTTACATCACCAGTCTCGTAAGAAATACCAAGAAGCCTTTCTATCACTCAATAATATCCTCAT
  GGTTGCGCCTGACGTTATGATTGGTGTGTAGTTCTCTTTACCCAACTCAAGTTTTCACTTACTCATTTTTTGA
  CCGTTCTATCTAGTCACGTGGCCTTCTCCATTCCTATCGTGGTCTTGATGGTCTTGCCTCGACTCAAGGAAATGAA
  TGGCGACATGATTCATGCGGCCTATGACTTGGGAGCTAATTTCAGATGTTCAAGGAAATCATCTTTTTGT
  AACAGGAAATGGCTTTTCAACCCTATCAGTCGAGAATTTACTCTCGTAGAAGGGGATTTCCTTAGAAATCAAT
  GCCCTGTCTGCTCTAGTCTTTCTCTTTAGTATTATCCTAGTTGAGGTTATTACTTTATCTCTCGTGAGAAAGGAGGA
  GCCAAGCATGA
- MKKFANLYLGLVFLVLYLPIFYLIGYAFNAGDDMNSFTGFSWTHFETMFGDGRLMLILAQTFFLAFLSALIATIIGTFGA IYIYQSRKKYQEAFLSLNNILMVAPDVMIGASFLILFTQLKFSLGFLTVLSSHVAFSIPIVVLMVLPRLKEMNGDMIHAAY DLGASQFQMFKEIMLPYLTPSIITGYFMAFTYSLDDFAVTFFVTGNGFSTLSVEIYSRARKGISLEINALSALVFLFSIILVV GYYFISREKEEQAZ

#### ID59 1071bp

**AAATGTATCGGAAGTAG** 

- 45 ATGAAAAAATCTATTCATTTTTAGCAGGAATTGCAGCGATTATCCTTGTCTTGTGGGGAATTGCGACTCATTTAG ATAGTAAAATCAATAGTCGAGATAGTCAAAAATTGGTTATCTATAACTGGGGAGACTATATCGATCCTGAACTCTT GACTCAGTTTACAGAAGAAACAGGAATTCAAGTTCAGTACGAGACTTTTGACTCCAACGAAGCCATGTACACTAA GATAAAGCAGGTGGAACGACCTACGATATTGCCATTCCAAGTGAATACATGATTAACAAGATGAAGGACGAAG ACCTCTTGGTTCCGCTTGATTATTCAAAAATTGAAGGAATCGAAAATATCGGACCAGAGTTTCTCAACCAGTCCTT 50 TGACCCAGGTAATAAATTCTCCATCCCTTACTTCTGGGGAACCTTAGGAATTGTCTACAACGAAACCATGGTAGAT GAAGCGCCTGAGCATTGGGATGACCTTTGGAAGCCGGAGTATAAGAATTCTATCATGCTCTTTGATGGGGCGCGT GAGGTGCTGGGACTAGGACTCAATTCCCTCGGCTACAGCCTCAACTCCAAGGATCTGCAGCAGTTGGAAGAGACA GTGGATAAGCTCTACAAACTGACTCCAAATATCAAGGCTATCGTTGCGGACGAGATGAAGGGCTATATGATTCAG 55 GTGGTACCGACAGAGGCCAGCAATCTTTGGTTTGACAATATGGTCATTCCCAAAACAGTTAAAAACCAAAACTCA GCCTATGCCTTTATCAACTTTATGTTGAAACCTGAAAATGCTCTCCAAAATGCGGAGTATGTCGGCTATTCAACAC CAAACCTACCAGCGAAGGAATTGCTCCCAGAGGAAACAAAGGAAGATAAGGCCTTCTATCCCGATGTTGAAACCA TGAAACACCTAGAAGTTTATGAGAAATTTGACCATAAATGGACAGGGAAATATAGCGACCTCTTCCTACAGTTTA
- 60

  MKKIYSFLAGIAAIILVLWGIATHLDSKINSRDSQKLVIYNWGDYIDPELLTQFTEETGIQVQYETFDSNEAMYTKIKQGG
  TTYDIAIPSEYMINKMKDEDLLVPLDYSKIEGIENIGPEFLNQSFDPGNKFSIPYFWGTLGIVYNETMVDEAPEHWDDLW
  KPEYKNSIMLFDGAREVLGLGLNSLGYSLNSKDLQQLEETVDKLYKLTPNIKAIVADEMKGYMIQNNVAIGVTFSGEAS
  QMLEKNENLRYVVPTEASNLWFDNMVIPKTVKNQNSAYAFINFMLKPENALQNAEYVGYSTPNLPAKELLPEETKED
  KAFYPDVETMKHLEVYEKFDHKWTGKYSDLFLQFKMYRKZ

#### ID61 1851bp

- 5 GGAATATTTGATATTTCAGTATGGTGGTTTCCATCATTGTATCTTATATTTTTATTGGGCTGATTAATCCAGC ACCTGTTGACTACATTATCTATACGAGTTTGGCCTTCCTGTTCTATCAATTGATGATTGGTTTTTTGGGGGTTGAACG CGAGCATTAGTCGTTACAGCAAGATTACGGATTTCATGAAAATCTTTTTTGGTGTGACTGCTAGCAGTGTCTTGTC ATATAGTATCTGTTATGCCTTCTTGCCACTCTTCTCCATCCGTTTCATCATTCTCTTTATCTTGTTGAGTACCTTCTT GATTTTATTGCCACGGATTACTTGGCAGTTAATCTACTCCAGACGCAAAAAAGGTAGTGGTGATGGAGAACACCG 10 TCGGACCTTCTTGATTGGTGCCGGTGATGGTGGGGCTCTTTTTATGGATAGTTACCAACATCCAACCAGTGAATTA GAACTGGTCGGTATTTTGGATAAGGATTCTAAGAAAAAGGGTCAAAAACTTGGTGGTATTCCTGTTTTGGGCTCTT ATGACAATCTGCCTGAATTAGCCAAACGCCATCAAATCGAGCGTGTCATCGTTGCGATTCCGTCGCTGGATCCGTC AGAATATGAGCGTATCTTGCAGATGTGTAATAAGCTGGGTGTCAAATGTTACAAGATGCCTAAGGTTGAAACTGT TGTTCAGGGCCTTCACCAAGCAGGTACTGGCTTCCAAAAAATTGATATTACGGACCTTTTGGGTCGTCAGGAAATC 15 CGTCTTGACGAATCGCGTCTGGGTGCAGAACTGACAGGTAAGACCATCTTAGTCACAGGAGCTGGAGGTTCAATC GGTTCTGAAATCTGTCGTCAAGTTAGTCGCTTCAATCCTGAACGCATTGTCTTGCTCGGTCATGGGGAAAACTCAA CTATGATCGTTTGTTGCAAGTCTTTGAGCAGTACAAACCTGCTATTGTTTATCATGCGGCAGCCCACAAGCATGTT CCTATGATGGAGCGCAATCCAAAAGAAGCCTTCAAAAACAATATCCGTGGAACTTACAATGTTGCTAAGGCTGTT 20 GATGAAGCTAAAGTGTCTAAGATGGTTATGATTTCGACAGATAAGGCAGTCAATCCACCAAATGTTATGGGAGCA ACCAAGCGCGTGGCGGAGTTGATTGTCACTGGCTTTAACCAACGTAGCCAATCAACCTACTGTGGAGTTGGTFFTG GGAATGTTCTTGGTAGCCGTGGTAGTGTCATTCCAGTCTTTGAACGTCAGATTGCTGAAGGTGGGCCTGTAACGGT GACAGACTTCCGTATGACCCGTTACTTTATGACCATTCCAGAAGCTAGCCGTCTGGTTATCCATGCTGGTGCTTAT GCCAAAGATGGGGAAGTCTTTATCCTTGATATGGGCAAACCAGTCAAGATTTATGACTTGGCCAAGAAGATGGTG 25 CTTCTAAGTGGCCACACTGAAAGTGAAATTCCAATCGTTGAAGTTGGAATCCGCCCAGGTGAAAAACTCTACGAA GAACTCTTGGTATCAACCGAACTCGTTGATAATCAAGTTATGGATAAGATTTTCGTTGGTAAGGTTAATGTCATGC CCTTTGCTAATCAAACAACCCACATTGAATAA
- 30 MNKKLTDYVIDLVEILNKQQKQVFWGIFDIFSMVVSIIVSYILFYGLINPAPVDYIIYTSLAFLFYQLMIGFWGLNASISRY SKITDFMKIFFGVTASSVLSYSICYAFLPLFSIRFIILFILLSTFLILLPRITWQLIYSRRKGSGDGEHRRTFLIGAGDGGALF MDSYQHPTSELELVGILDKDSKKKGQKLGGIPVLGSYDNLPELAKRHQIERVIVAIPSLDPSEYERILQMCNKLGVKCYK MPKVETVVQGLHQAGTGFQKIDITDLLGRQEIRLDESRLGAELTGKTILVTGAGGSIGSEICRQVSRFNPERIVLLGHGEN SIYLVYHELIRKFQGIDYVPVIADIQDYDRLLQVFEQYKPAIVYHAAAHKHVPMMERNPKEAFKNNIRGTYNVAKAVD EAKVSKMVMISTDKAVNPPNVMGATKRVAELIVTGFNQRSQSTYCAVRFGNVLGSRGSVIPVFERQIAEGGPVTVTDFR MTRYFMTIPEASRLVIHAGAYAKDGEVFILDMGKPVKIYDLAKKMVLLSGHTESEIPIVEVGIRPGEKLYEELLVSTELV DNQVMDKIFVGKVNVMPLESINQKIGEFRTLSGDELKOAIIAFANOTTHIEZ

## 40 <u>ID101 1338bp</u>

- ATGATTGAACTTTATGATAGTTACAGTCAAGAAAGTCGAGATTTACATGAAAGTCTAGTCGCTACTGGTCTTTCTC AACTTGGAGTGGTCATCGATGCAGATGGTTTTCTGCCTGATGGTCTGCTTTTCCCTTTTACCTATTATCTAGGTTAC GAGGATGGAAAACCTCTCTATTTTAATCAAGTTCCCGTTTCAGATTTTTTGGGAAATTTTAGGAGATAATCAGTCTG 45 GGTAGACTGGAAAGACCTAGAAGGTCGAGTACGTCAGGTTGACCACTACAATCGCTTCGGAGCTTGTTTTGCTAC AACGACTTATAGCGCAGATAGCGAGCCGATTATGACAGTTTACCAAGATGTCAATGGTCAACAAGTTTTACTGGA AAACCATGTGACGGGTGATATCTTATTGACTTTGCCAGGTCAGTCCATGCGTTACTTTGCAAATAAAGTTGAATTT ATCACCTTCTTTTTGCAAGATTTGGAAATAGATACCAGTCAGCTTATCTTTAATACTCTAGCGACTCCTTTCTTGGT TTCCTTCCATCATCAGATAAATCTGGCTCGGATGTCTTGGTATGGCAGGAACCTCTCTATGATGCCATTCCAGGT 50 AATATGCAGTTGATTTTGGAAAGTGATAATGTGCGTACTAAGAAGATCATCATTCCAAATAAGGCGACTTATGAG CGCGCTTTAGAGTTAACTGACGAGAAATACCATGATCAGTTTGTGCACTTGGGTTATCATTACCAGTTCAAACGTG ATAATTTCCTAAGACGAGATGCCTTAATCTTGACCAATTCAGATCAGATTGAGCAAGTAGAAGCAATCGCAGGAG CCTTGCCTGATGTCACTTTCCGTATTGCAGCGGTGACAGAGATGTCTTCTAAGCTCTTAGACATGCTTTGCTATCCT AATGTGGCCCTTTACCAGAACGCTAGTCCACAGAAGATTCAGGAGCTGTATCAACTGTCGGATATTTACTTGGATA 55 TAAACCACAGTAATGAGTTGCTACAGGCAGTGCGTCAGGCCTTTGAGCACAATCTCTTGATTCTTGGCTTTAATCA GACGGTGCACAATAGACTTTATATCGCTCCAGACCATCTATTTGAAAGTAGTGAAGTTGCTGCTTTGGTTGAGACC ATTAAATTGGCCCTTTCAGATGTTGATCAAATGCGTCAGGCACTTGGCAAACAAGGCCAACATGCAAATTATGTTG ACTTGGTGAGATATCAGGAAACCATGCAAACTGTTTTAGGAGGCTAA
- MIELYDSYSQESRDLHESLVATGLSQLGVVIDADGFLPDGLLSPFTYYLGYEDGKPLYFNQVPVSDFWEILGDNQSACIE DVTQERAVIHYADGMQARLVKQVDWKDLEGRVRQVDHYNRFGACFATTTYSADSEPIMTVYQDVNGQQVLLENHV TGDILLTLPGQSMRYFANKVEFITFFLQDLEIDTSQLIFNTLATPFLVSFHHPDKSGSDVLVWQEPLYDAIPGNMQLILES DNVRTKKIIIPNKATYERALELTDEKYHDQFVHLGYHYQFKRDNFLRRDALILTNSDQIEQVEAIAGALPDVTFRIAAVT EMSSKLLDMLCYPNVALYQNASPQKIQELYQLSDIYLDINHSNELLQAVRQAFEHNLLILGFNQTVHNRLYIAPDHLFE SSEVAALVETIKLALSDVDQMRQALGKQGQHANYVDLVRYQETMQTVLGGZ

#### ID102 1512bp

- ATGACAATTTACAATATAAATTTAGGAATTGGTTGGGCTAGTAGCGGTGTTGAATACGCTCAAGCCTATCGTGCTG 5 GTGTTTTTCGGAAATTAAATCTGTCCTCTAAGTTTATCTTTACAGATATGATTTTAGCCGATAATATTCAGCACTTA ACAGCCAATATTGGTTTTGATGATAATCAGGTTATCTGGCTTTATAATCATTTCACAGATATCAAAATTGCACCTA CTAGCGTGACAGTGGATGATGTCTTGGCTTACTTTGGTGGTGAAGAAAGTCACAGAGAAAAAAATGGCAAGGTTT TACGTGTATTCTTTTTTGACCAAGATAAGTTTGTAACCTGTTATTTGGTTGATGAGAACAAGGACTTGGTTCAACA TGCCGAGTATGTTTTTAAGGGAAACCTGATTCGGAAGGATTACTTTTCTTATACGCGTTATTGTAGCGAGTATTTT 10 GCTCCCAAGGACAATGTTGCAGTCTTATACCAACGAACTTTTTATAATGAAGACGGGACTCCAGTCTATGATATCT CCTTTATGAAATCTTTGAATTTGAATAAGTCTGATTTGGTCATTCTCGATAGGGAGACAGGTATTGGACAGGTTGT GTTTGAGGAAGCACAGACAGCACATCTAGCGGTAGTTGTTCATGCGGAGCATTATAGTGAAAATGCTACAAATGA GGACTATATCCTTTGGAATAACTATTATGACTATCAGTTTACCAATGCAGATAAGGTTGACTTCTTTATCGTGTCT 15 **ACTGATAGACAAAATGAAGTTCTACAAGAGCAATTTGCCAAATATACTCAGCATCAGCCAAAGATTGTTACCATT** CCTGTAGGCAGTATTGATTCCTTGACAGATTCAAGTCAAGGGCGCAAACCATTTTCATTGATTACGGCTTCACGTC TTGCCAAAGAAAAGCACATTGATTGGCTTGTGAAAGCTGTGATTGAAGCTCATAAGGAGTTACCGGAACTAACCT TTGATATCTATGGTAGTGGTGGAGAAGATTCTCTGCTTAGAGAAATTATTGCAAATCATCAGGCAGAGGACTATAT CCAACTCAAGGGGCATGCGGAACTTTCGCAGATTTATAGCCAGTATGAGGTCTACTTAACGGCTTCTACCAGCGA 20 AGGATTTGGTCTGACCTTGATGGAAGCTATTGGTTCAGGTCTACCTCTAATTGGTTTTGATGTGCCTTATGGTAATC AGACCTTTATAGAGGATGGGCAAAATGGTTATTTGATTCCAAGTTCATCTGACCATGTAGAAGACCAAATCAAGC **AAGCTTATGCCGCTAAGATTTGTCAATTGTATCAAGAAAATCGTTTTGGAAGCTATGCGTGCCTATTCTTACCAAAT** TGCAGAAGGCTTCTTGACCAAAGAAATTTTAGAAAAGTGGAAGAAAACAGTAGAGGAGGTGCTCCATGATTGA
- 25 mtiyninlgigwassgveyaqayragvfrklnlsskfiftdmiladniqhltanigfddnqviwlynhftdikiaptsvt vddvlayfggeeshrekngkvlrvfffdqdkfvtcylvdenkdlvqhaeyvfkgnlirkdyfsytrycseyfapkdn vavlyqrtfynedgtpvydilmnqgkeevyhfkdkifygkqafvrafmkslnlnksdlvildretgigqvvfeeaqta hlavvhaehysenatnedyilwnnyydyqftnadkvdffivstdrqnevlqeqfakytqhqpkivtipvgsidsltds sqgrkpfslitasrlakekhidwlvkavieahkelpeltfdiygsggedsllreiianhqaedyiqlkghaelsqiysqye vyltastsegfgltlmeaigsglpligfdvpygnqtfiedgqngylipsssdhvedqikqayaakicqlyqenrleamra ysqqaegfltkeilekwkktveevlhdz

## ID103 2292bp

35

ATGTCCTCTCTTTCGGATCAAGAATTAGTAGCTAAAACAGTAGAGTTTCGTCAGCGTCTTTCCGAGGGAGAAAGTC 40 TAGACGATATTTTGGTTGAAGCTTTTGCTGTGGTGCGTGAAGCAGATAAGCGGATTTTAGGGATGTTTCCTTATGA TGTTCAAGTCATGGGAGCTATTGTCATGCACTATGGAAATGTTGCTGAGATGAATACGGGGGAAGGTAAGACCTT GACAGCTACCATGCCTGTCTATTTGAACGCTTTTTCAGGAGAAGGAGTGATGGTTGTGACTCCTAATGAGTATTTA TCAAAGCGTGATGCCGAGGAAATGGGTCAAGTTTATCGTTTTCTAGGATTGACCATTGGTGTACCATTTACGGAAG ATCCAAAGAAGAGATGAAAGCTGAAGAAAAGAAGCTTATCTATGCTTCGGATATCATCTACACAAACCAATAGTA 45 ATTTAGGTTTTGATTATCTAAATGATAACCTAGCCTCGAATGAAGAAGGTAAGTTTTTACGACCGTTTAACTATGT GATTATTGATGAAATTGATGATATCTTGCTTGATAGTGCACAAACTCCTCTGATTATTGCGGGTTCTCCTCGTGTTC AGTCTAATTACTATGCGATCATTGATACACTTGTAACAACCTTGGTCGAAGGAGGAGTTATATCTTTAAAGAGGA GAAAGAGGAGGTTTGGCTCACTACTAAGGGGGCCAAGTCTGCTGAGAATTTCCTAGGGATTGATAATTTATACAA GGAAGAGCATGCGTCTTTTGCTCGTCATTTGGTTTATGCGATTCGAGCTCATAAGCTCTTTACTAAAGATAAGGAC 50 TATATCATTCGTGGAAATGAGATGGTACTGGTTGATAAGGGAACAGGGCGTCTAATGGAAATGACTAAACTTCAA GGAGGTCTCCATCAGGCTATTGAAGCCAAGGAACATGTCAAATTATCTCCTGAGACGCGGGCTATGGCCTCGATC ACCTATCAGAGTCTTTTTAAGATGTTTAATAAGATATCTGGTATGACAGGGACAGGTAAGGTCGCGGAAAAAGAG ATCTATATATCACTTTACCTGAAAAAGTGTATGCATCCTTGGAGTACATCAAGCAATACCATGCTAAGGGAAATCC 55 TTTACTCGTTTTTGTAGGCTCAGTTGAAATGTCTCAACTCTATTCGTCTCTTGTTTCGTGAAGGGATTGCCCATA ATGTCCTAAATGCTAATAATGCGGCGCGTGAGGCTCAGATTATCTCCGAGTCAGGTCAGATGGGGGCTGTGACAG TGGCTACCTCTATGGCAGGACGTGGTACGGATATCAAGCTTGGTAAAGGAGTCGCAGAGCTTGGGGGGCTTGATTG TTATTGGGACTGAGCGGATGGAAAGTCAGCGGATCGACCTACAAATTCGTGGCCGTTCTGGTCGTCAGGGAGATC CTGGTATGAGTAAATTTTTTTGTATCCTTAGAGGATGATGTTATCAAGAAATTTGGTCCATCTTGGGTGCATAAAAA 60 GTACAAAGACTATCAGGTTCAAGATATGACTCAACCGGAAGTATTGAAAGGTCGTAAATACCGGAAACTAGTCGA AAAGGCTCAGCATGCCAGTGATAGTGCTGGACGTTCAGCACGTCGTCAGACTCTGGAGTATGCTGAAAGTATGAA TATACAACGGGATATAGTCTATAAAGAGAGAAATCGTCTAATAGATGGTTCTCGTGACTTAGAGGATGTTGTTGTG GATATCATTGAGAGATATACAGAAGAGGTAGCGGCTGATCACTATGCTAGTCGTGAATTATTGTTTCACTTTATTG TGACCAATATTAGTTTTCATGTTAAAGAGGTTCCAGATTATATAGATGTAACTGACAAAACTGCAGTTCGTAGCTT 65 TATGAAGCAGGTGATTGATAAAGAACTTTCTGAAAAGAAGAATTACTTAATCAACATGACTTATATGAACAGTT

TTTACGACTTTCACTGCTTAAAGCCATTGATGACAACTGGGTAGAGCAGGTAGACTATCTACAACAGCTATCCATG
GCTATCGGTGGTCAATCTGCTAGTCAGAAAAATCCAATCGTAGAGTACTATCAAGAAGCCTACGCGGGCTTTGAA
GCTATGAAAGAACAGATTCATGCGGATATGGTGCGTAATCTCCTGATGGGGCTGGTTGAGGTCACTCCAAAAGGT
GAAATCGTGACTCATTTTCCATAA

5

MSSLSDQELVAKTVEFRQRLSEGESLDDILVEAFAVVREADKRILGMFPYDVQVMGAIVMHYGNVAEMNTGEGKTLT
ATMPVYLNAFSGEGVMVVTPNEYLSKRDAEEMGQVYRFLGLTIGVPFTEDPKKEMKAEEKKLIYASDIIYTTNSNLGF
DYLNDNLASNEEGKFLRPFNYVIIDEIDDILLDSAQTPLIIAGSPRVQSNYYAIIDTLVTTLVEGEDYIFKEEKEEVWLTTK
GAKSAENFLGIDNLYKEEHASFARHLVYAIRAHKLFTKDKDYIIRGNEMVLVDKGTGRLMEMTKLQGGLHQAIEAKEH
VKLSPETRAMASITYQSLFKMFNKISGMTGTGKVAEKEFIETYNMSVVRIPTNRPRQRIDYPDNLYITLPEKVYASLEYIK

QYHAKGNPLLVFVGSVEMSQLYSSLLFREGIAHNVLNANNAAREAQIISESGQMGAVTVATSMAGRGTDIKLGKGVAE LGGLIVIGTERMESQRIDLQIRGRSGRQGDPGMSKFFVSLEDDVIKKFGPSWVHKKYKDYQVQDMTQPEVLKGRKYRK LVEKAQHASDSAGRSARRQTLEYAESMNIQRDIVYKERNRLIDGSRDLEDVVVDIIERYTEEVAADHYASRELLFHFIVT NISFHVKEVPDYIDVTDKTAVRSFMKQVIDKELSEKKELLNQHDLYEQFLRLSLLKAIDDNWVEQVDYLQQLSMAIGG QSASQKNPIVEYYQEAYAGFEAMKEQIHADMVRNLLMGLVEVTPKGEIVTHFPZ

#### ID104 879bp

15

- MKQEWFESNDFVKTTSKNKPEEQAQEVADKAEERIPDLDTPIEKNTQLEEEVSQAEVELESQQEEKIEAPEDSEARTEIE EKKASNSTEEEPDLSKETEKVTIAEESQEALPQQKATTKEPLLISKSLESPYIPDQAPKSRDKWKEQVLDFWSWLVEAIKS PTSKLETSITHSYTAFLLLILFSASSFFFSIYHIKHAYYGHIASINSRFPEQLAPLTLFSIISILVATTLFFFSFLLGSFVVRRFIH QEKDWTLDKVLQQYSQLLAIPISSLLLLVSLLSLIAYDLQPSCVZ

#### ID106 327bp

- ATGTACTITCCAACATCCTCTGCCTTGATTGAATTTCTCATCTTGGCTGTACTGGAGCAGGGTGATTCTTATGGTTA

  TGAGATTAGCCAAACCATTAAGCTGATCGCTAATATCAAAGAATCCACACTCTATCCCATTCTCAAAAAAATTGGAT;
  AGGCAATAGCTTTCTGACAACCTATTCTAGAGAGTTCCAAGGTCGCATGCGCAAATACTACTCCTTGACAAACGG
  TGGTATAGAGCAGCTCTTGACCCTAAAAGATGAATGGCACCTCTATACAGACACCATCAATGGCATCATAGAAGG
  GAGTATCCGCCATGACAAGAACTGA
- 45 MYFPTSSALIEFLILAVLEQGDSYGYEISQTIKLIANIKESTLYPILKKLEGNSFLTTYSREFQGRMRKYYSLTNGGIEQLLT LKDEWALYTDTINGIIEGSIRHDKNZ

## ID108 954bp

- TGTGGAAGAGTTGTTTAAAGAGGAGGAAATTACTATCCTCGAAATGGGTTCTGGGATGGGAATTCTAGGCGCTAT
  TTTCTTGACCTCGCTTACTAAAAAAGGTGGATTACTTGGGAATGGAAGTGGATGATTTGCTGATCTGGCAGCT
  AGCATGGCAGATGTAATTGGTTTGCAGGCTGGCTTTGTCCAAGGAGATGCCGTTCGCCCACAAATGCTCAAAGAA
  AGCGATGTGGTCATCAGTGACTTGCCTGTCGGCTATTATCCTGATGATGCCGTTGCGTCGCCCATCAAGTTGCTT
  CTAGCCAAGAACATACTTACGCCCATCACTTGCTCATGGAACAAGGGCTTAAGTACCTCAAGTCAGACGGATACG
  CTATTTTTCTAGCTCCGAGTGATTTGTTGACCAGTCCTCAAAGTGATTTGTTAAAAGAATGGCTGAAAGAAGAGGC
- 60 GAGTCTGGTTGCTATGATTAGTCTGCCTGAAAAATCTCTTTGCTAATGCCAAACAATCTAAGACTATTTTTATCTTAC
  AGAAGAAAAATGAATAGCAGTAGAGCCTTTTGTTTATCCACTTGCTAGCTTGCAAGATGCAAGTGTTTTAATGAA
  ATTTAAAGAAAATTTTCAAAAATGGACTCAAGGTACTGAAATATAA
- MDFEKIEQAYIYLLENVQVIQSDLATNFYDALVEQNSIYLDGETELNQVKDNNQALKRLALRKEEWLKTYQFLLMKA GQTEPLQANHQFTPDAIALLLVFIVEELFKEEEITILEMGSGMGILGAIFLTSLTKKVDYLGMEVDDLLIDLAASMADVI

 ${\tt GLQAGFVQGDAVRPQMLKESDVVISDLPVGYYPDDAVASRHQVASSQEHTYAHHLLMEQGLKYLKSDGYAIFLAPSDLLTSPQSDLLKEWLKEEASLVAMISLPENLFANAKQSKTIFILQKKNEIAVEPFVYPLASLQDASVLMKFKENFQKWTQGTEIZ$ 

## 5 <u>ID110 1902bp</u>

ATGATTATTTTACAAGCTAATAAAATTGAACGTTCTTTTGCAGGAGAGGTTCTTTTCGATAATATCAACCTGCAGG TTGATGAACGAGATCGGATTGCTCTTGTTGGGAAAAATGGTGCAGGTAAGTCTACTCTTTTGAAGATTTTAGTTGG AGAAGAGGAGCCAACTAGCGGAGAAATCAATAAGAAAAAAGATATTTCTCTGTCTTACCTAGCCCAAGATAGCCG 10  ${\tt CGTCAGATGGAGCTGGAGATGGGTGAAAAGTCTGGTGAGGATTTGGATAAACTGATGTCAGATTATGACCGCTTA}$ TCTGAGAATTTTCGCCAAGCAGGTGGCTTTACCTATGAAGCTGATATTCGAGCGATTTTGAATGGATTCAAGTTTG ACGAGTCTATGTGGCAGATGAAAATTGCTGAGCTTTCTGGTGGTCAAAATACTCGTTTGGCACTTGCCAAAATGCT CCTTGAAAAGCCCAATCTCTTGGTCTTGGACGAGCCAACTAACCACTTGGATATTGAAACCATCGCCTGGCTAGA 15 GAATTACTTGGTAAACTATAGCGGTGCCCTCATTATCGTCAGCCACGACCGTTATTTCTTGGACAAGGTTGCGACA ATTACGCTAGATTTGACCAAGCATTCCTTGGATCGCTATGTGGGGAATTACTCTCGTTTTTGTCGAATTGAAGGAGC AAAAGCTAGTTACTGAGGCAAAAAACTATGAAAAGCAACAGAAGGAAATCGCTGCTCTGGAAGACTTTGTCAATC GCAATCTAGTTCGTGCTTCAACGACTAAACGTGCTCAATCTCGCCGTAAACAACTAGAAAAAAATGGAGCGTTTTGG ACAAGCCTGAAGCTGGCAAGAAAGCAGCCAACATGACCTTCCAGTCTGAAAAAACGTCGGGCAATGTTGTTTTGA 20 CTGTTGAAAATGCAGCTGTTGGCTATGACGGGGAAGTCTTGTCACAACCTATCAACCTAGATCTTCGTAAGATGAA TGCTGTCGCTATCGTTGGTCCAAATGGTATCGGCAAGTCAACCTTTATCAAGTCTATTGTGGACCAGATTCCTTTT AGTAATACGGTGCTGGATGAACTCTGGAATGATTTCAAACTGACACCAGAAGTTGAAATCCGCAACCGTCTTGGA GCCTTCCTTTCTCAGGAGATGATGTTAAAAAATCAGTCGGCATGCTATCTGGTGGCGAAAAAGCTCGTTTGCTTT 25 CGTGTGGCAACTCATGTTTTGGAATTGTCTGAGAATGGTTCAACTCTCTACCTTGGAGATTACGACTACTATGTTG AGAAGAAAGCAACAGCAGAAATGAGTCAGACTGAGGAAGCTTCAACTAGCAATCAAGCAAAGGAAGCAAGTCCA GTCAATGACTATCAGGCCCAGAAAGAAAGTCAAAAAGAAGTTCGCAAACTCATGCGACAAATCGAAAGTCTAGA 30 **AACTCATGGAATTACAGGCTGAGCTGGACAAAATCAGCCATCGTCAGGAAGAAGCTATGCTTGAGTGGGAAGAAT** 

MIILQANKIERSFAGEVLFDNINLQVDERDRIALVGKNGAGKSTLLKILVGEEEPTSGEINKKKDISLSYLAQDSRFESENT
IYDEMLHVFNDLRRTERQLRQMELEMGEKSGEDLDKLMSDYDRLSENFRQAGGFTYEADIRAILNGFKFDESMWQMK
IAELSGGQNTRLALAKMLLEKPNLLVLDEPTNHLDIETIAWLENYLVNYSGALIIVSHDRYFLDKVATITLDLTKHSLDR
YVGNYSRFVELKEQKLVTEAKNYEKQQKEIAALEDFVNRNLVRASTTKRAQSRRKQLEKMERLDKPEAGKKAANMTF
QSEKTSGNVVLTVENAAVGYDGEVLSQPINLDLRKMNAVAIVGPNGIGKSTFIKSIVDQIPFIKGEKRFGANVEVGYYDQ
TOSKLTPSNTVLDELWNDFKLTPEVEIRNRLGAFLFSGDDVKKSVGMLSGGEKARLLLAKLSMENNNFLILDEPTNHL
DIDSKEVLENALIDFDGTLLFVSHDRYFINRVATHVLELSENGSTLYLGDYDYYVEKKATAEMSQTEEASTSNQAKEAS
PVNDYQAQKESQKEVRKLMRQIESLEAEIEELESQSQAISEQMLETNDADKLMELQAELDKISHRQEEAMLEWEELSEQ

#### ID111 1179bp

45

TATCAGAGCAGGTGTAA

ATGAATCGCTATGCAGTGCAGTTGATTAGCCGTGGGGCTATCAATAAAATGGGAAATATGCTCTATGATTATGGA CATCTATTCTCGTCAATCCCTTTGGCGGAGTTATTTCAGACCGTTTTTCTCGTCGTAAGATTTTAATGACGGCAGAT CTTGTTTGTGGGATTCTTTGTCTGGCTATTTCTTTCATAAGGAATGATAGCTGGATGATTGGCGCTTTGATTGTTGC 50 TAACATTGTGCAGGCTATTGCTTTTTGCCTTTTCTCGCACAGCCAATAAAGCTATCATAACTGAAGTGGTGGAGAAA GATGAGATTGTGATCTATAATTCTCGCTTAGAGCTGGTTTTGCAGGTTGTAGGTGTTAGCTCTCCTGTTCTTTCCTT CCTTGTTTTACAGTTTGCAAGTCTCCATATGACGCTACTGCTAGACTCGCTGACTTTTTTTCATTGCTTTTGTTCTAG TGGCTTTCCTTCCAAAAGAGGAAGCAAAAGTTCAAGAGAAAAAGGCTTTTACTGGGAGAGATATTTTTGTAGATA TCAAGGATGGGTTACACTATATCTGGCATCAGCAAGAAATTTTCTTCCTTTTGCTGGTAGCTTCCAGCGTTAATTT 55 CTTTTTTGCAGCTTTTGAATTTCTACTTCCCTTTTCGAATCAGCTTTACGGGTCAGAAGGAGCCTATGCAAGTATTT TAACTATGGGGGCTATTGGTTCCATCATTGGGGCTCTTCTAGCTAAAAATTAAAGCTAATATTTATAATCTTTT ATTTAGTTTGTGAATTGTTTATGACGATTTTTAATATTCACTTTTTTACTCAAGTACAAACCAAGGTTGAGAGCGAA TTTCTTGGAAGAGTACTGAGTACAATTTTTACCTTAGCTATTCTATTTATGCCTATTGCAAAAGGATTTATGACAGT 60 CTTGCCAAGTGTCCATCTTTATTCTTTGTTATTATTGGACTTGGAGTTGTAGCCTTATATTTCTTAGCTCTCGGAT ATGTTCGAACTCATTTTGAAAAATTGATATAA

MNRYAVQLISRGAINKMGNMLYDYGNSVWLASMGTIGQTVLGMYQISELVTSILVNPFGGVISDRFSRRKILMTADLV CGILCLAISFIRNDSWMIGALIVANIVQAIAFAFSRTANKAIITEVVEKDEIVIYNSRLELVLQVVGVSSPVLSFLVLQFASL HMTLLLDSLTFFIAFVLVAFLPKEEAKVQEKKAFTGRDIFVDIKDGLHYIWHQQEIFFLLLVASSVNFFFAAFEFLLPFSN

QLYGSEGAYASILTMGAIGSIIGALLASKIKANIYNLLILLALTGVGVFMMGLPLPTFLSFSGNLVCELFMTIFNIHFFTQVQTKVESEFLGRVLSTIFTLAILFMPIAKGFMTVLPSVHLYSFLIIGLGVVALYFLALGYVRTHFEKLIZ

#### ID113 2466bp

- 5 GCTAGACCTGGCAAGAAGGTTCAAGTACCAAAAAATCTAAAACCTTAGATAAGTCAGCCATTTTCCCAGCTATT TTACTGAGTATAAAAGCCTTATTTAACTTACTCTTTGTACTCGGTTTTCTAGGAGGAATGTTGGGAGCTGGGATTG 10 ACATCTCTTCTATTTCAGAGATTACCTATTCGGACGGGACGGTGATTGCTTCCATAGAGAGTGATTTGTTGCGCAC TTCTATCTCATCTGAGCAAATTTCGGAAAATCTGAAGAGGCTATCATTGCGACAGAAGATGAACACTTTAAAGA ACATAAGGGTGTAGTACCCAAGGCGGTGATTCGTGCGACCTTGGGGAAATTTGTAGGTTTGGGTTCCTCTAGTGGG GGTTCAACCTTGACCCAGCAACTAATTAAACAGCAGGTGGTTGGGGATGCGCCGACCTTGGCTCGTAAGGCGGCA GAGATTGTGGATGCTCTTGCCTTGGAACGCGCCATGAATAAAGATGAGATTTTAACGACCTATCTCAATGTGGCTC 15 CCTTTGGCCGAAATAATAAGGGACAGAATATTGCAGGGGCTCGGCAAGCAGCTGAGGGAATTTTCGGTGTAGATG **AAATACTGGGGAGTTGAAGAGTGATGAAGACCTAGAAATTGGCTTAAGACGGGCTAAGGCAGTTCTTTACAGTAT** GTATCGTACAGGTGCATTAAGCAAAGACGAGTATTCTCAGTACAAGGATTATGACCTTAAACAGGACTTTTTACC 20 GACTATCTAGCTCAGAGAGACAATGTCTCCGCTAAGGAGTTGAAAAATGAGGCAACTCAGAAGTTTTATCGAGAT CAAAGTGCGGTTGCTGATTATGGCTATCTTTTAGACGATGGAACAGGTCGTGTAGAAGTAGGGAATGTCTTGATG GATAACCAAACAGGTGCTATTCTAGGCTTTGTAGGTGGTCGTAATTATCAAGAAAATCAAAATAATCATGCCTTTG ATACCAAACGTTCGCCAGCTTCTACTACCAAGCCCTTGCTGGCCTACGGTATTGCTATTGACCAGGGCTTGATGGG 25 AACAGGAATGATGACCTTGGGAGAAGCTCTGAACTATTCATGGAATATCCCTGCTTACTGGACCTATCGTATGCTC CGTGAAAAGGGTGTTGATGTCAAGGGTTATATGGAAAAGATGGGTTACGAGATTCCTGAGTACGGTATTGAGAGC TTGCCAATGGGTGGTGTATTGAAGTCACAGTTGCCCAGCATACCAATGGCTATCAGACCTTAGCTAATAATGGA GTTTATCATCAGAAGCATGTGATTTCAAAGATTGAAGCAGCAGATGGTAGAGTGTGTATGAGTATCAGGATAAA 30 CCGGTTCAAGTCTATTCAAAAGCTACTGCGACGATTATGCAGGGATTGCTACGAGAAGTTCTATCCTCTCGTGTGA CAACAACCTTCAAGTCTAACCTGACTTCTTTAAATCCTACTCTGGCTAATGCAGATTGGATTGGGAAGACTGGTAC AACCAACCAAGACGAAAATATGTGGCTCATGCTTTCGACACCTAGATTAACCCTAGGTGGCTGGATTGGGCATGA TGATAATCATTCACTAGAGAGCAGGTTATTCTAATAACTCTAATTACATGGCTCATCTGGTAAATGCGATT CAGCAAGCTTCCCCAAGCATTTGGGGGAACGAGCGCTTTGCTTTAGATCCTAGTGTAGTGAAATCGGAAGTCTTG 35 AAATCAACAGGTCAAAAACCAGAGAAGGTTTCTGTTGAAGGAAAAGAAGTAGAGGTCACAGGTTCGACTGTTACC AGCTATTGGGCTAATAAGTCAGGAGCGCCAGCGACAAGTTATCGCTTTGCTATTGGCGGAAGTGATGCGGATTAT

ATAGCAGTAACTCAAGTACTACACGACCTTCTTCTTCAAGGGCGAGACGATAA

#### ID114 1974bp

CAGTTTATTTTGGTGGTGGGTCTGCTTCAATCAAGCGTACACGGACTCGTACGCGCGCTATGATGACAGCTAT TTCAGATAAGATTCGGAGTGTAGATCAGGTTTTTGTAGTCGGTCACAAAAATTTAGACATGGATGCTTTGGGCTCT GCTGTAGGTATGCAGTTGTTCGCCAGCAATGTGATTGAAAATAGCTATGCTCTTTATGATGAAGAACAAATGTCTC CAGATATTGAACGAGCTGTTTCATTCATAGAAAAAGAAGGAGTTACGAAGTTGTTGTCTGTTAAGGATGCAATGG 5 GGATGGTGACCAATCGTTCTTTGTTGATTCTTGTAGACCATTCAAAGACAGCCTTAACATTATCAAAAGAATTTTA TGATTTATTTACCCAAACCATTGTTATTGACCACCATAGAAGGGATCAGGATTTTCCAGATAATGCGGTTATTACT TATATCGAAAGTGGTGCAAGTAGTGCCAGTGAGTTGGTAACGGAATTGATTCAGTTCCAGAATTCTAAGAAAAAT CGTTTGAGTCGTATGCAAGCAAGTGTCTTGATGGCTGGTATGATGTTGGATACTAAAAATTTCACCTCGCGAGTAA CTAGTCGGACATTTGATGTTGCTAGCTATCTCAGAACGCGCGGAAGTGATAGTATTGCTATCCAGGAAATCGCTGC 10 GACAGATTTTGAAGAATATCGTGAGGTCAATGAACTTATTTTACAGGGGCGTAAATTAGGTTCAGATGTACTAATA GCAGAGGCTAAGGACATGAAATGCTATGATACAGTTGTTATTAGTAAGGCAGCAGATGCCATGTTAGCCATGTCA GGTATTGAAGCGAGTTTTGTTCTTGCGAAGAATACACAAGGATTTATCTCTATCTCAGCTCGAAGTCGTAGTAAAC TGAATGTACAACGGATTATGGAAGAGTTAGGCGGTGGAGGCCACTTTAATTTGGCAGCAGCTCAAATTAAAGATG 15

MKKFYVSPIFPILVGLIAFGVLSTFIIFVNNNLLTVLILFLFVGGYVFLFKKLRVHYTRSDVEQIQYVNHQAEESLTALLE QMPVGVMKLNLSSGEVEWFNPYAELILTKEDGDFDLEAVQTIIKASVGNPSTYAKLGEKRYAVHMDASSGVLYFVDVS REQAITDELVTSRPVIGIVSVDNYDDLEDETSESDISQINSFVANFISEFSEKHMMFSRRVSMDRFYLFTDYTVLEGLMN DKFSVIDAFREESKQRQLPLTLSMGFSYGDGNHDEIGKVALLNLNLAEVRGGDQVVVKENDETKNPVYFGGGSAASIK RTRTRTRAMMTAISDKIRSVDQVFVVGHKNLDMDALGSAVGMQLFASNVIENSYALYDEEQMSPDIERAVSFIEKEGV TKLLSVKDAMGMVTNRSLLILVDHSKTALTLSKEFYDLFTQTIVIDHHRRDQDFPDNAVITYIESGASSASELVTELIQFQ NSKKNRLSRMQASVLMAGMMLDTKNFTSRVTSRTFDVASYLRTRGSDSIAIQEIAATDFEEYREVNELILQGRKLGSDV LIAEAKDMKCYDTVVISKAADAMLAMSGIEASFVLAKNTQGFISISARSRSKLNVQRIMEELGGGGHFNLAAAQIKDVT LSEAGEKLTEIVLNEMKEKEKEEZ

## ID115 663bp

- MKCLLCGQTMKTVLTFSSLLLLRNDDSCLCSDCDSTFERIGEENCPNCMKTELSTKCQDCQLWCKEGVEVSHRAIFTY
  40 NQAMKDFFSRYKFDGDFLLRKVFASFLSEELKKYKEYQFVVIPLSPDRYANRGFNQVEGLVEAAGFEYLDLLEKREER
  ASSSKNRSERLGTELPFFIKSGVTIPKKILLIDDIYTTGATINRVKKLLEEAGAKDVKTFSLVRZ

#### ID116 1299bp

- 45 GAGAAACTTCCAGCAATGAGAAAGGAGAAGGGGAAACTTTTCTGTCAACGCTGTAATAGTACTATTCTAGAAGAA ACTATTTTCCGCAGGAGGATTTTCCAAAGCAAGATGTTCTCAAATGGCGCGGCCAATTAACTCCTTTTCAAGAGAA GGTGTCAGAGGGATTGCTTCAAGTAGTAGACAAGCCAAAAGCCAACCTTAGTTCATGCGGTAACAGGAGCTGGAAA 50 GACAGAAATGATTTATCAAGTAGTGGCTAAAGTGATCAATGCGGGTGGTGCAGTGTTTTGGCTAGTCCTCGCAT AGATGTTTGTTTGGAGCTGTACAAGCGCCTGCAACAGGATTTTTCTTGCGGGATAGCTTTGCTACATGGAGAATCG GAACCTTATTTTCGAACACCACTAGTTGTTGCAACAACCCATCAGTTATTGAAGTTTTATCAAGCTTTTGATTTGCT GATAGTGGATGAAGTAGATGCTTTTCCTTATGTTGATAATCCCATGCTTTACCACGCTGTCAAGAATAGTGTAAAG GAGAATGGATTGAGAATCTTTTTAACAGCGACTTCGACCAATGAGTTAGATAAAAAGGTCCGTTTAGGAGAACTA 55 AAAAGACTGAATTTACCGAGACGGTTTCATGGAAATCCGTTGATTATTCCAAAACCAATTTGGTTATCGGATTTTA ATCGCTACTTAGACAAGAATCGTTTGTCACCAAAGTTAAAGTCCTATATTGAGAAGCAGGAGAAAGACAGCTTATC CGTTACTCATTTTTGCTTCAGAAATTAAGAAAGGGGAGCAGTTAGCAGAAATCTTACAGGAGCAATTTCCAAATG AGAAAATTGGCTTTGTATCTTCTGTAACAGAGGATCGATTAGAGCAAGTACAAGCTTTTCGAGATGGAGAACTGA CAATACTTATCAGTACGACAATCTTGGAGCGCGGAGTTACCTTCCCTTGTGTGGATGTTTTCGTAGTAGAGGCCAA 60 TCATCGTTTGTTTACCAAGTCTAGTTTGATTCAGATTGGTGGACGAGTTGGACGAAGCATGGATAGACCGACAGGA GATTTGCTTTCCATGATGGGTTAAATGCTTCAATCAAGAAGGCGATTAAGGAAATTCAGATGAATAAGG **AGGCTGGTCTATGA**
- MKVNLDYLGRLFTENELTEEERQLAEKLPAMRKEKGKLFCQRCNSTILEEWYLPIGAYYCRECLLMKRVRSDQTLYYF PQEDFPKQDVLKWRGQLTPFQEKVSEGLLQVVDKQKPTLVHAVTGAGKTEMIYQVVAKVINAGGAVCLASPRIDVCL

ELYKRLQQDFSCGIALLHGESEPYFRTPLVVATTHQLLKFYQAFDLLIVDEVDAFPYVDNPMLYHAVKNSVKENGLRIF LTATSTNELDKKVRLGELKRLNLPRRFHGNPLIIPKPIWLSDFNRYLDKNRLSPKLKSYIEKQRKTAYPLLIFASEIKKGE QLAEILQEQFPNEKIGFVSSVTEDRLEQVQAFRDGELTILISTTILERGVTFPCVDVFVVEANHRLFTKSSLIQIGGRVGRS MDRPTGDLLFFHDGLNASIKKAIKEIQMMNKEAGLZ

ID117 870bp

5

- 20
  MOIQKSFKGQSPYGKLYLVATPIGNLDDMTERAIQTLKEVDWIAAEDTRNTGLLLKHFDISTKQISFHEHNAKEKIPDLI
  GFLKAGQSIAQVSDAGLPSISDPGHDLVKAAIEEEIAVVTVPGASAGISALIASGLAPQPHIFYGFLPRKSGQQKQFFGLKK
  DYPETQIFYESPHRVADTLENMLEVYGDRSVVLVRELTKIYEEYQRGTISELLESIAETPLKGECLLIVEGASQGVEEKDE
  EDLFVEIQTRIQQGVKKNQAIKEVAKIYQWNKSQLYAAYHDWEEKQZ

ID118 345bp

- ATGATAAAGAAAGGAAAGGCTGTTTTATGGACAAAAAAGAATTATTTGACGCGCTGGATGATTTTTCCCAACAA
  TTATTGGTAACCTTAGCCGATGTGGAAGCCATCAAGAAAAATCTCAAGAGCCTGGTAGAGGAAAATACAGCTCTT
  CGCTTGGAAAATAGTAAGTTGCGAGAACGCTTGGGTGAGGTGGAAGCAGATGCTCCTGTCAAGGCCAAGCATGTT
  CGCGAAAGTGTCCGTCGTATTTACCGTGATGGATTTCACGTATGTAATGATTTTTATGGACAACGTCGAGAGCAGG
  ACGAAGATGTATGTTTTTGTGACGAGTTGTTATACAGGGAGTAA
- MIKKGKGCFMDKKELFDALDDFSQQLLVTLADVEAIKKNLKSLVEENTALRLENSKLRERLGEVEADAPVKAKHVRES VRRIYRDGFHVCNDFYGQRREQDEECMFCDELLYREZ

ID119 639bp

- MSKGFLVSLEGPEGAGKTSVLEALLPILEEKGVEVLTTREPGGVLIGEKIREVILDPSHTQMDAKTELLLYIASRRQHLVE KVLPALEAGKLVIMDRFIDSSVAYQGFGRGLDIEAIDWLNQFATDGLKPDLTLYFDIEVEEGLARIAANSDREVNRLDL EGLDLHKKVRQGYLSLLDKEGNRIVKIDASLPLEQVVETTKAVLFDGMGLAKZ

ID120 408bp

- 55 ATGGTAGAACAAAGAAAATCAATTACCATGAAAGATGTTGCTTTAGAAGCAGGAGTTAGTGTTGGAACTGTTTCA
  CGTGTAATTAATAAAGAAAAAGGCATTAAAGAAGTAACTTTGAAAAAAAGTGGAACAAGCGATTAAAAACTTTGAAT
  TACATTCCAGATTACTACGCTAGAGGGAATGAAAAAAAATCGAACAGAAACGATTGCAATCATTGTACCAAGTATC
  TGGCATCCCTTCTTTTCAGAATTTGCTATGCATGTGGAAAATGAAGTCTATAAGAGAAATAACAAATTACTCTTAT
  GTTCTATCAATGGTACAAATAGAGACCAAGACTATCTGGAGATGTTGCGTCATAATAAAGTTGATGGAGTGGTTG
  CCATTACCTATAGGCCAATTGAACATTACTTGACGTCAGGAATTCCCTTTGTTAGTATTGACCGCACATACTCAGA
  GATTGCCATTCCTTGTGTTTCA
  - MVEQRKSITMKDVALEAGVSVGTVSRVINKEKGIKEVTLKKVEQAIKTLNYIPDYYARGMKKNRTETIAIIVPSIWHPFF SEFAMHVENEVYKRNNKLLLCSIŅGTNREQDYLEMLRHNKVDGVVAITYRPIEHYLTSGIPFVSIDRTYSEIAIPCVS

#### ID121 285bp

- MNIFRTKNVSLDKTEMHRHLKLWDLILLGIGAMVGTGVFTITGTAAATLAGPALVISIVISALCVGLSALFFAEFASRVP ATGGAYSYLYAILGEFPAWLAGWLTMMEFMTAISGVASGWAAYF

#### ID124 1311bp

- ATGAAATCAAGAGTAAAGGAAACGAGTATGGATAAAATTGTGGTTCAAGGTGGCGATAATCGTCTGGTAGGAAGC.
  GTGACGATCGAGGGAGCAAAAAATGCAGTCTTACCCTTGTTGGCAGCGACTATTCTAGCAAGTGAAGGAAAGACC
  GTCTTGCAGAATGTTCCGATTTTGTCAGGTGCTTTATTATGAATCAGGTAGTTGGTGGTTTTGAATGCCAAGGTTG
  ACTTTGATGAGGAAGCTCATCTTGTCAAGGTGGATGCTACTGGCGACATCACTGAGGAAGCCCCTTACAAGTATG
  TCAGCAAGATGCCGCCTCCATCGTTGTATTAGGGCCAATCCTTGCCCGTGTGGGTCATGCCAAGGTATCCATGCC
  AGGTGGTTGTACGATTGGTAGTCATCTTCATTTGAAAGGTCTGGAAGCTATGGGGTTAAGATTAGT
  CAGACAGCTGGTTACATCGAAGCCAAGGCAGAACGCTTGCATGGTGCTCATATCTAATGGACTTTCCAAGTGTTG
  GTGCAACGCAGAACTTGATGATGGCAGCGACTCTGGCTGATGGGGTGACAGTGATTGAGAATGCTGCGCGTGAGC
  CTGAGATTGTTGACTTAGCCATTCTCCTTAATGAAATGGGAGCCAAGGTCAAAGGTGCTGGTACAGAGACTATAA
- 30 AATTGGTTCACTTGGATAGAGGTTACTACGGTTTCCATGAGAAGTTGGCGCAGCTAGGTGCTAAGATTCAGCGGAT TGAGGCAAGTGATGAAGATAAA MKSRVKETSMDKIVVQGGDNRLVGSVTIEGAKNAVLPLLAATILASEGKTVLQNVPILSDVFIMNQVVGGLNAKVDFD
- EEAHLVKVDATGDITEEAPYKYVSKMRASIVVLGPILARVGHAKVSMPGGCTIGSRPIDLHLKGLEAMGVKISQTAGYIE
  AKAERLHGAHIYMDFPSVGATQNLMMAATLADGVTVIENAAREPEIVDLAILLNEMGAKVKGAGTETITITGVEKLHG
  TTHNVVQDRIEAGTFMVAAAMTGGDVLIRDAVWEHNRPLIAKLLEMGVEVIEEDEGIRVRSQLENLKAVHVKTLPHP
  GFPTDMQAQFTALMTVAKGESTMVETVFENRFQHLEEMRRMGLHSEIIRDTARIVGGQPLQGAEVLSTDLRASAALIL
  TGLVAQGETVVGKLVHLDRGYYGFHEKLAQLGAKIQRIEASDEDEZ

## 40 <u>ID125 1101bp</u>

- GAATTAGGGGATAAGATTGCGGAATATGCTATTCAAAATATGGCCAGCCGTGGCATTAGTTACATCATCTGGAAA
  CAACGTTTCTATGCTCCATTCGATAGCAAATATGGGCCAGCCGTGGCATTAGTTACATCATCTGGAAA
  CAACGTTTCTATGCTCCATTCGATAGCAAATATGGGCCAGCTAACACTTGGAACCCCAATGCCAGACCGTGGTAGT
  GTGACAGAAAATCACTATGATCACGTTTCAATGAATGGATAA
- MLLASTVALSFAPVLATQAEEVLWTARSVEQIQNDLTKTDNKTSYTVQYGDTLSTIAEALGVDVTVLANLNKITNMDL IFPETVLTTTVNEAEEVTEVEIQTPQADSSEEVTTATADLTTNQVTVDDQTVQVADLSQPIAEVTKTVIASEEVAPSTGTS VPEEQTTETTRPVAEEAPQETTPAEKQETQTSPQAASAVEATTTSSEAKEVASSNGATAAVSTYQPEETKVISTTYEAPA APDYAGLAVAKSENAGLQPQTAAFKKKLLTCLALHPLVVIVQETVEITEKVWLSTLWYQNVQNZGIRLRNMLFKIWPA VALVTSSGNNVSMLHSIANMGQLTLGTQCQTVVVZQKITMITFTFQZMD

#### ID126 1281bp

TAATGGTFFFCGCTGGTFATFFCFACGCTATCGTFACCAGCGCTATATGAGCTTGAAAGGATAG

LFKKNKDILNIALPAMGENFLQMLMGMVDSYLVAHLGLIAISGVSVAGNIITIYQAIFIALGAAISSVISKSIGQKDQSKLA YHVTEALKITLLLSFLLGFLSIFAGKEMIGLLGTERDVAESGGLYLSLVGGSIVLLGLMTSLGALIRATHNPRLPLYVSFL SNALNILFSSLAIFVLDMGIAGVAWGTIVSRLVGLVILWSQLKLPYGKPTFGLDKELLTLALPAAGERLMMRAGDVVIIA LVVSFGTEAVAGNAIGEVLTQFNYMPAFGVATATVMLLARAVGEDDWKRVASLSKQTFWLSLFLMLPLSFSIYVLGVP LTHLYTTDSLAVEASVLVTLFSLLGTPMTTGTVIYTAVWQGLGNARLPFYATSIGMWCIRIGTGYLMGIVLGWGLPGIW AGSLLDNGFRWLFLRYRYQRYMSLKGZ

## 30 <u>ID127 894bp</u>

- AGGTCTTCCAGAGCAAGTAGCCTATTATCAGGAACACTACGAAAAATTTGTCAAAAGTTAA

  45

  VGRIIRAGVKMEHLGKVFREFRTSGNYSLKEAAGESCSTSQLSRFELGESDLAVSRFFEILDNIHVTIENFMDKARNFHN
  HEHVSMMAQIIPLYYSNDIAGFQKLQREQLEKSKSSTTPLYFELNWILLQGLICQRDASYDMKQDDLGKVADYLFKTEE
  WTMYELILFGNLYSFYDVDYVTRIGREVMEREEFYQEISRHKRLVLILALNCYQHCLEHSSFYNANYFEAYTEKIIDKGI
  KLYERNVFHYLKGFALYQKGQCKEGCKQMQEAMHIFDVLGLPEQVAYYQEHYEKFVKSZ

TGCCTTATATCAAAAAGGACAGTGTAAAGAAGGCTGTAAGCAGATGCAAGAGGCCATGCATATTTTTTGATGTGTT

#### TABLE 3

#### ID1 1068bp

- ATGTCTAACATTCAAAACATGTCCCTGGAGGACATCATGGGAGAGCGCTTTGGTCGCTACTCCAAGTACATTATTC 5 AAGACCGGGCTTTGCCAGATATTCGTGATGGGTTGAAGCCGGTTCAGCGCCGTATTCTTTATTCTATGAATAAGGA CGGGGATTCTTCTATCTATGATGCCATGGTTCGTATGTCACAGAACTGGAAAAATCGTGAGATTCTAGTTGAAATG CACGGTAATAACGGTTCTATGGACGGAGATCCTCCTGCGGCTATGCGTTATACTGAGGCACGTTTGTCTGAAATTG 10 CAACGGTCTTGCCAGCAGCCTTTCCAAACCTCTTGGTCAATGGTTCGACTGGGATTTCGGCTGGTTATGCCACAGA CATTCCTCCCATAATTTAGCTGAGGTCATAGATGCTGCAGTTTACATGATTGACCACCCAACTGCAAAGATTGAT AAACTCATGGAATTCTTGCCTGGACCAGACTTCCCTACAGGGGCTATTATTCAGGGTCGTGATGAAATCAAGAAA GCTTATGAGACTGGGAAAGGGCGCGTGGTTGTTCCTTCCAAGACTGAAATTGAAAAGCTAAAAGGTGGTAAGGAA 15 CAAATCGTTATTATTGAGATTCCTTATGAAATCAATAAGGCCAATCTAGTCAAGAAAATCGATGATGTTCGTGTTA ATAACAAGGTAGCTGGGATTGCTGAGGTTCGTGATGAGTCTGACCGTGATGGTCTTCGTATCGCTATCGAACTTAA GAAAGACGCTAATACTGAGCTTGTTCTCAACTACTTATTTAAGTACACCGACCTACAAATCAACTACAACTTTAAT ATGGTGGCGATTGACAATTTCACACCTCGTCAGGTTGGATTGTTCCAATCCTGTCTAGCTATATCGCTCACCGTCG AGAAGTGA
- 20
  MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSNTFDKSYRKSAKSVGNIMGNFHPHGDS
  SIYDAMVRMSQNWKNREILVEMHGNNGSMDGDPPAAMRYTEARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTVLP
  AAFPNLLVNGSTGISAGYATDIPPHNLAEVIDAAVYMIDHPTAKIDKLMEFLPGPDFPTGAIIQGRDEIKKAYETGKGRV
  VVRSKTEIEKLKGGKEQIVIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAIELKKDANTELVLNYLFK
  YTDLOINYNFNMVAIDNFTPROVGLFOSCLAISLTVEKZ

#### ID12 684bi

- 40 mptleiaqkklefikkaeeyynalctniqlsgdklkvisvtsvnpgegktttsiniawsfaragyktllidgdtrnsvml gvfksrekitglteflsgtadlshglcdtnienlfvvqsgsvspnptallqsknfndmietlrkyfdyiiidtppigividaa iitqkcdasilvtatgeankrdiqkakqqlkqtgklflgvvlnkldisvnkygvygsygnygkkz

#### ID13 1182bp

- 45 ATGGAGGCAAATATGAAACATCTAAAAACATTTTACAAAAAAATGGTTTCAATTATTAGTCGTTATCGTCATTAGCT TAGTACTATTACACAAACTGCCTATAAGAACGAAAATTCAACAACACAGGCTGTTAACAAAGTAAAAGATGCTGT TGTTTCTGTTATTACTTATTCGGCAAACAGACAAAATAGCGTATTTGGCAATGATACTGACACAGATTCTCAG 50 CGAATCTCTAGTGAAGGATCTGGAGTTATTTATAAAAAGAATGATAAAGAAGCTTACATCGTCACCAACAATCAC GTTATTAATGGCGCCAGCAAAGTAGATATTCGATTGTCAGATGGGACTAAAGTACCTGGAGAAATTGTCGGAGCT GACACTTTCTCTGATATTGCTGTCGTCAAAATCTCTTCAGAAAAAGTGACAACAGTAGCTGAGTTTGGTGATTCTA GTAAGTTAACTGTAGGAGAAACTGCTATTGCCATCGGTAGCCCGTTAGGTTCTGAATATGCAAATACTGTCACTCA AGGTATCGTATCCAGTCTCAATAGAAATGTATCCTTAAAATCGGAAGATGGACAAGCTATTTCTACAAAAGCCAT 55 CCAAACTGATACTGCTATTAACCCAGGTAACTCTGGCGGCCCACTGATCAATATTCAAGGGCAGGTTATCGGAAT TACCTCAAGTAAAATTGCTACAAATGGAGGAACATCTGTAGAAGGTCTTGGTTTCGCAATTCCTGCAAATGATGCT ATCAATATTATTGAACAGTTAGAAAAAAACGGAAAAGTGACGCGTCCAGCTTTGGGAATCCAGATGGTTAATTTA TCTAATGTGAGTACAAGCGACATCAGAAGACTCAATATTCCAAGTAATGTTACATCTGGTGTAATTGTTCGGTTCGG TACAAAGTAATATGCCTGCCAATGGTCACCTTGAAAAATACGATGTAATTACAAAAGTAGATGACAAAGAGATTG 60 CTTCATCAACAGACTTACAAAGTGCTCTTTACAACCATTCTATCGGAGACACCATTAAGATAACCTACTATCGTAA
- MEANMKHLKTFYKKWFQLLVVIVISFFSGALGSFSITQLTQKSSVNNSNNNSTITQTAYKNENSTTQAVNKVKDAVVSV ITYSANRQNSVFGNDDTDTDSQRISSEGSGVIYKKNDKEAYIVTNNHVINGASKVDIRLSDGTKVPGEIVGADTFSDIAV VKISSEKVTTVAEFGDSSKLTVGETAIAIGSPLGSEYANTVTQGIVSSLNRNVSLKSEDGQAISTKAIQTDTAINPGNSGGP

CGGGAAAGAAGAACTACCTCTATCAAACTTAACAAGAGTTCAGGTGATTTAGAATCTTAA

LINIQGQVIGITSSKIATNGGTSVEGLGFAIPANDAINIIEQLEKNGKVTRPALGIQMVNLSNVSTSDIRRLNIPSNVTSGVIV RSVQSNMPANGHLEKYDVITKVDDKEIASSTDLQSALYNHSIGDTIKITYYRNGKEETTSIKLNKSSGDLESZ

ID15 939bp

TGGCTATCTATTGCCTTACTTAAACAAATAA

- ATGGCAGAAATTTATCTAGCAGGTGGTTGTTTTTGGGGCCTAGAGGAATATTTTTCACGCATTTCTGGAGTGCTAG
  AAACCAGTGTTGGCTACGCTAATGGTCAAGTCGAAACGACCAATTACCAGTTGCTCAAGGAAACAGACCATGCAG
  AAACCGGTCCAAGTGATTTACGATGAGAAGGAAGTGTCACTCAGAGAGATTTTACTTTATTATTTCCGAGTTATCGA
  TCCTCTATCTATCAATCAACAAGGGAATGACCGTGGTCGCCAATATCGAACTGGGATTTATCAGGATGAAGC
  AGATTTGCCAGCTATCTACACAGTGGTGCAGGAGCAGGACGCATGCTGGGTCGAAAGATTGCAGTAGAAGTTGCA
  GCAATTACGCCACTACATTCTGGCTGAAGACTACCACCAAGAACTATCAAGAAGCCTAGTCAAGAGGTTTGAAG
  GCCAGTCTATCTGAAGAGTCTTATCGTGTCACACAAGAAGCTTACTACAAGAGCTCATTTACCAATGCCTATGACC
  AAACCTTTGAAGAGGGGATTTATCGTGTCACACAAGAAGCTGCTACAGAGGTCCATTTACCAATGCCTATGACC
  AAACCTTTGAAGAGGGGATTTATGTAGATATTACGACAGGTGAGCCACTCTTTTTTGCCAAGGATCAGAGCTTCTC
  AGGTTGTGGTTGGCCAAGTTTTAGCCGTCCGATTTCCAAAGAGTTGATTCATTATTACAAGGATCTGAGCCATGGA
  ATGGAGCGAATTGAAGTTCGTTCTCGTTCAGGCAGTGCTCACTTGGGTCATGAGAGATGGACCGCGGGAGT
  TAGGCGGCCTCCGTTACTGTATCAATTCTGCTTCTTTTACGCTTTTTTGCGCCAAGGATGGACAGGATA
- 20 MAEIYLAGGCFWGLEEYFSRISGVLETSVGYANGQVETTNYQLLKETDHAETVQVIYDEKEVSLREILLYYFRVIDPLSI NQQGNDRGRQYRTGIYYQDEADLPAIYTVVQEQERMLGRKIAVEVEQLRHYILAEDYHQDYLRKNPSGYCHIDVTDA DKPLIDAANYEKPSQEVLKASLSEESYRVTQEAATEAPFTNAYDQTFEEGIYVDITTGEPLFFAKDKFASGCGWPSFSRPI SKELIHYYKDLSHGMERIEVRSRSGSAHLGHVFTDGPRELGGLRYCINSASLRFVAKDEMEKAGYGYLLPYLNKZ
- 25 <u>ID17 870bp</u>
- 40 MKIIVPATSANIGPGFDSVGVAVTKYLQIEVCEERDEWLIEHQIGKWIPHDERNLLLKIALQIVPDLQPRRLKMTSDVPLA RGLGSSSSVIVAGIELANQLGQLNLSDHEKLQLATKIEGHPDNVAPAIYGNLVIASSVEGQVSAIVADFPECDFLAYIPNY ELRTRDSRSVLPKKLSYKEAVAASSIANVAVAALLAGDMVTAGQAIEGDLFHERYRQDLVREFAMIKQVTKENGAYAT YLSGAGPTVMVLASHDKMPTIKAELEKQPFKGKLHDLRVDTQGVRVEAKZ
- 45 <u>ID20 564bp</u>
- - MKYHDYIWDLGGTLLDNYETSTAAFVETLALYGITQDHDSVYQALKVSTPFAIETFAPNLENFLEKYKENEARELEHPI LFEGVSDLLEDISNQGGRHFLVSHRNDQVLEILEKTSIAAYFTEVVTSSSGFKRKPNPESMLYLREKYQISSGLVIGDRPID IEAGQAAGLDTHLFTSIVNLROVLDIZ
- 60 <u>ID21</u> 1875bp

55

CTTTACAGTCCTTCACGCTGGAGGAAAGTTCGGCGGTGGTGGATACAAGGTTTCAGGTGGTCTTCACGGGGTGGG GTCGTCAGTAGTTAATGCCCTTTCCACTCAATTAGACGTTCATGTTCACAAAAATGGTAAGATTCATTACCAAGAA TACCGTCGTGGTCATGTTGTCGCAGATCTTGAAATAGTTGGAGATACGGATAAAACAGGAACAACTGTTCACTTC 5 GCCTTTCTAAATCGCGGTCTTCAAATTTCAATTACAGATAAGCGCCAAGGTTTGGAACAAACCAAGCATTATCATT ATGAAGGTGGGATTGCTAGTTACGTTGAATATATCAACGAGAACAAGGATGTAATCTTTGATACACCAATCTATA CAGACGGTGAGATGGATATCACAGTTGAGGTAGCCATGCAGTACACAACTGGTTACCATGAAAATGTCATGA GTTTCGCCAATAATATTCATACCCATGAAGGTGGAACACATGAACAAGGTTTCCGTACAGCCTTGACACGTGTTAT CAACGATTATGCTCGTAAAAATAAGTTACTGAAAGACAATGAAGATAATTTAACAGGGGAAGATGTTCGCGAAGG 10 CTTAACTGCAGTTATCTCAGTTAAACACCCAAATCCACAGTTTGAAGGACAAACCAAGACCAAATTGGGAAATAG CGAAGTGGTCAAGATTACCAATCGCCTCTTCAGTGAAGCTTTCTCCGATTTCCTCATGGAAAATCCACAGATTGCC AAACGTATCGTAGAAAAAGGAATTTTGGCTGCCAAGGCTCGTGTGGCTGCCAAGCGTGCGCGAAGTCACACGT AAAAAATCTGGTTTGGAAATTTCCAACCTTCCAGGGAAACTAGCAGACTGTTCTTCTAATAACCCTGCTGAAACAG AACTCTTCATCGTCGAAGGAGACTCAGCTGGTGGATCAGCCAAATCTGGTCGTAACCGTGAGTTTCAGGCTATCCT 15 TCCAATTCGCGGTAAGATTTTGAACGTTGAAAAAGCAAGTATGGATAAGATTCTAGCCAACGAAGAAATTCGTAG TCTTTTCACAGCCATGGGAACAGGATTTGGCGCAGAATTTGATGTTTCGAAAGCCCGTTACCAAAAACTCGTTTTG ATGACCGATGCCGATGTCGATGGAGCCCACATTCGTACCCTTCTTTTAACCTTGATTTATCGTTATATGAAACCAA TCCTAGAAGCTGGTTATGTTTATATTGCCCAACCACCAATCTATGGTGTCAAGGTTGGAAGCGAGATTAAAGAATA TATCCAGCCGGGTGCAGATCAAGAAATCAAACTCCAAGAAGCTTTAGCCCGTTATAGTGAAGGTCGTACCAAACC 20 GACTATTCAGCGTTATAAGGGGGCTAGGTGAAATGGACGATCATCAGCTGTGGGAAACAACCATGGATCCCGAACA TCGCTTGATGGCTAGAGTTTCTGTAGATGATGTGCAGAAGCAGATAAAATCTTTGATATGTTGA MTEEIKNLQAQDYDASQIQVLEGLEAVRMRPGMYIGSTSKEGLHHLVWEIVDNSIDEALAGFASHIQVFIEPDDSITVVD DGRGIPVDIQEKTGRPAVETVFTVLHAGGKFGGGGYKVSGGLHGVGSSVVNALSTQLDVHVHKNGKIHYQEYRRGHV

DGRGIPVDIQEKTGRPAVETVFTVLHAGGKFGGGGYKVSGGLHGVGSSVVNALSTQLDVHVHKNGKIHYQEYRRGHV
VADLEIVGDTDKTGTTVHFTPDPKIFTETTIFDFDKLNKRIQELAFLNRGLQISITDKRQGLEQTKHYHYEGGIASYVEYI
NENKDVIFDTPIYTDGEMDDITVEVAMQYTTGYHENVMSFANNIHTHEGGTHEQGFRTALTRVINDYARKNKLLKDN
EDNLTGEDVREGLTAVISVKHPNPQFEGQTKTKLGNSEVVKITNRLFSEAFSDFLMENPQIAKRIVEKGILAAKARVAAK
RAREVTRKKSGLEISNLPGKLADCSSNNPAETELFIVEGDSAGGSAKSGRNREFQAILPIRGKILNVEKASMDKILANEEI
RSLFTAMGTGFGAEFDVSKARYQKLVLMTDADVDGAHIRTLLLTLIYRYMKPILEAGYVYIAQPPIYGVKVGSEIKEYI
QPGADQEIKLQEALARYSEGRTKPTIQRYKGLGEMDDHQLWETTMDPEHRLMARVSVDDVQKQIKSLICZ

#### ID54 1446bp

- 35 TATTGTTAGTTTGTTTTTTATTGTTCTTAATCTTTAAGTACAATATCCTTGCTTTTAGATATCTTAATCTAGTGGTAA CTGCGTTAGTCCTACTAGTTGCCTTGGTAGGGCTACTCTTGATTATCTATAAAAAAGCTGAAAAGTTTACTATITTT CTGTTGGTGTTCTCTATCCTTGTCAGCTCTGTGTCGCTCTTTGCAGTACAGCAGTTTGTTGGACTGACCAATCGTTT AAATGCGACTTCTAATTACTCAGAATATTCAATCAGTGTCGCTGTTTTTAGCAGATAGTGAGATCGAAAATGTTACG CAACTGACGAGTGTGACAGCACCGACTGGGACTAATAATGAAAATATTCAGAAATTACTAGCTGATATCAAGTCA 40 AGTCAGAATACCGATTTGACGGTCAACCAGAGTTCGTCTTACTTGGCAGCTTACAAGAGTTTGATTGCAGGGGAG ACTAAGGCCATTGTCCTAAATAGTGTCTTTGAAAACATCATCGAGTCAGAGTATCCAGACTACGCATCGAAGATA TATGTTAGTGGAATTGACACCTATGGTCCTATTAGTTCGGTGTCGCGATCAGATGTCAACATCCTGATGACTGTCA ATCGAGATACCAAGAAAATCCTCTTGACCACAACGCCACGTGATGCCTATGTACCAATCGCAGATGGTGGAAATA 45 ATCAAAAAGATAAATTGACTCATGCGGGCATTTATGGAGTTGATTCGTCCATTCACACCTTAGAAAATCTCTATGG TTTATAATGATCAAGAATTTACTGCCCATACGAATGGAAAGTATTACCCTGCAGGCAATGTTCATCTTGATTCAGA ACAGGCTCTCGGTTTTGTTCGTGAGCGCTACTCCCTAGCAGATGGCGATCGTGACCGCGGGCGCCATCAACAAA GGTGATTGTGGCTATCCTTCAAAAATTAACGTCAACCGAAGTGCTGAAAAATTATAGTACGATCATTAATAGCTTG 50 CAAGATTCTATCCAAACAAATATGCCACTTGAGACCATGATAAATTTGGTCAATGCTCAGTTAGAAAGTGGAGGG ACCTCTATGTGATGGAAATAGATGATAGTTTAGCTGTAGTTAAAGCAGCTATACAGGATGTGATGGAGGGTA
- 55 MSRRFKKSRSQKVKRSVNIVLLTIYLLLVCFLLFLIFKYNILAFRYLNLVVTALVLLVALVGLLLIIYKKAEKFTIFLLVFS ILVSSVSLFAVQQFVGLTNRLNATSNYSEYSISVAVLADSEIENVTQLTSVTAPTGTNNENIQKLLADIKSSQNTDLTVNQ SSSYLAAYKSLIAGETKAIVLNSVFENIIESEYPDYASKIKKIYTKGFTKKVEAPKTSKSQSFNIYVSGIDTYGPISSVSRSDV NILMTVNRDTKKILLTTTPRDAYVPIADGGNNQKDKLTHAGIYGVDSSIHTLENLYGVDINYYVRLNFTSFLKLIDLLGG IDVYNDQEFTAHTNGKYYPAGNVHLDSEQALGFVRERYSLADGDRDRGRHQQKVIVAILQKLTSTEVLKNYSTIINSLQ DSIQTNMPLETMINLVNAQLESGGNYKVNSQDLKGTGRMDLPSYAMPDSNLYVMEIDDSSLAVVKAAIQDVMEGRZ

#### ID55 732bp

MIDIHSHIVFDVDDGPKSREESKALLAESYRQGVRTIVSTSHRRKGMFETPEEKIAENFLQVREIAKEVASDLVIAYGAEI YYTPDVLDKLEKKRIPTLNDSRYALIEFSMNTPYRDIHSALSKILMLGITPVIAHIERYDALENNEKRVRELIDMGCYTQV NSSHVLKPKLFGERYKFMKKRAQYFLEQDLVHVIASDMHNLDGRPPHMAEAYDLVTQKYGEAKAQELFIDNPRKIVM DQLIZ

#### ID58 3990bp

15

TTGATTTATATATCGCTATCAATATAACAATGCAATCAGGAGGTTTTGCAATGAAACATGAAAAACAACAGCGT 20 TTTTCTATTCGTAAATACGCTGTAGGAGCAGCTTCTGTTCTAATTGGATTTGCCTTCCAAGCACAGACTGTTGCAG AAATCGGACTGAGGAAACACCTAAAGCAGTGCTTCAACCAGAAGCTCCAAAAACTGTAGAAACAGAAACTCCAG AAGCAGAAGTGGTAACTCCAACTTCTGCTGAAAAAGAAACTGCTAATAAAAAGGCAGAAGAAGCTAGCCCTAAA 25 AAGGAAGAGCGAAAGAGGTTGATTCTAAAGAGTCAAATACAGACAAGACTGACAAGGATAAAACCAGCTAAAAA AGATGAAGCGAAAGCAGAGGCTGACAAACCGGCAACAGAGGCAGGAAAGGAACGTGCTGCAACTGTAAATGAAA AACTAGCGAAAAAGAAAATTGTTTCTATTGATGCTGGACGTAAATATTTCTCACCAGAACAGCTCAAGGAAATCA TCGATAAAGCGAAACATTATGGCTACACTGATTTACACCTATTAGTCGGAAATGATGGACTCCGTTTCATGTTGGA CGATATGAGCATCACAGCTAACGGCAAGACCTATGCCAGTGACGATGTCAAACGCGCCCATTGAAAAAGGTACAAA 30 TGATTATTACAACGATCCAAACGGCAATCACTTAACAGAAAGTCAAATGACAGATCTGATTAACTATGCCAAAGA TAAAGGTATCGGTCTCATTCCGACAGTAAATAGTCCTGGACACATGGATGCGATTCTCAATGCCATGAAAGAATT GGGAATCCAAAACCCTAACTTTAGCTATTTTGGGAAGAAATCAGCCCGTACTGTCGATCTTGACAACGAACAAGC TGTCGCTTTTACAAAAGCCCTTATCGACAAGTATGCTGCTTATTTCGCGAAAAAGACTGAAATCTTCAACATCGGA CTTGATGAATATGCCAATGATGCGACAGATGCTAAAGGTTGGAGTGTGCTTCAAGCTGATAAATACTATCCAAAC 35 GGTCTCAAACCAATGGCTTTTAACGACGGTATCTACTACAATAGCGACACAAGCTTTGGTAGTTTTTGACAAAGAC ATCATCGTTTCTATGTGGACTGGTTGGGGAGGCTACGATGTCGCTTCTTCTAAACTACTAGCTGAAAAAGGTC ACCAAATCCTTAATACCAATGATGCTTGGTACTACGTTCTTGGACGAAACGCTGATGGCCAAGGCTGGTACAATCT CGATCAGGGGCTCAATGGTATTAAAAACACACCAATCACTTCTGTACCAAAAACAGAAGGAGCTGATATCCCAAT 40 CATCGGTGGTATGGTAGCTGGGCTGACACTCCATCTGCACGTTATTCACCATCACGCCTCTTCAAACTCATG CCAAAAGACCTGAACCGTTATACTGCAGAAAGCGTCACGGCCGTAAAAGAAGCTGAAAAAGCTATTCGCTCTCTC GATAGCAACCTTAGCCGTGCCCAACAAGATACGATTGATCAAGCCATTGCTAAACTTCAAGAAACTGTCAACAAC TTGACCCTCACGCCTGAAGCTCAAAAAGAAGAAGAAGCTAAACGTGAGGTTGAAAAACTTGCCAAAAACAAGGT 45 AATCTCAATCGATGCTGGACGCAAATACTTTACTCTGAACCAGCTCAAACGCATCGTAGACAAGGCCAGTGAGCT CGGATATTCTGATGTCCATCTCCTTCTAGGAAATGACGGACTTCGCTTTCTACTCGATGATATGACCATTACTGCC AACGGAAAAACCTATGCTAGTGATGACGTTAAAAAAGCTATTATCGAAGGAACTAAAGCTTACTACGACGATCCA AACGGTACTGCACTAACACAGGCAGAAGTAACAGAGCTAATTGAATACGCTAAATCTAAGGACATCGGTCTCATC CCAGCTATTAACAGTCCAGGTCACATGGATGCTATGCTGGTTGCCATGGAAAAATTAGGTATTAAAAATCCTCAA 50 GCCCACTTTGATAAAGTTTCAAAAACAACTATGGACTTGAAAAACGAAGAAGCGATGAACTTTGTAAAAGCCCTC ATCGGTAAATACATGGACTTCTTTGCAGGTAAAACAAAGATTTTCAACTTTTGGTACTGACGAATACGCCAACGAT GCGACTAGTGCCCAAGGCTGGTACTACCTCAAGTGGTATCAACTCTATGGCAAATTTGCCGAATATGCCAACACC CTCGCAGCTATGGCCAAAGAAGAGGGCTTCAACCAATGGCCTTCAACGATGGCTTCTACTATGAAGACAAGGAC GATGTTCAGTTTGACAAAGATGTCTTGATTTCTTACTGGTCTAAAGGCTGGTGGGGATATAACCTCGCATCACCTC 55 AATACCTAGCAAGCAAAGGCTATAAATTCTTGAATACCAACGGTGACTGGTACTACATTCTTGGTCAAAAACCAG AATATCCTGAAGTAGATCTTCCAACAGTCGGAAGTATGCTTTCAATCTGGGCAGATAGACCAAGCGCTGAATACA AGGAAGAGGAAATCTTTGAACTCATGACTGCCTTTGCAGACCACAACAAGACTACTTTCGTGCTAATTATAATG 60 CAGCTAAAACAGCTCTAAATTACAACCTCAACCGTAATAAACAAGCTGAGCTTGACACGCTTGTAGCCAACCTAA AAGCCGCTCTTCAAGGCCTCAAACCAGCTGTAACTCATTCAGGAAGCCTAGATGAAAATGAAGTGGCTGCCAATG AAAATGGAAAAACAACAGAAACAGTCCTTGATAGCCAGGTAACCAAAGAAGTTATAAACCAAGTGGTTGAAGTT . 65 GGCGCTCCTGTAACTCACAAGGGTGATGAAAGTGGTCTTGCACCAACTACTGAGGTAAAACCTAGACTGGATATC

CAAGAAGAAAATTCCATTTACCACAGTGACTTGTGAAAATCCACTCTTACTCAAAGGAAAAACACAAGTCATT
ACTAAGGGCGTCAATGGACATCGTAGCAACTTCTACTCTGTGAGCACTTCTGCCGATGGTAAGGAAGTGAAAACA
CTTGTAAATAGTGTCGTAGCACAGGAAGCCGTTACTCAAATAGTCGAAGTCGGAACTATGGTAACACATGTAGGC
GATGAAAACGGACAAGCCGCTATTGCTGAAGAAAAACCAAAACTAGAAATCCCAAGCCAACCAGCTCCATCAAC
TGCTCCTGCTGAGGAAAGCAAAGTTCTTCCTCAAGATCCAGCTCCTGTGGTAACAGAGAAAAAACTTCCTGAAAC
AGGAACTCACGATTCTGCAGGACTAGTAGTCGCAGGACTCATGTCCACACTAGCAGCCTATGGACTCACTAAAAG
AAAAGAAGACTAA

 ${\tt MIYIIAINITMQSGGFAMKHEKQQRFSIRKYAVGAASVLIGFAFQAQTVAADGVTPTTTENQPTIHTVSDSPQSSENRTEE}$ 10 TPKAVLQPEAPKTVETETPATDKVASLPKTEEKPQEEVSSTPSDKAEVVTPTSAEKETANKKAEEASPKKEEAKEVDSKE SNTDKTDKDKPAKKDEAKAEADKPATEAGKERAATVNEKLAKKKIVSIDAGRKYFSPEOLKEIIDKAKHYGYTDLHLL VGNDGLRFMLDDMSITANGKTYASDDVKRAIEKGTNDYYNDPNGNHLTESQMTDLINYAKDKGIGLIPTVNSPGHMDAILNAMKELGIQNPNFSYFGKKSARTVDLDNEQAVAFTKALIDKYAAYFAKKTEIFNIGLDEYANDATDAKGWSVLQA DKYYPNEGYPVKGYEKFIAYANDLARIVKSHGLKPMAFNDGIYYNSDTSFGSFDKDIIVSMWTGGWGGYDVASSKLLA 15 EKGHQILNTNDAWYYVLGRNADGQGWYNLDQGLNGIKNTPITSVPKTEGADIPIIGGMVAAWADTPSARYSPSRLFKL MRHFANANAEYFAADYESAEQALNEVPKDLNRYTAESVTAVKEAEKAIRSLDSNLSRAQQDTIDQAIAKLQETVNNLT LTPEAQKEEEAKREVEKLAKNKVISIDAGRKYFTLNQLKRIVDKASELGYSDVHLLLGNDGLRFLLDDMTITANGKTYA SDDVKKAIIEGTKAYYDDPNGTALTQAEVTELIEYAKSKDIGLIPAINSPGHMDAMLVAMEKLGIKNPQAHFDKVSKTT MDLKNEEAMNFVKALIGKYMDFFAGKTKIFNFGTDEYANDATSAQGWYYLKWYQLYGKFAEYANTLAAMAKERGL 20 QPMAFNDGFYYEDKDDVQFDKDVLISYWSKGWWGYNLASPQYLASKGYKFLNTNGDWYYILGQKPEDGGGFLKKAI ENTGKTPFNQLASTKYPEVDLPTVGSMLSIWADRPSAEYKEEEIFELMTAFADHNKDYFRANYNALREELAKIPTNLEG YSKESLEALDAAKTALNYNLNRNKQAELDTLVANLKAALQGLKPAVTHSGSLDENEVAANVETRPELITRTEEIPFEVI

KKENPNLPAGQENIITAGVKGERTHYISVLTENGKTTETVLDSQVTKEVINQVVEVGAPVTHKGDESGLAPTTEVKPRL
DIQEEEIPFTTVTCENPLLLKGKTQVITKGVNGHRSNFYSVSTSADGKEVKTLVNSVVAQEAVTQIVEVGTMVTHVGDE
NGQAAIAEEKPKLEIPSQPAPSTAPAEESKVLPQDPAPVVTEKKLPETGTHDSAGLVVAGLMSTLAAYGLTKRKEDZ

#### ID122 825bp

CACAAGCAATCCTAAAAACATTGCTGTTCAGACAGCCTGGGCAAATCAGGCGTTGGATGGTTTGGATGCCTAAACAGCAATCCTAAAAACATTGCTGTTCAGACAGCCTGGGCAAAACAGCGTGTCCGGTTACCGTTAACCCTTTACTAAAACTACTATGAAAGCAGAGTTTAGTTCCCTCAGCTTCACAGATTGAAGCCAAGTCTTCGGATGGAGAATTGAATTCAATGTTCTAGTTCCCAAATGTTCAAAAGGGACTTCAACTGGATTACCGAACTGGAGAAGTAACTGTAACTCAGTAA

MNKKTRQTLIGLLVLLLLSTGSYYIKQMPSAPNSPKTNLSQKKQASEAPSQALAESVLTDAVKSQIKGSLEWNGSGAFIV NGNKTNLDAKVSSKPYADNKTKTVGKETVPTVANALLSKATRQYKNRKETGNGSTSWTPPGWHQVKNLKGSYTHAV DRGHLLGYALIGGLDGFDASTSNPKNIAVQTAWANQAQAEYSTGQNYYESKVRKALDQNKRVRYRVTLYYASNEDL VPSASQIEAKSSDGELEFNVLVPNVQKGLQLDYRTGEVTVTQZ

#### ID123 225bp

GTGCTAAGATTCAGCGGATTGAGGCAAGTGATGAAGATGAATAAGAAATCAAGCTACGTAGTCAAGCGTTTACTT
TTAGTCATCATAGTACTGATTTTAGGTACTCTGGCCTCTAGGAATCGGTTTAATGGTAGGTTATGGAATCTTGGGCA
AGGGTCAAGATCCATGGGCTATCCTGTCTCCAGCAAAATGGCAGGAATTGATTCATAAATTTACAGGAAATTAG

VLRFSGLRQVMKMNKKSSYVVKRLLLVIIVLILGTLALGIGLMVGYGILGKGQDPWAILSPAKWQELIHKFTGNZ

25

40

## **CLAIMS:**

1. A Streptococcus pneumoniae protein or polypeptide having a sequence selected from those shown in table 1.

5

- 2. A Streptococcus pneumoniae protein or polypeptide having a sequence selected from those shown in table 2.
- 3. A protein or polypeptide as claimed in claim 1 or claim 2 provided in substantially pure form.
  - 4. A protein or polypeptide which is substantially identical to one defined in any one of claims 1 to 3.
- 15 5. A homologue or derivative of a protein or polypeptide as defined in any one of claims 1 to 4.
  - 6. An antigenic and/or immunogenic fragment of a protein or polypeptide as defined
- 20 in Tables 1-3.
  - 7. A nucleic acid molecule comprising or consisting of a sequence which is:
    - (i) any of the DNA sequences set out in Table 1 or their RNA equivalents;

25

(ii) a sequence which is complementary to any of the sequences of (i);

		(iii)	a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
. 5		(iv)	a sequence which is substantially identical with any of those of (i), (ii) and (iii);
		(v)	a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 1.
10 8. A nucleic acid molecule comprising or		A nuc	leic acid molecule comprising or consisting of a sequence which is:
		(i)	any of the DNA sequences set out in Table 2 or their RNA equivalents;
15		(ii)	a sequence which is complementary to any of the sequences of (i);
		(iii)	a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
20	·	(iv)	a sequence which is substantially identical with any of those of (i), (ii) and (iii);
		(v)	a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 2.
25	9		se of a protein or polypeptide having a sequence selected from those
	shown in Tables 1-3, or homologues, derivatives and/or fragments thereof, as an		

immunogen and/or antigen.


20


- 10. An immunogenic and/or antigenic composition comprising one or more proteins or polypeptides selected from those whose sequences are shown in Tables 1-3, or homologues or derivatives thereof, and/or fragments of any of these.
- 5 11. An immunogenic and/or antigenic composition as claimed in claim 10 which is a vaccine or is for use in a diagnostic assay.
  - 12. A vaccine as claimed in claim 11 which comprises one or more additional components selected from excipients, diluents, adjuvants or the like.
  - 13. A vaccine composition comprising one or more nucleic acid sequences as defined in Tables 1-3.
- 14. A method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one protein or polypeptide as defined in Tables 1-3, or homologue, derivative or fragment thereof.
  - 15. An antibody capable of binding to a protein or polypeptide as defined in Tables 1-3, or for a homologue, derivative or fragment thereof.
  - 16. An antibody as defined in claim 15 which is a monoclonal antibody.
  - 17. A method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested and at least one antibody as define din claim 15 or claim 16.
  - 18. A method for the detection/diagnosis of S.pneumoniae which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid

10

sequence as defined in claim 7 or claim 8.

- 19. A method of determining whether a protein or polypeptide as defined in Tables 1-3 represents a potential anti-microbial target which comprises inactivating said protein or polypeptide and determining whether *S. pneumoniae* is still viable.
- 20. The use of an agent capable of antagonising, inhibiting or otherwise interfering with the function or expression of a protein or polypeptide as defined in Tables 1-3 in the manufacture of a medicament for use in the treatment or prophylaxis of *S.pneumoniae* infection





SUBSTITUTE SHEET (RULE 26)